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Abstract 
Mucus lines the moist cavities in the body and acts as a barrier for these surfaces, 
protecting the underlying cells against the external environment but also unfortunately 
hindering the permeation of drugs and delivery systems. As the rate of diffusion across 
this barrier is low, the development of drug delivery systems that can increase 
retention time at the mucosal interface would be beneficial. Mucus is highly rich in 
cysteine groups, which have been targeted recently for a new generation of 
mucoadhesive thiol-functional polymers, able to form disulphide bonds with cysteine 
rich areas. The aim of this study was to synthesise thiol-functional branched 
copolymers to stabilise oil-in-water emulsions and test their potential as mucoadhesive 
therapeutic drug delivery systems. 
Atom-transfer radical polymerisation was used to synthesise amphiphilic linear and 
branched copolymers of oligo (ethylene glycol) monomethyl ether methacrylate, with 
a hydrophobic initiator, dodecyl α-bromoisobutyryl bromide, for testing as polymeric 
surfactants for oil-in-water macroemulsions and nanoemulsions. Branched polymer 
architecture was determined to be critical for the formation of successful and stable 
emulsions. The number of hydrophobic chain ends which can be substituted with 
hydrophilic functionality, while retaining emulsion stabilisation was evaluated by co-
initiating branched copolymerisations with a poly(ethylene glycol)-derived initiator. 
Systematic reduction of hydrophobic chain ends showed that a minimum of 25 mole 
percent were necessary to retain emulsion stability. 
Mucoadhesive functionality was incorporated into the branched copolymers via a 
xanthate based initiator which contains a masked thiol group. The polymers were then 
deprotected post-polymerisation to reveal thiol groups at varying concentrations, and 
used as surfactants to successfully generate functional macroemulsions and 
nanoemulsions. Mucoadhesive properties of the thiol functionalised emulsions were 
tested using a novel flow through model which determined that an increase in mole 
percentage of thiol chain ends did lead to an increase in nanoemulsion adherence to 
biosimilar mucus. Ex vivo multiple particle tracking, using porcine intestinal mucus 
confirmed that an increase in thiol chain ends was critical to the mucoadhesive 
behaviour, where 42 % of particles tracked from a non-thiol functional nanoemulsion 
were highly diffusive and an increase to 90 mole percent thiol chain ends drastically 
reduced the amount of diffusive particles to 6 %. 
The potential of using the mucoadhesive emulsions for ophthalmic treatments utilising 
mucus content within the tear film was investigated. Cytotoxicity of nanoemulsions 
was evaluated against mucus secreting human conjunctival epithelial cells and human 
corneal epithelial cells, and determined to be non-toxic below 9.1 v/v % concentration 
of emulsion diluted in culture media. Nanoemulsions were also successfully loaded 
with two common drugs for ophthalmic treatments, amphotericin B and cyclosporin 
A at doses matching commercial topically dosed products. Overall the potential for 
thiol-functional macroemulsions and nanoemulsions to have mucoadhesive 
characteristics has been demonstrated, and the number of thiol chain ends critical to 
the level of adhesion determined.  
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1.1. MUCUS AND MUCOSAL MEMBRANES 
 
Mucus is defined as a viscoelastic, gel-like substance which lines many of the cavities 
within the body, including the oral, gastrointestinal, genital and ocular regions.  Its 
main function is to act as a barrier for these surfaces, protecting the underlying cells 
against the external environment. Mucus is secreted by goblet cells which are found 
scattered within the epithelium lining of organs, for example in the gastrointestinal 
(GI) tract mucus is secreted along the epithelial surfaces which lines the stomach to 
the colon, Figure 1.1.1 The structure of epithelia can either be a single layer of cells as 
in the GI tract, or the cells are stratified and are next to specialised glands, such as in 
the cornea; in both models the goblet cells are vital to mucus production.2 
 
Figure 1.1 Intestinal epithelium containing a number of cells including the goblet cells 
which secret mucus to produce a layer of mobile and stationary mucus. Adapted from 
J.H Rothchild et al.3  
Mucus linings are composed of a mobile layer which is removed quickly and a 
stationary gel–like layer,4 which is secreted sporadically through the villi and adheres 
to the surface of the goblet cells,5 Figure 1.2. The life-cycle of the stationary mucosal 
layer varies depending on the part of the body, but it is usually short lived as it is 
continuously being reformed.6 The ocular and respiratory tract mucosal life-time is 
short at 5-8 and 10-20 minutes respectively, whereas the mucus in the gastrointestinal 
tract of a rat has a longer life-time of 4-6 hours, similar values likely to be found in 
humans.7  
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Figure 1.2 An illustration of the layers of adherent and non-adherent mucus, where 
rapid clearance of particles occurs in the mobile layer. Adapted from L. M. Ensign et 
al.8,7  
The thickness of mucus layers also varies depending on the physical location within 
the body, for example the average thickness of the mucus layer in the eye is 0.035 μm,9 
but the mucin containing tear film has been reported to vary from 5 - 40 μm.9- 11 
Reports of human mucus thickness in the GI tract are rare, however, the adherent GI 
mucus layer in humans has been reported to have a thickness of up to 200 μm.7 Studies 
have highlighted person to person variability of the thickness of the mucus layers; a 
multiple patient investigation sampled the antrum mucus which is located near the 
bottom of the stomach, next to the pyloric sphincter and found to range between 112 
– 180 μm.12 More commonly the thickness of GI mucus has been studied in animals 
such as pigs, rats and rabbits and despite inter-species differences it was generally 
found that the thickness of the mucus lining was stomach>large intestine>small 
intestine.1,7,12 The values shown in Table 1.1 detail the thickness of the mucus layer 
lining of the GI tract of a rat, and exhibits the increasing thickness of both the adherent 
and non-adherent layer of mucus from the stomach through to the colon. An alternate 
in vivo study was conducted on rat GI mucus and showed contradictory values between 
30 – 60 μm, therefore, showing the inherent study-to-study variability when measuring 
mucus thickness.12 The thickness of porcine  antrum mucus was also studied and found 
to be most representative of human mucus, at 222 μm compared to 112 – 180 μm.12  
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Table 1.1 Mucus thickness of mobile and adhered layers from an in vivo study of rat 
GI mucus including the antrum (near the bottom of the stomach), duodenum (first 
section of the small intestine close to the stomach), jejunum (middle section of the 
small intestine), ileum (final section of the small intestine close to the colon) and colon 
(also known as the large intestine). Mucus thickness presented as mean values (µm) 
with ± standard error.13 
Mean 
Mucus 
Thickness 
(μm) 
 
Antrum 
 
Duodenum 
 
Jejunum 
 
Ileum 
 
Colon 
Total 274±41 170±38 123±4 480±47 830±110 
Adhered 154±16 16±3 15±2 29±8 116±51 
Mobile 120±38 154±39 108±5 447±47 714±109 
 
In vivo studies of the rat GI mucus gel layer have also shown that the mobile layer is 
loosely adhered and could be removed with gentle suction, while the stationary layer 
was fully adhered to the surface and could not be removed. It was observed that the 
loosely adhered mucus layer was continuous; however upon removal of the firmly 
adhered layer the contours of the villi were found. Alternatively the adhered mucus 
layer of the stomach and colon was continuous but had sporadic distribution in the 
small intestine.13,8 
 
1.1.1 Mucins  
 
Mucins are high molecular weight, heavily glycosylated proteins and are the main 
components of mucus. Mucins can vary considerably in length with some composed 
of >500 amino acid subunits (AA), whilst others are composed of thousands of repeat 
units, therefore can be classed as one of the largest proteins in the body.14 There are 
various mucins found around the body, within the GI tract the following membrane 
bound mucins are expressed: MUC1, MUC3, MUC4, MUC12, MUC13, MUC16 and 
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MUC17,15,16 as well as the mobile mucins: MUC2, MUC5AC, MUC5B, MUC6 and 
MUC7. These mobile mucins are typical gel-forming mucins which are produced by 
the goblet cells.17,18 The MUC2 mucin is the main mucin secreted in the small intestine 
of rats,19 mice20 and humans21 with the mucin monomer being formed of 5100 AA.22,23 
In comparison to another gel-forming mucin, MUC5AC which in humans has been 
determined to only have 8 AA in its tandem repeat unit.24 Each mucin ranges in size 
from 200 kDa to 200 MDa and is formed of a linear peptide backbone, which consist 
of carbohydrate side chains which are O- and N-linked.25,19  
A common feature of mucins is that they are mainly composed of carbohydrates at 
approximately 80 % mass, the remainder is composed of the protein core.26 Mucin 
polypeptide chains repeat serine, threonine and proline (STP) AA,27 which form 
O-glycosidic linkages with oligosaccharides between hydroxyl groups of the rich AA 
domains. This results in a ‘bottle-brush’ like structure with cysteine-rich subdomains 
flanking the repeat units, shown in Figure 1.3.28,29 The repeat units of mucins can vary 
in terms of sequence and amount of amino acids, but in all cases the high concentration 
of serine and threonine results in a high potential of  O-glycosylation.30 Cysteine 
regions flank both the amino and carboxyl terminals as cysteine knots and are 
dispersed through the STP repeat units.31 The cysteine sections of the glycoproteins 
form disulphide bonds to form mucin oligomers from the monomers present, which 
give rise to the gel-like network of the mucus structure.17 Studies show that alongside 
the cysteine knot that is necessary for forming dimers, the N-linked oligosaccharides 
also functions in the disulphide linkage between monomers.32,33 These repeat 
sequences differ between mucins and vary in length and number.30  
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Figure 1.3 Cartoon representations of the glycosylated regions, N-terminal with 
N-linked oligosaccharide, cysteine rich domains present in a mucin as well as 
disulphide bond formation through cysteine knot leading to dimers and multimers. 
Adapted from R. Bansil et al. and M. T. Cook et al.34,35 
 
1.1.2 Mucus Mesh Spacing 
 
Individual mucins aggregate together to form a highly crosslinked network of mucin 
fibres and a dense porous structure also known as mucus mesh.  The mesh pore size 
(10 - 200 nm)36 between these fibres has been shown to have size filtering properties, 
with smaller nanoparticles being able to diffuse through and avoid steric obstruction 
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to reach the underlying cells, Figure 1.4.37 Larger particles however, can become 
entangled in the mobile mucus layer which forms adhesive interactions via 
hydrophobic and electrostatic interactions and hydrogen bonding, these larger 
particles are therefore cleared more rapidly due to mucus turnover.25,38  
 
Figure 1.4 An illustration of the effect of particle size on the ability to permeate 
through the mobile and stationary mucosal layers. Adapted from O. Lieleg et al.37 
Ex vivo studies of porcine intestinal mucus have shown that both adhered and mobile 
mucus layers were present and the pore sizes were determined to be heterogeneous, 
with a 7-fold range in pore size (60 - 400 nm). The distribution consisted of 50 % pores 
sizes of less than 200 nm, whilst 33 % of the population was between 300 - 400 nm.39 
Pore sizes of 211 ± 7 nm  have been successfully stained from a  porcine small intestine 
MUC2 layer, and shown a continuous layer of mucus throughout the small intestine 
which covered the villi.40 Alternatively atomic force microscopy has been utilised to 
image porcine jejunum including trimers of MUC2 which had assembled into a mesh 
structure with pore sizes between 20 – 200 nm.41 Overall the discrepancy between 
pore size determination from methodology used to visual the mucus structure studies 
has been highlighted.  
 
1.1.3 Drug Delivery through Mucosal Membranes 
 
Mucus acts as a barrier for the epithelial surfaces it lines and protects underlying cells 
against the external environment inhibiting many infectious diseases.42 Unfortunately 
the mucosal membrane also hinders the permeation of drugs and delivery systems, and 
therefore has become a high priority for healthcare research programmes.43, 44, 45 The 
rate of drug diffusion across this barrier is low and impedes drug efficacy, therefore 
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the development of drug delivery systems that can increase retention time at the 
mucosal interface and increase permeation would be beneficial.23  
The mucus mesh network does not usually sterically hinder the permeation of drugs 
as they are commonly smaller than the pore size, however, interactions with drugs can 
occur due to the overall hydrophilicity of mucus and the negative charge of mucus 
glycoproteins. Studies have shown that poorly soluble drugs will interact with mucus 
glycoproteins.44 Unfortunately as many drugs are poorly water soluble they are 
reformulated to improve dosing, however this does lead to the production of bigger 
particles which can be removed by the mobile phase of the mucus.  
As mentioned the mesh network can form adhesive interactions with particles, 
therefore particle surface properties can exert a major influence on the diffusion of 
particles through mucus. For example, particles which exhibit strong interactions with 
the mucus matrix may become firmly entangled and remain in the mobile mucus layer 
and are rapidly cleared.  Stealthy particles however, may only demonstrate weak 
interactions with the mucus and be able to diffuse through to the underlying cells. 
Multiple particle tracking (MPT) was used to probe the diffusion depth of polystyrene 
particles over the size range 20 - 500 nm coated simultaneously with carboxylate and 
polyethylene glycol (PEG) functionality.46 It was shown that the carboxylate coated 
particles had increased permeation ability with decreasing particle size, and 
PEGylated particles led to a large increase on particle diffusion.  Further studies have 
shown that regardless of mucus pore size, particles of 500 nm or greater can permeate 
through the mucin network if coated in a suitable mucus penetrating functionality.36,47 
Variation in number average molecular weight (Mn) PEG has been studied and shown 
that a greater Mn achieved particles which exhibited more adhesive properties than 
their lower Mn counterparts, i.e. entrapment of larger particles in the mobile mucus 
layer, Figure 1.4.6 In an ex vivo study of human cervicovaginal mucus it was shown 
that PEG (10-40 kDa) densely grafted onto the surface of nanoparticles enhanced 
diffusion through the mucus. These particles have also exhibited the ability to line the 
colorectal mucus and vaginal epithelium in vivo.48  
A balance between stealth properties of the particles and ability to adhere to the 
mucosal layer, factoring in molecular weight of grafted polymers, particle size and 
chemical interaction with the mucosal layer are all necessary for producing a mucus 
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penetrating system.  Alternatively a system which retains drug particles at the site of 
action within the mucus via adhesion may be advantageous to drug efficacy.   
Mucoadhesive systems have the potential to be used as prophylaxis treatments, where 
prevention is one of the most effective actions against diseases that can be spread 
through sexual contact. For example, microbicides have been assessed for their ability 
of prevention;49 human immunodeficiency virus (HIV) could have increased 
prevention rates if a drug was able to be administered to the cervicovaginal mucus. 
The development of these microbicides can lead to better protection than current 
prevention strategies as they offer bidirectional protection to both partners.50 
 
1.2. MUCOADHESION 
 
1.2.1 Theory of Mucoadhesion 
 
Adhesion is defined as the ‘the sticking together of particles of different substances’51, 
while the terminology referring to the biologically relevant mechanism is known as 
bioadhesion.52 Mucoadhesion can be further classified when one of the two substances 
being referred to is a mucosal surface. 
Mucoadhesion occurs through various physical and chemical mechanisms, and is 
dependent on the properties of the polymer or material tested. For adhesion to occur 
bonds must be formed: ionic, covalent, hydrogen, Van-der-Waals or hydrophobic 
bonds. There are six general theories of adhesion which can be adapted to investigate 
mucoadhesion including: wetting (the contact stage for liquid systems), adsorption, 
diffusion, consolidation (establishment of interactions), electronic and fracture 
processes.  
 
1.2.1.1 Adhesive Theory of Liquid Systems 
 
The wetting theory of mucoadhesion applies mainly to liquid adhesive systems and 
incorporates surface and interfacial energies. It suggests observed adhesive properties 
results from the successful flow of liquid into the cavities of the substrate with 
subsequent hardening,53 Figure 1.5. The contact angle of the interaction is therefore 
highly important as it indicates the wettability of the surface by the contact liquid. The 
contact angle between the liquid system and mucosal surface must be near zero to 
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form a site in which systems can adhere.54 The surface tension subsequently restricts 
the movement of the substance along the substrate site, and can therefore be used to 
predict the spreading.  
 
Figure 1.5 Wetting theory of mucoadhesion mechanism in a liquid system; A) 
Successful wetting of a mucosal surface, with spreading into surface irregularities and 
contact angle near zero. B) Poor wetting of a mucosal surface, low affinity of the liquid 
to the surface and large contact angle. Adapted from J.D. Smart et al.55 
 
1.2.1.2 Adhesive Theories of Polymers and Solid Dosing Systems 
 
The electronic theory of mucoadhesion is based on the occurrence of electron transfer 
upon contact of adhering surfaces with differing electronic structure, for example 
between mucoadhesive polymer and mucous glycoproteins. Adhesion is then caused 
through the formation of an electronic double layer.56 
An alternative theory is the diffusion theory which states that the interdiffusion and 
entanglement of both the polymer and mucins chains are required for adhesion, where 
the more structurally similar the mucoadhesive is to the mucosa the greater the extent 
of mucoadhesion, Figure 1.6. This process is driven by a concentration gradient, the 
chain length and the flexibility of the polymer chain.57  
 
Figure 1.6 Diffusion theory of adhesive polymer and mucus; interdiffusion and 
entanglement between polymer and mucin chains across an adhesive interface. 
The basis for adsorption theory in mucoadhesion is centred on chemical interactions 
and bonding; the adhesion between the substrate and the adhesive is due to primary 
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and secondary bonding. The primary bonding results from permanent bonding (ionic 
or covalent bonding), whereas the secondary bonding is due to weaker interactions 
such as Van-der-Waals forces, hydrophobic interactions or hydrogen bonding.58  
Fracture theory differs from the previous theories as it is based on the force required 
for the detachment of the two substrates after adhesion.  This theory is typically used 
to determine mucoadhesion of solid substrates, usually polymers, gels or tablets. The 
maximum tensile strength produced during detachment can be determined, i.e. the 
force required to separate two surfaces after adhesion which assumes failure of the 
adhesive bond occurs at interface. The fracture however normally occurs at the 
weakest component, where cohesive failure can cause a break in adhesive substrate or 
in the mucosal surface.  
 
1.2.2 Mucoadhesive Polymers 
 
Mucoadhesive polymers can be categorised as either water-soluble or water-insoluble 
polymers which are usually as a swellable network formed by covalent or ionic bonds 
via a cross-linking agent. These are separated by the water-soluble polymers’ retention 
on the surface of the mucosal tissue controlled by the dissolution of the polymer, where 
it is removed from the surface as it dissolves. Whereas the water insoluble polymer 
has a surface retention time based on the mucosal life cycle.59 Common factors 
controlling mucoadhesion have become apparent across the various materials; the 
bioadhesive must be able to spread across the substrate, be able to interdiffuse into the 
mucus to give a greater contact area and exhibit dominant attractive forces such as 
Van der Waals or hydrogen bonding.59 
The ‘first-generation’ mucoadhesive polymers were hydrophilic macromolecules 
which contained hydroxyl and amine groups capable of forming hydrogen bonds with 
the mucosal membrane,60,61 Figure 1.7. These mucoadhesives are termed ‘wet’ 
adhesives as they are activated upon moistening when in contact with the mucosal 
surface.62 These hydrated adhesives however, were shown to have stronger 
interactions with dry surfaces over mucosal ones, where if they are left to dry, strong 
adhesive bonds are formed.60 
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Figure 1.7 Structure of the common ‘first-generation’ mucoadhesive polymers; A) 
Poly(acrylic acid) R= allyl sucrose or allyl pentaerythritol (carbopols) or divinyl 
glycol (polycarbophil), B) Chitosan. Adapted from J.D Smart et al.55 
 
1.2.3 Thiolated Polymers 
 
A recent advancement in mucoadhesive polymers by Bernkop-Schnürch et al. 
produced novel thiolated polymers deemed ‘thiomers’,63 which contain multiple thiol 
groups to form strong covalent disulphide bonds to the mucus glycoproteins. 
Examples of thiomers include hydrophilic polymers with side chains containing thiol 
groups,64 such as poly(acrylates)65 and chitosans.66 Thiomer structures can include 
cationic and anionic polymers for mucoadhesion. Cationic thiomers are typically 
based on chitosans, where the primary amino group can covalently attach to sulfhydryl 
groups.67 One example, is a cysteine modified chitosan polymer as shown in Figure 
1.8, where the carboxyl acid group has reacted with a number of primary amine groups 
pendant to the main carbohydrate chain to generate amine and thiol functionality.68 To 
avoid oxidation of the thiol groups during synthesis, the reaction was performed under 
inert conditions as well as keeping the reaction conditions at a pH <5 to reduce the 
presence of reactive thiolate-anions.67 Anionic thiomers have also been synthesised, 
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where the sulfhydryl can be attached to the polymer by formation of amide bonds 
mediated by carbodiimides.69 
 
Figure 1.8 Thiolated polymer structure; Chitosan-Cysteine. Adapted from A. 
Bernkop-Schnürk et al.67 
Mucoadhesive thiomers improve the retention time of polymers at their intended 
therapeutic sites due to the formation of intrachain and interchain disulphide bonds, 
this provides adhesion through covalent bonding as shown in Figure 1.9.64  
 
Figure 1.9 Covalent bond formation between thiolated polymers and sulphide linked 
mucin glycoproteins via; A) Thiol/disulphide exchange reaction and B) Oxidation of 
the free thiol group. Adapted from V. M. Leitner et al.64 
One proposed mechanism for the interaction of thiol groups with mucus is based on 
disulphide exchange reactions,70 cleavage of the intramolecular disulphide bridges in 
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the mucus causes a breakdown of the mucus. The other is an oxidation reaction 
between the reactive thiol groups on the mucoadhesive polymer and the cysteine rich 
subdomains of the mucin monomer.28 Thiomers are also thought to improve 
mucoadhesion by in situ cross-linking via the free thiol chain ends during the 
interpenetration of the polymer chains into the mucus, therefore anchoring the polymer 
into the mucosal layer, Figure 1.10. 
 
Figure 1.10 Representation of the interpenetration of polymer chain (purple) into the 
mucus layers, with in situ cross-linking of free thiol chain ends. Adapted from A. 
Bernkop-Schnürk et al. and J. O. Morales et al.67,71 
 
1.3. EMULSIONS 
 
An emulsion is comprised of two immiscible phases;72 one phase is dispersed within 
the other and typically stabilised by a surface active agent, commonly known as a 
surfactant. Emulsions are typically described as either oil-in-water (o/w) or water-in-
oil (w/o), which defines the dispersed and continuous phases within each example. 
Figure 1.11 shows the formation of an o/w emulsion.  
 
 
Figure 1.11 Schematic representation of the dispersion of oil (yellow) in water (blue) 
to form an oil-in-water emulsion. 
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Emulsions typically have a cloudy white appearance due to the scattering of light 
through the dispersed phase, and can be subdivided into macroemulsions, 
miniemulsions, microemulsions and nanoemulsions, due to the droplet sizes. The 
IUPAC definition of the subclasses of emulsions state that macroemulsions have 
diameters ranging from 1 to 100 μm, while miniemulsions have diameters from 50 nm 
to 1 μm and microemulsions have diameters varying between 1 to 100 nm but mainly 
in the 10 to 50 nm range.73 Nano- and microemulsions have a translucent appearance 
as droplets are less than 100 nm, which is less than the range of  the wavelengths of 
visible light (400 – 700 nm).74  Macroemulsions have droplets with larger diameters, 
therefore have an opaque appearance as they readily interact with visible light.75  
Whereas there is currently no IUPAC definition for nanoemulsions, the two terms 
miniemulsion and nanoemulsions are used interchangeably. Microemulsions and 
nanoemulsions can be separated by their thermodynamic stabilities; nanoemulsions 
are thermodynamically unstable while microemulsions are thermodynamically stable. 
Microemulsions have a lower free energy state (ΔG) than the separated phases but 
nanoemulsions have a higher free energy state.76 This is because as the droplet radius 
is decreased below 1000 nm, there is an increase in free energy once droplet size 
decreases to a minimum. However, the free energy increases again when droplet 
surface is further reduced. Nanoemulsions can be preferable due to their much lower 
surfactant content (3-10 wt %) compared to microemulsions (20 wt%).77 Typically 
nanoemulsion is the preferred terminology over microemulsions as it leads to less 
confusion as droplet diameters are quoted on the nanoscale.78  
 
1.3.1 Emulsion Instability 
 
Emulsions can be formed spontaneously if immiscible liquids are in non-equilibrium 
and the different chemical potential between phases triggers emulsification.79,80 More 
commonly however the formation of an emulsion is a non-spontaneous process with 
the need for a sufficient amount of energy to be put into the system for the dispersion 
of one phase into the other. This is thermodynamically unfavourable, with the two 
phases constantly trying to reduce their interfacial free energy by forming two separate 
layers.  
The free energy change associated with the formation of dispersed droplets can be 
modelled by the Gibbs surface free energy term (ΔGI) and the entropy of configuration 
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(ΔSconfig). At constant temperature (T) and pressure, Equation 1.1 is equal to Equation 
1.2, where there is a change in surface area (ΔA) and interfacial tension (γ). 
ΔGformation = ΔGI - TΔSconfig                       (1.1) 
              ΔGI = γΔA                        (1.2) 
Equation 1.3 is taken from the second law of thermodynamics, where γΔA >> -TΔS, 
meaning that as ΔG is positive, emulsion formation is nonspontaneous and 
thermodynamically unstable without the presence of a surfactant.81 
      ΔGformation = γΔA - TΔSconfig            (1.3) 
The Laplace pressure is the difference in pressure between the inside and outside of a 
droplet, where the pressure difference is caused by the interfacial tension (γ).  
The Young-Laplace Equation (Equation 1.4), gives the ratio of the difference between 
the pressure inside (Pin) and outside (Pout) of the droplet, where the internal pressure is 
inversely proportional to the droplet radius (r). This is a driving force for emulsion 
instability which leads to an increase in droplet size. 
                                    Pin = Pout + 2γ/r                (1.4) 
If a high amount of energy is inputted into the system a deforming force occurs which 
breaks the droplets into smaller ones if the Laplace pressure is overcome.82 
As the two phases of an emulsion drive to separate to their lowest energy state, there 
are various ways in which the emulsion can return to a two layer state. As shown in 
Figure 1.12, an emulsion can become unstable via the phenomena of creaming, 
sedimentation, flocculation and coalescence.  
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Figure 1.12 A schematic representation of the various breakdown mechanisms of an 
oil-in-water emulsion; A) Stable oil-in-water emulsion, B) Creaming, C) Flocculation, 
D) Sedimentation, E) Coalescence.83 
Creaming occurs as the dispersed phase droplets rise to the surface of the emulsion 
due to their lower density in comparison to the continuous phase.84 Creaming leads to 
an increased likelihood of droplet collision and coalescence and therefore the 
formation of larger droplets. Flocculation occurs when the droplets join together to 
form ‘bunch-like’ aggregates85 and sediment as the droplets sink to the bottom of the 
sample due to the density difference. Coalescence is the most common form of 
instability and occurs via the merging of two or more individual droplets to form a 
larger, single droplet.86 Coalesence occurs when droplets collide and the attractive 
forces between the droplets is greater than repulsive forces, leading to rupture of the 
stabilising film. This leads to the total energy of the emulsion favourably decreasing 
as the size of the dispersed phase increases and overall interfacial area decreases.87 
Ostwald ripening occurs due to the increased pressure inside smaller droplets, to 
relieve this pressure the droplets dissolve through the continuous phase until they can 
collide.88,89 
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1.4 SURFACTANTS 
 
Surfactants or emulsifiers can be classified as: polymeric, anionic, cationic, 
zwitterionic and are typically amphiphilic molecules.90 Surfactants act at the interface, 
lowering interfacial tension between the two phases and allowing for successful 
dispersion.91 Surfactants form a thin layer over the dispersed droplets causing other 
droplets to repel by steric or electrostatic repulsion and decrease coalescence. They 
can also work by increasing the viscosity of the continuous phase which maintains the 
droplet suspension.92 Figure 1.13 shows the variety in surfactant structure that can be 
used to stabilise emulsions, including; Pickering emulsifiers, linear block copolymers, 
complex polymeric surfactants, polymeric nanoparticles, small molecule surfactants 
and branched polymeric surfactants.  
 
Figure 1.13 Oil-in-water emulsion droplet stabilised by various surfactants: Pickering 
emulsifiers, linear block copolymers, complex polymeric surfactants, polymeric 
nanoparticles, small molecule surfactants and branched polymeric surfactants.93–95 
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1.4.1 Hydrophilic-Lipophilic Balance 
 
The HLB is used to describe the ratio between hydrophobic and lipophilic components 
of a surfactant. It was first described by Griffin in 1949 to detail non-ionic surfactants 
as shown in Equation 1.5, where the molecular weight of the hydrophilic portion, Mh, 
is analysed as a percentage of the molecular weight of the entire molecule, M.96 This 
gives the HLB result on an arbitrary scale of 0 - 20, where a result of 0 corresponds to 
a completely hydrophobic surfactant, while the other end of the scale 20, results in a 
completely hydrophilic surfactant. Therefore if an o/w emulsion is targeted then a 
surfactant or surfactant blend should be chosen with a high HLB value and conversely 
a w/o emulsion would require a value low on the scale, <10 for greater emulsification. 
Griffin discovered that when two non-ionic surfactants, one hydrophilic and the other 
lipophilic were mixed together in varying ratios, the blend efficiency for a particular 
surfactant went through a maximum. This corresponded to same weight percent of 
hydrophilic surfactant in the mixture, where the HLB value is a function of the 
molecular weight of the hydrophilic portion in relation to the whole molecule. 
Griffin’s method, is shown in Equation 1.5, for HLB value of a non-ionic surfactant. 
Mh = molecular weight of hydrophilic of the surfactant, M = molecular weight of 
whole surfactant. 
𝐻𝐿𝐵 =
1
5
∗  (
𝑀ℎ
𝑀
∗ 100)               (1.5)           
 
1.4.2 Small Molecule Surfactants 
 
Small molecule surfactants incorporate amphiphilic characteristics, typically as a 
hydrophobic tail group and a hydrophilic head group, which lowers the interfacial 
tensions between the two phases.97 These surfactants can be classified as either non-
ionic, ionic (anionic or cationic) or zwitterionic. One of the most commonly used 
commercially available ionic surfactants is sodium dodecyl sulphate, shown in Figure 
1.14, frequently used in detergents, and  composed of a hydrophobic alkyl chain and 
an ionic hydrophilic head group.  
 
Figure 1.14 Structure of sodium dodecyl sulphate. 
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1.4.3 Linear Polymeric Surfactants  
 
Linear polymers with amphiphilic character have also been shown to successfully 
stabilise emulsions. These polymers have clear defined hydrophobic and hydrophilic 
sections, shown in Figure 1.15. An advantage of these block copolymers is that there 
is a variety of monomers that can be used to design a purpose fit surfactant. However, 
the majority of linear polymers studied have been limited to poly(ethylene oxide) as 
the hydrophilic block and poly(propylene oxide) as the hydrophobic block.98 
 
Figure 1.15 Schematic representations of linear polymeric surfactants with 
hydrophilic (yellow) and hydrophobic (green) regions; A) AB copolymer and B) ABA 
block copolymer. 
 
1.4.4 Pickering Emulsifiers 
 
Pickering emulsions99 are stabilised by solid particles instead of surfactants, with one 
common stabiliser being silica.100 They act to reduce the interfacial tension by 
accumulating at the oil/water interface, Figure 1.16. An advantage of using a Pickering 
emulsifier is that they are highly resistant to coalescence, with the particles absorbing 
at the oil/water interface creating a steric barrier between neighbouring droplets. The 
most widely accepted theory for this behaviour is that the particles are able to 
irreversibly absorb at the interface which leads to a more efficient stabilising effect 
compare to typical surfactants.101 
 
Figure 1.16 Schematic representation of Pickering emulsion stabilised by solid 
particles (grey). 
For a solid particle to stabilise an emulsion it has to be partially wetted by each of the 
liquid phases. The wettability of Pickering emulsifiers is determined by their contact 
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angle (as measured through the water phase); if the contact angle is < 90 o particles are 
termed hydrophilic and are oil-in-water stabilisers, while a contact angle of > 90 o 
particles are more hydrophobic and act as water-in-oil stabilisers.102 In a study by 
Binks and Lumsdon it was determined that the contact angle had to be near 90 o to be 
an efficient Pickering emulsifier,103 otherwise the particles tended to remain dispersed 
in either the water or oil phase if the contact angle is too high or too low.  
 
1.4.5 Complex Polymeric Surfactants 
 
Due to their relatively simple structure, block copolymers are usually studied as 
surfactants, but the use of more complex polymer structures can vary the interaction 
at the oil/water interface over a linear copolymer. Diblock copolymers have been 
shown to form polymeric nanoparticles which absorb onto the interface in a similar 
manner as Pickering emulsifiers, leading to semi-stable emulsions, Figure 1.17 A.93 
These diblock copolymers were composed of hydrophilic poly(glycerol 
monomethacrylate) (PGMA) and hydrophobic poly(2,2,2-trifluoroethyl methacrylate) 
(PTFEMA) and nanoparticles produced by polymerisation-induced self-assembly 
(PISA). The block copolymer nanoparticles (7 % w/w) were able to stabilise n-
dodecane based macroemulsions (22 – 46 μm) by mechanical homogenisation, with 
further processing using a high pressure microfluidiser to refine the coarse 
macroemulsion reducing droplet size to sub 200 nm. Similarly, ABC triblocks of 
PGMA, poly(2-hydroxypropyl methacrylate) (PHPMA)-poly(benzyl methacrylate) 
(PBzMA) synthesised via PISA, formed worms, Figure 1.17 B.
94 These again were 
used to form dodecane based macroemulsions, however using only low-shear 
homogenisation (hand shaking), which produced macroemulsions (1 % w/w surfactant 
concentration) with droplet diameters of 115 μm.  
 
Figure 1.17 Schematic representation of A) diblock copolymer nanoparticles of 
PGMA (red), PTFEMA (black) and B) ABC triblock worms of PGMA (red), PHPMA 
(black) and PBzMA (green) as oil-in-water emulsion stabilisers. 
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Recently amphiphilic brush copolymers have been utilised as w/o emulsion stabilisers, 
which were described as a fusion of diblock copolymers. The polymer was composed 
of hydrophilic poly(ethylene oxide) (PEO) and hydrophobic poly(n-butyl acrylate) 
(PBA) side chains, allowing for arrangement at the oil/water interface due to their 
difference in solubility. It was shown that having a higher number of PEO side chains 
improved emulsification due to increased affinity for the aqueous phase, and was able 
to stabilise the emulsion at low surfactant content, 0.005 wt %.104  
 
1.4.6 Branched Polymeric Surfactants  
 
Branched polymeric surfactants have been shown to be more successful as stabilising 
groups over linear equivalents due to the increased steric bulk offered. Due to the 
branched architecture, polymers have multiple linear primary chains joined together, 
which under specific polymerisation conditions can lead to multiple anchoring points 
being available for interaction with the emulsion droplet. The interaction between 
branched polymers at the oil/water interface will be unfavourable due to the thicker 
polymer ‘film’ leading to repulsive interactions. Branched polymers also allow for 
functionality to be incorporated into their architecture due to variation of the monomer, 
chain end, or divinyl component leading to responsive emulsions. This has allowed 
for formulation of emulsions which can be effected be stimuli responsive.95  
Weaver et al., synthesised branched copolymers using poly(ethylene glycol) 
methacrylate (PEGMA) with a pH responsive 2-(dimethylamino) ethyl methacrylate 
(DEA)  component, with ethylene glycol dimethacrylate (EGDMA) used as the 
branching unit. The polymer chain end composition was varied between hydrophobic 
1-dodecanethiol (DDT), non-ionic hydrophilic 1-thioglycerol (TG) and ionic 
hydrophilic mercaptopronanoic acid (MPA). In a previous study, nanoparticles 
composed of branched copolymers of PEGMA with DEA blocks were fully 
protonated in aqueous media at pH 2, with a subsequent increase to pH 10 leading to 
DEA becoming fully deprotonated, creating compact amphiphilic nanoparticles with 
diameters of 24 nm.105 The branched analogues of these copolymers were used to 
stabilise n-dodecane macroemulsions at pH 10 at a polymeric surfactant concentration 
of 0.05 w/v %. The rate of demulsification was studied over a 12 hour period after the 
addition of acid; it was shown polymers containing hydrophobic chain ends were not 
subject to any demulsification, whereas polymers with TG and MPA chain ends were 
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subject to 30 and 50 % demulsification.  It was suggested that the high emulsion 
droplet stability was due to branched copolymer surfactant stabilising the emulsion by 
the multiple hydrophobic chain ends anchoring into the oil droplet surface.106 To 
further probe these properties the branching unit was changed for hydrophilic 
poly(ethylene glycol)dimethacrylate (PEGDMA). Unsurprisingly, the branched 
copolymers containing hydrophilic chain ends were subject to complete 
demulsification after 12 hours, while the branched copolymer with a hydrophobic 
chain end remained stable. This further confirmed the importance of hydrophobic 
chain ends in the branched polymer architecture for emulsion stability. 
 
Most recently oligo ethylene glycol(methyl ether) methacrylate (OEGMA) was 
polymerised with a hydrophobic initiating group, dodecyl α-bromoisobutyrate 
bromide (DBiB) with divinyl monomer ethylene glycol dimethacrylate (EGDMA) to 
produce a highly branched, high molecular weight amphiphilic polymer, with a 
targeted degree of polymerisation (DPn) of 90. This branched copolymeric surfactant 
was shown to stabilise a castor oil o/w nanoemulsion with droplet diameters of less 
than 250 nm, at a concentration of 5 wt % (with respect to the aqueous phase).107 These 
nanoemulsions were also highly stable against dilution, with a 4096-fold dilution in 
distilled water achievable without any loss in droplet stability. These nanoemulsions 
also had neutral charge as expected for a highly branched OEGMA containing 
polymer.  
 
1.5 RESEARCH HYPOTHESIS 
 
As mentioned a branched homopolymer of hydrophilic OEGMA has been synthesised 
using DBiB, a hydrophobic ATRP initiator, to achieve a polymeric structure with 
amphiphilic characteristics.107 The resultant amphiphilic branched polymer structure 
had the ability to stabilise an o/w emulsion while remaining water soluble. This 
investigation confirmed that solitary OEGMA was required to give the polymer the 
hydrophilicity required to produce a successful polymeric surfactant. A question arises 
whether all of the chain ends are required to be hydrophobic to successfully stabilise 
nanoemulsions; it is hypothesised that some of the hydrophobic chain ends can be 
removed whilst still maintaining their stabilising properties. Utilising a co-initiation 
technique shown previously in literature with dendritic initiators,108,109 mixed chain 
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end functionality could be incorporated and a range of polymers with varying chain 
end composition could be synthesised, see Figure 1.18.  
 
 
Figure 1.18 Reduction of hydrophobic chain ends following manipulation of starting 
materials for polymer synthesis using the co-initiation technique. 
The surfactant properties of the linear and branched homopolymers will be assessed 
by their ability to produce stable emulsions. The reduction of hydrophobic chain ends 
of the branched polymers will be investigated to determine if the oil/water interface 
can be successfully stabilised in comparison to a more classic branched polymeric 
surfactant, as shown in Figure 1.19.   
 
Figure 1.19 Arrangement of branched polymeric surfactants at the interface of the oil 
droplets with differing chain end functionality; A) All hydrophobic chain ends and B) 
Inclusion of both hydrophobic and hydrophilic chain ends.  
Synthetic aims include co-initiation of OEGMA via ATRP inclusive of both a 
hydrophilic PEG initiator and a long alkyl chain hydrophobic initiator of varying 
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molar ratios. If polymerisations and subsequent emulsifications are successful, the 
hydrophilic chain ends will be substituted for functional groups where o/w 
macroemulsions and nanoemulsions are consistent with emulsions previously 
reported. This would allow for introduction of thiol groups into the polymeric 
architecture via the discussed co-initiation strategy, creating a new thiomer based 
surfactant and functional emulsion. Through the incorporation of thiol groups there is 
potential for the emulsions to have mucoadhesive properties. 
 
1.6 RESEARCH AIMS  
 
This project will begin by investigating the role of hydrophobic chain ends in 
stabilising o/w macroemulsions and nanoemulsions, with systematic removal of 
hydrophobic stabilising groups. Firstly initiators will be synthesised to incorporate the 
functionality required and ATRP conducted to produce branched polymers, see Figure 
1.20. Co-initiation of ATRP allows the ratio of hydrophobic to hydrophilic chain ends 
can be systematically varied by altering the molar ratios of each initiator.  
 
Figure 1.20 Co-initiation of an ATRP reaction using hydrophilic (green) and 
hydrophobic (purple) initiator molecules to synthesise an amphiphilic branched 
polymeric surfactant of OEGMA (blue) with EGDMA (orange), with mixed chain end 
functionality.  
If the removal of some of the hydrophobic chain ends is successful, the stability of 
emulsions will be studied to determine the minima of hydrophobic chain ends required 
without sacrificing emulsion stability. A proof-of-concept PEG based, hydrophilic 
initiator will initially be used, followed by replacement with a functional thiol based 
initiator group. Thiol functionality will allow potential mucoadhesive character to be 
incorporated into the polymers and therefore emulsions. Mucoadhesive emulsions 
could be tailored by varying the ratio of functional initiator to hydrophobic initiator 
group in the same way as for the hydrophilic initiator molecule. Therefore, it is 
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anticipated that functional mucoadhesive particles could be formulated to exhibit 
greater adhesive effect with increased thiol content, as well as greater mucus 
penetrating character when the amount of thiol groups are vastly reduced. If material 
characterisation and functionalisation is successful, biological evaluation of these 
materials will be undertaken, including in vitro, ex vivo and in vivo testing. 
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Amphiphilic Branched Copolymers 
and Linear Homopolymers for use 
as Surfactants 
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2.1 INTRODUCTION 
 
The aim of this investigation was to synthesise a polymeric surfactant via atom-
transfer radical polymerisation (ATRP) for use in an oil-in-water (o/w) emulsion.110  
A surfactant is used to lower the surface tension between two liquids; in o/w emulsions 
this is the interface between the small volume of oil and the continuous phase of water. 
Therefore the polymer synthesised to be used as a surfactant must be amphiphilic i.e. 
have both hydrophilic and hydrophobic components to be able to stabilise the 
interface.  For an o/w emulsion the surfactant must have a large portion of hydrophilic 
properties and in comparison a small amount of hydrophobic.  ATRP allows 
functionality/hydrophilicity/hydrophobicity to be incorporated into polymeric 
structures at various points by integration of different components: initiator (chain 
end), monomer (chain) and branching unit, see Figure 2.1.   In this study a novel 
branched polymeric surfactant was synthesised which exhibited amphiphilic 
properties; a hydrophobic initiator group and a hydrophilic monomer was used.  
 
 
Figure 2.1 Representation of an amphiphilic branched copolymer with hydrophobic 
chain end (purple), hydrophilic polymer monomer, oligo (ethylene glycol) 
methacrylate (OEGMA) (blue) and branching unit, ethylene glycol dimethacrylate 
(EGDMA) (orange). 
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By incorporating a hydrophobic initiator, and a hydrophilic monomer each growing 
polymer chain had amphiphilic characteristics. Through the addition of a divinyl 
monomer, the polymeric surfactant is given a novel branched structure, with a high 
molecular weight. This branching element allows for multiple amphiphilic polymer 
chains to be joined together, giving the surfactant multiple anchoring points via the 
hydrophobic initiator groups into the oil droplets. It is hypothesised that the novel 
branched architecture does not require a co-surfactant to stabilise o/w emulsions, 
which can be typical for successful emulsion generation, due to the high molecular 
weight polymers and multiple anchoring points being able to cover to the droplet 
surface.   
2.1.1 Synthesis of Branched Copolymers by ATRP 
 
ATRP is a controlled radical polymerisation (CRP), where the atom transfer stage is 
key for the controlled nature of the polymerisation. It is a controlled polymerisation 
due to a low concentration of active species which guarantees the rate of 
polymerisation being maintained, this is done by establishing equilibrium with the 
dormant state. In ATRP the active species (R·) is generated by a reversible redox 
reaction which is catalysed by a transition metal complex (Mtn-Y/Ligand).110 The 
transition metal complex undergoes a one electron oxidation process by abstraction of 
a halogen atom from the dormant species (R-X). One successful route to controlled 
ATRP polymers and copolymers is the use of the catalytic system: copper (Cu(I)Br, 
Cu(I)Cl)) and bypyridyl (bpy) which complexes together. An initiator which is usually 
an alkyl halide (R-X)111 is used, but the synthesis of these can be designed  for 
inclusion of specific functionality into the polymer. The reversible redox reaction 
occurs with an activation rate constant (Kact) and a deactivation constant of (Kdeact) 
with the general mechanism for ATRP shown in Scheme 2.1.  
 
Scheme 2.1 General ATRP mechanism where an alkyl halide (R-X) is under 
equilibrium with the active species (R·) which can undergo propagation with the 
monomer at a rate of kp or termination at a rate of kt.  
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The rate of activation (kact) is kept low in comparison to rate of deactivation (kdeact), 
pushing the equilibrium to the left to keep the concentration of radicals low thereby 
reducing the probability of unfavourable termination reactions occurring. Due to this 
low number of propagating radical species, there is a high concentration of dormant 
chains present. Kinetic studies of the polymerisation allows monitoring of ATRP 
reactions and determination of rate; when monomer conversion is plotted against time 
on a semi-logarithmic scale and a linear increase in molecular weight with conversion 
is observed it indicates that the polymerisation obeys first order kinetics.112,113 This 
means the active species undergoes monomer addition with the propagation rate 
constant (kp) but also terminated with rate constant (kt). Termination reactions are 
unfavourable, but they are controlled due to the low concentration of the active species 
during polymerisation. 
 
Figure 2.2 Synthesis of linear polymer, where the concentration of monomer:initiator 
is varied to control the degree of polymerisation (DPn), in this example DPn  = 10.  
The formation of branched copolymers via ATRP occurs by the addition of a divinyl 
monomer which is statistically added to growing polymer chains.114 In a branched 
polymerisation, Figure 2.3, there is a statistical incorporation of divinyl and vinyl 
monomers in a ratio to give each growing primary chain less than one potential 
branching point through the pendant vinyl chain per chain.115 This ratio avoids gelation 
of the polymer at high molecular weight through in situ cross-linking which occurs if 
there is 1 or more branching points per chain. At low conversion during 
polymerisation, monomer concentration is relatively high in comparison to the 
pendant vinyl groups, so branching is limited. During this stage, the evolution of Mn 
is identical to linear polymerisations where there is a linear increase in Mn with 
monomer conversion. At intermediate conversion the number of branching points per 
chain is increased. At high conversion, the polymerisation is dominated by 
  Chapter 2 
31 
 
intermolecular coupling of the primary polymer chains by reaction of the pendant 
vinyl groups. This is more likely to occur at high conversion as there is an increased 
likelihood for reaction between pendant vinyl groups due to the low concentration of 
monomer. It is at high conversion that the large increase in Mw and Mn is observed due 
to chain growth being dominated by the intermolecular coupling.  
 
Figure 2.3 Synthesis of branched copolymers by ATRP,115 primary chain growth is 
initiated and at low conversion propagation more likely to occur with vinyl monomers. 
At intermediate conversion statistical incorporation of divinyl monomer occurs and at 
high conversion intermolecular branching of chains occurs. 
 
2.2 AMPHIPHILIC COPOLYMER SYNTHESIS 
 
2.2.1 ATRP Initiator Synthesis 
 
As discussed in Section 2.1 hydrophobic initiators were required to give the surfactant 
amphiphilic properties. To introduce hydrophobic chain ends into the branched 
copolymer structure, the  long alkyl chain ATRP initiator, dodecyl α-bromoisobutyrate 
(DBiB),  was synthesised (Scheme 2.2). The trimethylamine catalysed esterification 
reaction was conducted using 1-dodecanol and α-bromoisobutyryl bromide; the 
Et3NH
+Br- salt that formed immediately on addition of α-bromoisobutyryl bromide 
was filtered after the reaction had been left to stir for 24 hours. The purified product 
was analysed by 1H, 13C nuclear magnetic resonance spectroscopy (NMR), 
electrospray mass spectroscopy and elemental analysis. 
b = <1 w.r.t to [I] 
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Scheme 2.2 Schematic of dodecyl α-bromoisobutyrate (DBiB) synthesis. 
The 1H NMR spectrum of purified DBiB is presented in Figure 2.4A. The reaction is 
shown to be completed via a well resolved singlet peak at 1.8 ppm attributed to 
CH3CH3 (labelled e). If any unreacted starting material (α-bromoisobutyryl bromide) 
is present in the material, a secondary singlet is seen up field of this peak, therefore 
the product would require further purification. The 13C NMR spectrum confirmed the 
lack of impurities present in the sample. 
 
Figure 2.4 Nuclear magnetic resonance spectra of dodecyl α-bromoisobutyrate 
(DBiB) A) 1H NMR spectra (CDCl3, 400 MHz) and B) 
13C NMR spectra (CDCl3, 100 
MHz). 
  Chapter 2 
33 
 
2.2.2 Synthesis of Linear Homopolymers and Branched Copolymers 
 
ATRP was used to synthesise both branched and linear amphiphilic polymers.  The 
monomer polymerised was hydrophilic OEGMA, number average degree of 
polymerisation (DPn) = 4-5 ethylene glycol units, Mn = 300 g/mol). Initial studies to 
establish the polymerisation conditions targeted a linear polymeric chain as it is more 
simplistic than the branched analogue as there are fewer components. The subsequent 
branched polymerisations were only varied by the inclusion of a divinyl monomer, 
EGDMA, therefore any changes observed in molecular weight were attributed to the 
presence of a branching unit. 
 The polymerisation of OEGMA under aqueous conditions has been previously 
reported,107,116,117 with the presence of water accelerating the polymerisation of 
OEGMA. In this study the catalytic system for ATRP was CuCl:bpy  and the solvent 
mixture was isopropyl alcohol/water (IPA:H2O, 92.5:7.5 v/v) at 55 % w/v 
(monomer:solvent).  The reaction was conducted at 40 oC, the schematic is shown in 
Scheme 2.3. A DPn of 50 monomer units (DP50), was targeted for the ATRP of 
OEGMA, this followed previous research from within the Rannard research group 
where DP90 was targeted.
107 Reducing the DPn increased the weight fraction of 
hydrophobic chain end per polymer primary chain which was required for the polymer 
to be used successfully as a surfactant of o/w emulsions.  
Polymerisation reactions were monitored via 1H NMR, and the conversion determined 
via inclusion of an internal standard, anisole, to which the vinyl monomer peaks could 
be referred against.  All reactions were left to reach high conversion (target > 99 %), 
this was especially important when conducting ATRP targeting branched polymeric 
architectures. Removal of the copper-based catalytic system was performed by using 
a neutral alumina column; the polymers and copolymers were purified by precipitation 
into petroleum ether (40/60). 
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Scheme 2.3 ATRP of i) DBiB-p(OEGMA50) and the branched analogue ii)  DBiB-
p(OEGMA50-co-EGDMA0.8). 
Branched copolymers with synthesised via ATRP under the same conditions as 
described for the linear homopolymers but with the addition of a branching unit, 
ethylene glycol dimethacrylate (EGDMA). EGDMA was incorporated at an initiator 
ratio of 0.80:1.00 ([EGDMA]0 / [I]0 = 0.80) and yielded branched copolymers after 24 
hours, shown in Scheme 2.3 ii. Linear and branched polymers take the compositions 
DBiB-p(OEGMA50) and DBiBp(OEGMA50-co-EGDMA0.8) respectively.  
 
2.3 POLYMER CHARACTERISATION 
 
All polymers were characterised by gel permeation chromatography (GPC) and 1H 
NMR, GPC data is shown below in Table 2.1. Reaction conversion was determined 
via 1H NMR; a crude sample of the reaction mixture was taken and the disappearance 
of vinyl monomer peaks against an internal standard, anisole, was measured to 
calculate conversion of monomer to polymer. Branched polymerisations were left to 
reach > 99 % conversion to allow for maximum branching between chains through the 
incorporation of divinyl monomer.  
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Table 2.1 GPC data for linear and branched p(OEGMA).  
 1H NMRb  GPCa  
Target Polymer 
Composition 
Conversion  
(%) 
Theoretical 
Mn 
Mw 
(g/mol) 
Mn 
(g/mol) 
Ɖ 
(Mw/Mn) 
DP
n 
DBiB-p(OEGMA50) 99 15 353 39 760 30 750 1.2 101 
       
DBiB-p(OEGMA50-
co-EGDMA0.8) 
>99% - 235 700 57 600 4.09 - 
aDetermined using GPC (DMF/0.01 M LiBr Eluent 60oC) bDetermined using 1H NMR 
(CDCl3,400 MHz) 
 
Figure 2.5 A and B compares the refractive index (RI) chromatograms of the linear 
and branched p(OEGMA50), and the increase in molecular weight from the addition 
of branching unit EGDMA is shown. Branched polymers have a higher weight average 
molecular weight (Mw), and elute at a much lower retention volume in comparison to 
the linear polymer. Branched polymers have a broad distribution of polymer due to 
the statistical incorporation of EGDMA and subsequent branching between growing 
polymer chains through the pendant vinyl group on the branching unit. A broad 
distribution is therefore observed as the primary chains joined together. The right angle 
light scattering (RALS) detector responds to a polymer chain (or grouped chains) 
particularly those with a high molecular weight which scatter light based on the r6 
dependence, therefore a small number of large molecules will dominate the scattering 
from any broad distribution polymer solution. In contrast the RI response is dependent 
on the concentration of the individual separated fractions of the polymer sample. The 
RALS chromatographs, Figure 2.6 B confirm the presence of high Mw branched 
material, with an intense scattering signal seen at low elution volumes that correspond 
to the low concentrations of high molecular weight material seen in the RI analysis. 
This is in contrast to the linear polymer RALS trace, which is scattering at a higher 
retention volume due to the lack of high Mw species.  
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Figure 2.5 GPC chromatograms of DBiB-p(OEGMA50) (black) and 
DBiB-p(OEGMA50-co-EGDMA0.8) (red) A) RI and B) RALS. 
The RI trace of the DBiB-p(OEGMA50) is typical of a linear polymerisation, eluting 
at a higher retention volume due to the presence of low molecular weight species, 
however there is a slight shoulder to the higher Mw side of the trace. This could be due 
to coupling of the chain ends at high conversion, which correlates with the Mw data 
for the linear polymer being higher than theoretically expected.  
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2.3.1 Linear Polymer Kinetics 
 
To investigate whether a polymerisation is controlled, an experiment to investigate the 
kinetics of the reaction was conducted to determine the rate of reaction.  Samples were 
taken at defined time points throughout the polymerisation and analysed via 1H NMR 
to determine whether the polymerisation follows first order kinetics with respect to 
monomer concentration.  
As discussed in Section 2.1.1, the rate of polymerisation is dependent on the 
concentration of active species throughout the reaction, this is controlled by the 
equilibrium constant (Keq = kact / kdeact) of the redox reaction which generates the active 
species.118 If Keq is small then the active species concentration will be low and the rate 
of polymerisation slow,119 conversely if Keq is high the concentration of the active 
species will be high which will result in a faster rate of polymerisation. However, an 
increase in active species concentration also increases the probability of unfavourable 
reactions occurring such as chain termination, which will impact the dispersity of the 
polymer chains. 
The synthesis of a linear p(OEGMA50) initiated by DBiB was monitored to determine 
whether the polymerisation was controlled and followed first order kinetics with 
respect to the monomer concentration. The conversion of OEGMA was monitored by 
1H NMR spectroscopy; the vinyl peaks at 6.13 and 5.58 ppm decreased throughout the 
reaction indicating that the monomer was being consumed, Figure 2.7. The 
polymerisation was sampled every hour for 7 hours and the ratio between OEGMA 
vinyl peaks and O-CH3 p(OEGMA) pendant chain at 3.4 ppm used to determine 
conversion, as shown in Figure 2.6.  
The kinetic plot of DBiB-p(OEGMA50) is shown in Figure 2.7, and this analysis 
confirms high conversion was reached between 4–7 hours and that the linear 
polymerisation followed first order kinetics as shown by semi-logarithmic plot 
obtained. This provides confidence for the copolymerisation of OEGMA to form a 
branched copolymer with divinyl monomer EGDMA. 
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Figure 2.6 1H NMR spectra (CDCl3, 400 MHz) for DBiB-p(OEGMA50) sampled over 
7 hours, monitoring decrease of monomer OEGMA vinyl peaks at 6.13 and 5.58 ppm. 
 
Figure 2.7 Kinetic plot of A) DBiB-p(OEGMA50) determined by 
1H NMR, sampled 
every hour for t = 7.  
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 2.4 EMULSION FORMATION AND CHARACTERISATION 
 
Following successful synthesis of linear and branched copolymers, these polymers 
were tested for their ability to successfully stabilise emulsions as surfactant molecules. 
Macroemulsions were generated via mechanical shearing, using an overhead shear 
homogeniser (Ultra-Turrax 25, IKA). Dodecane was chosen as the oil phase due to its 
high compatibility with the chosen hydrophobic chain end functionality (DBiB). 
Aqueous polymer solutions were prepared at concentrations of 5 mg/mL and were 
homogenised with dodecane in a 1:1 ratio for 2 minutes at 24,000 rpm as per the 
previously reported method and left overnight to equilibrate.107 Quantitative analysis 
was performed by laser diffraction spectroscopy using distilled water as dispersant and 
measurements taken at 20 oC.  
 
2.4.1 Visual Characterisation of Macroemulsions 
 
Successfully stabilised macroemulsions were characteristically white opaque 
solutions. Due to the lower oil density of dodecane compared to water, creaming of 
the oil-in-water emulsion was observed however no oil separation was apparent after 
40 days storage at ambient temperature, as shown in Figure 2.8. Linear polymers 
showed no ability to stabilise o/w emulsions, with demulsification occurring after 3 
days, as shown in Figure 2.8 D presumably due to the rapid desorption of linear 
polymer chains from the oil/water interface, inducing coalescence of neighbouring 
droplets. This is in agreement with previously published research within the group, for 
branched DBiB initiated OEGMA copolymers and linear polymers with a higher 
target DPn = 90.
107 
 
Figure 2.8 Visual characterisation of branched DBiB-p(OEGMA50-co-EGDMA0.8) (5 
mg/mL) stabilised macroemulsion with dodecane as oil phase stored at ambient 
temperature for A) 24 hrs and B) 40 days, and DBiB-p(OEGMA50) (5 mg/mL) 
stabilised macroemulsions after C) 24 hrs and D) 3 days. 
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2.4.2 Laser Diffraction 
 
Analysis of o/w macroemulsions was performed using laser diffraction using 
Mastersizer 2000 (Malvern), quoting the D[4,3] (De Brouckere Mean Diameter) value, 
Equation 2.1. D[4,3] is the volume average mean of droplets present in emulsion, which 
does not rely on knowing the number of droplets present. The D[4,3] is widely quoted 
as it reflects the size of the particles that make up the bulk of the sample volume, and 
is more appropriate then the surface area moment mean (D[3,2]) in this study, which is 
more sensitive to the fine particles present.120 The laser diffraction technique averages 
the various droplet dimensions, to produce a size distribution. The particle size 
measurement includes percentiles, where D50 is the median, therefore the diameter 
where half the population lies below this value. Whereas D10 represents the value at 
which 10 % of the population lie below and D90 represents the diameter at which 
90 % of the population fall below. 
             D[4,3] = Ʃd4/ Ʃd3       (2.1) 
Dodecane based macroemulsion stabilised with DBiB-p(OEGMA50-co-EGDMA0.8) a 
branched copolymer surfactant was measured via laser diffraction, with water as the 
dispersant. Figure 2.9 shows a typical graphical size distribution of the DBiB-
p(OEGMA50-co-EGDMA0.8) stabilised dodecane macroemulsion, plotting volume 
percent against particle diameter (D[4,3]). The D[4,3] analysis determined the average 
droplet diameter to be 11.9 µm.  
 
Figure 2.9 Particle size distribution curve of dodecane macroemulsion stabilised with 
DBiB-p(OEGMA50-co-EGDMA0.8) as polymeric surfactant after 24 hrs of storage at 
ambient temperature. 
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The impact of polymer concentration in the aqueous phase of the emulsion was studied 
to assess the ability of the branched copolymer surfactant, DBiB-p(OEGMA50-co-
EGDMA0.8), used to stabilise a dodecane based o/w emulsion.  Aqueous polymer 
solutions of DBiB-p(OEGMA50-co-EGDMA0.8) at 1, 3 and 5 mg/mL were generated 
for use within the emulsions. After homogenisation, emulsions were stored at ambient 
temperature, and samples taken at regular intervals over a 40 day time period for laser 
diffraction analysis.  
As shown in Figure 2.10, emulsions with the lowest surfactant concentration of 1 
mg/mL produced oil droplets which had increased in size from 13.8 µm at 1 day to 23 
µm at 5 days.  Whereas when higher concentrations of 3 and 5 mg/mL branched 
copolymer surfactant had been used there was relatively little variation in droplet sizes 
over the 30 day time period with D[4,3] values of 12.7 – 14.2 µm and 11.9 – 13.4 µm 
respectively. After 40 days however, the final droplet diameters of the 3 mg/mL 
branched copolymer surfactant concentration rose to 34 µm whilst 5 mg/mL still 
showed consistent D[4,3] values of 13.5 µm. The sharp rise in droplet diameter in the 
emulsion produced using a surfactant concentration of 3 mg/mL could be indicative 
of droplet coalescence within the emulsion layer, therefore a lower polymer 
concentration could potentially not provide a great enough stabilising film at the 
oil/water interface.  
It was concluded from this study that emulsions stabilised by a branched copolymer 
surfactant concentration of 5 mg/mL, yielded the smallest droplet diameter with 
prolonged levels of stability and least variation in droplet size, therefore all further 
emulsions in this work were generated using a 5 mg/mL polymeric surfactant 
concentration in the aqueous phase. 
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Figure 2.10 Concentration study of polymeric surfactant DBiB-p(OEGMA50-co-
EGDMA0.8) used to stabilise dodecane macroemulsions. Concentrations of 1, 3 and 5 
mg/mL DBiB-p(OEGMA50-co-EGDMA0.8) with respect to aqueous phase were 
generated and analysed by laser diffraction analysis over 40 days. Error bars = 
standard deviation, n= 3. 
2.4.3 Optical Microscopy Analysis  
 
An additional analytical technique of optical microscopy (Leica, DM4 B) was used to 
visually assess the droplet shape as well as to study the diameter, D[1,0]. Optical 
microscopy imaging is a good secondary analytical technique as it allows for 
visualisation of the oil droplet geometry as well as calculating the diameter of a vast 
amount of droplet diameters in a sample of the emulsion. Macroemulsions were 
imaged after 1 day and 11 months of storage at ambient temperature. Laser diffraction 
measurements were also taken at the same time points for comparison of analytical 
techniques.  
O/w macroemulsions were formulated in a 1:1 ratio of dodecane:aqueous polymer 
solution (5 mg/mL) and homogenised for 2 minutes at 24,000 rpm as described in 
Section 2.4. Concentrated emulsion was placed on a glass slide and viewed at 20x 
zoom magnification and imaged using a Leica DM4, Figure 2.12. 
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Figure 2.11 Optical microscopy image of a dodecane emulsion stabilised by DBiB-
p(OEGMA50-co-EGDMA0.8) after A) 1 day and B) 11 months of storage at ambient 
temperature. 20x zoom magnification, scale bar = 100 µm. 
A macroemulsion stabilised by DBiB-p(OEGMA50-co-EGDMA0.8) was comprised of 
spherical droplets, with clearly defined boundaries. Figure 2.11 shows that the 
macroemulsion is densely packed with individual well-defined oil droplets, with an 
intact stabilising film at the interface between droplets.  From optical microscopy 
imaging, a processing software (FIJI V 1.51n) was used to highlight individual droplet 
boundaries and calculate a circumference value based on the scaling. The diameters 
of individual droplets were then able to be calculated from the circumference, where 
the frequency of droplet diameters was determined in a range of 1 – 20 μm.  A 
histogram frequency distribution was plotted as it allows for an accurate representation 
of the distribution of the droplet diameters, assessing the frequency distribution as well 
as the cumulative frequency (%). A histogram of the 2-dimensional droplet diameters 
was able to be produced, as shown in Figure 2.12. 
 
 
 
 
 
 
 
 
 
  Chapter 2 
44 
 
 
Figure 2.12 Histogram of dodecane macroemulsion stabilised with polymeric 
surfactant DBiB-p(OEGMA50-co-EGDMA0.8) at 5 mg/mL comparing size (diameter) 
after A) 1 day and B) 11 months storage at ambient temperature.  
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From this analysis of DBiB-p(OEGMA50-co-EGDMA0.8) stabilised dodecane 
macroemulsion droplets after 24 hours of equilibration, Figure 2.12 A, it was 
determined that the greatest droplet frequency was for droplet diameters over 20 µm, 
with over 275 droplets, 17 % analysed in this range. However, over 80 % of the 
droplets analysed were under 20 µm, so for this sample, droplet diameters measured 
by microscopy would appear to be much more polydisperse than indicated by the 
D[4,3]. The histogram of the sample stored for 11 months, Figure 2.12 B, showed that 
the frequency of oil droplets was greatest at 9 µm with 273 droplets in this range, 
which equates to 52 % of the total population. Although 90 % of particles present were 
under 15 µm in comparison to the D[4.3] results after 40 days (13 µm) . Therefore the 
results after 11 months of storage of emulsion at ambient temperature correlate with 
that of D[4,3] measured via laser diffraction, this shows that it is representative of  the 
droplet volume which make up the bulk of the emulsion.   
 
2.4.4 Macroemulsion Dilution Studies  
 
Conventional surfactant-stabilised emulsions are subject to demulsification if they are 
diluted below the critical micelle concentration (CMC); the concentration above which 
micelles form and if additional surfactants are added also form micelles. However 
Pickering emulsions as discussed in Chapter 1 Section 1.6.3. are dilution stable due to 
the near-irreversible adsorption of particles to the droplet surface. It was hypothesised 
that the branched copolymer surfactants act somewhere in between a traditional 
surfactant and a Pickering emulsion due to the multiple chain ends which anchor one 
polymer to the surface of the droplet. The droplet stability of the branched copolymer 
stabilised emulsions was studied by diluting concentrated macroemulsions over a 
dilution range in distilled water. The diameter of these droplets was measured via 
optical microscopy so that the droplet geometry could easily be visualised, Figure 2.13 
A-D. 
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Figure 2.13 Optical microscopy images of DBiBp(OEGMA50-co-EGDMA0.8) 
stabilised dodecane macroemulsion, over serial dilutions in distilled water; A) 50 v/v 
%, B) 25 v/v %, C) 12.5 v/v % and D) 6.25 v/v %, 20 x magnification, scale bar = 100 
µm. E) droplet diameters  determined by FIJI (V 1.51n) over dilution range of 50 – 
1.56 v/v % in distilled water, error bars = standard deviations. 
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As shown via optical microscopy imaging, through serial dilution of a concentrated 
sample, emulsions remain stable to the increased volume of the continuous phase 
retaining their spherical geometry with good definition of individual stabilised 
droplets. The average diameter is shown in Figure 2.13 E, with macroemulsions 
maintaining a consistent average droplet diameter over a dilution range of 
50 - 1.56 v/v %.  
2.5 AMPHIPHILIC BRANCHED COPOLYMER STABILISED 
NANOEMULSIONS 
 
Following on from previously published work, nanoemulsions were generated 
utilising a solvent evaporation method, shown in Figure 2.14, homogenisation was 
conducted using an over-head shear homogeniser.107 Nanoemulsions were generated 
in a 1:1 ratio of oil:aqueous polymer solution, where the oil phase was a mixture of 
volatile and non-volatile oils, ethyl acetate and castor oil. Varying the ratio of the two 
oils altered the final nanoemulsion droplet diameter due to the removal of the volatile 
oil phase i.e. the higher the proportion of volatile oil the smaller the resulting emulsion 
droplet.  
 
Figure 2.14 General representation of nanoemulsion generation using solvent 
evaporation method; A – B) 1:1 Aqueous polymer solution (5 wt %) and oil phase 
composed of volatile and non-volatile oil is homogenised, B-C) emulsion is left 
overnight for full evaporation of the volatile oil, enabling the droplets to reduce to the 
nanoscale.  
In this study, the ability to tailor the size of nanoemulsions was investigated by varying 
the concentration of volatile co-solvent to non-volatile oil in ratios of: 50:50, 60:40, 
70:30, 80:20, 90:10 and 99:1. The branched copolymer concentration was maintained 
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at 5 wt % throughout. Castor oil, Figure 2.15 A, was selected as the non-volatile oil 
phase for nanoemulsion generation due to it being a naturally derived oil and highly 
biocompatible.  
Castor oil is a vegetable oil derivative which is obtained from the seeds of the plant 
Ricinus communis.121 It is a triglyceride in which approximately 90 % of fatty acid 
chains are ricinoleic acid, shown in Figure 2.15 B and the other 10 % consists of: oleic 
acid (~ 4 %), linoleic acid (~3 %), α-linoleic acid (~ 0.75 %), stearic acid (~ 0.75 %), 
palmitic acid (~ 0.75 %), dihydrooxystearic acid (~ 0.4 %) and others (~ 0.35 %). The 
medical value of castor oil can be traced back to ancient years, where it was commonly 
used as a laxative.122,123 In previously published work, castor oil was shown to be the 
oil of choice for the loading of anti-retroviral drugs as well as being a constituent of a 
non-toxic nanoemulsion formulation which was dosed in vitro to Caco-2 cells.107 
 
Figure 2.15 Structure of A) castor oil and B) ricinoleic acid the main constituent of 
castor oil. 
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2.5.1 Dynamic Light Scattering  
 
Following generation of the nanoemulsions via the homogenisation and solvent 
evaporation method dynamic light scattering (DLS) was used to characterise 
nanoemulsions.  DLS has an accuracy of up to 1 µm, while the laser diffraction 
Mastersizer values can be deemed accurate from 1 µm upwards. DLS calculates 
particle size by using the correlation between Brownian motion of particle and its 
hydrodynamic diameter. The software uses an autocorrelation function to correlate 
scattering over time which can be used to calculate particle size. The correlation will 
be high over a short period of time due to small movement of the particle, while over 
a long period of time correlation will be low due to the Brownian movement of the 
particle. This method of cumulants analysis is then used to calculate the z-average 
diameter (Dz). The Dz is calculated from the translational diffusion coefficient by using 
the Stokes-Einstein equation, Equation 2.2) where Dt is the intensity weighted average 
translation diffusion calculated by the method of cumulants analysis, k is Boltzmann’s 
constant, T is the absolute temperature, η is viscosity. 
 
                Dz  = kT/ 3πηDt                      (2.2) 
The polydispersity index (PdI) of the sample measures the size of distribution and is 
also calculated using the method of cumulants. DLS measurements were performed at 
a 1 % concentration of nanoemulsion in water, as consistent with published analysis. 
 
2.5.2 Tailoring of Nanoemulsion Droplet Diameter    
 
Aqueous polymer solutions were prepared at a 5 wt% concentration and solubilised in 
water overnight. O/w nanoemulsions were generated by over-head shear 
homogenisation of a 1:1 ratio of oil:aqueous polymer solution, where the oil phase 
was a mixture of volatile solvent to non-volatile oil. The oil phase was a mixture of 
ethyl acetate and castor oil, and ratios of volatile to non-volatile oil were varied 
between: 50:50, 60:40, 70:30, 80:20, 90:10 and 99:1. Emulsions were left at ambient 
temperature overnight following homogenisation, allowing for full removal of volatile 
co-solvent by evaporation which was monitored gravimetrically. The ratio of oil to co-
solvent was varied which allowed for systematic variation of the nanoemulsion droplet 
size, yielding a droplet range from 1044 – 203 nm, shown in Table 2.2.   
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Table 2.2 DLS characterisation of DBiBp(OEGMA50-co-EGDMA0.8) stabilised 
nanoemulsion with varied ratios of ethyl acetate:castor oil as volatile:non-volatile oil 
phase. 
Polymer Ethyl 
acetate:castor 
oil Ratio 
Dz 
 (nm) 
Dn 
(nm) 
PdI 
DBiBp(OEGMA50-
co-EGDMA0.8) 
50:50 1055 614 0.37 
60:40 689 544 0.21 
70:30 520 427 0.19 
80:20 470 395 0.15 
90:10 351 305 0.18 
99:1 203 177 0.06 
     
Increased volume of volatile oil (ethyl acetate) in the nanoemulsion preparation not 
only results in the droplet diameter being systematically reduced, but also the 
nanoemulsions becoming more monodisperse which is indicated by reduced value of 
PdI from 0.37 – 0.06, Figure 2.16.  
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Figure 2.16 DLS analysis of DBiB-p(OEGMA50-co-EGDMA0.8) stabilised 
nanoemulsions generated with ratios of ethyl acetate:castor oil at: A) 50:50, B) 60:40, 
C) 70:30, D) 80:20, E) 90:10 and F) 99:1. 
 
Figure 2.17 Dz (nm) of tailored nanoemulsions stabilised with DBiB-p(OEGMA50-
co-EGDMA0.8), showing the decrease in droplet size with increased volume of co-
solvent. Voltaile oil:non-volatile oil ratios of ethyl acetate:castor oil at 50:50 – 99:1 
were used. 
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2.6 CONCLUSIONS 
 
This study aimed to replicate previously published work using the surfactant DBiB-
p(OEGMA50-co-EGDMA0.8)  compared to DBiB-p(OEGMA90-co-EGDMA0.95)
107 
Protocols and procedures were established for a successful and controlled polymer 
synthesis where an understanding of how polymer synthesis could be manipulated to 
vary the polymeric architecture was vital to understanding how surfactant 
functionality could be varied.  
A hydrophobic ATRP initiator, DBiB, was synthesised via a successful 
trimethylamine catalysed esterification reaction and used in polymerisations of the 
hydrophilic OEGMA monomer which generated amphiphilic polymers.   Linear and 
branched polymers, DBiB-p(OEGMA50) and DBiB-p(OEGMA50-co-EGDMA0.8) 
were successfully polymerised using ATRP and well defined using NMR and GPC 
analytical techniques. The linear polymer was unable to successfully stabilise either a 
macroemulsions or nanoemulsion whilst the branched polymeric architecture was able 
to act as a single emulsifier and produce highly stable emulsions over sustained time 
periods. The high molecular weight branched copolymer contained multiple  
hydrophobic chain ends which act as stabilisers as they anchor into the oil and hold 
the extending hydrophilic polymer at the interface at the droplet surface. Which 
resulted in the branched copolymer surfactant having characteristics which lie 
somewhere between the characteristic behaviour of a classical amphiphilic surfactant 
and a Pickering emulsifier.  
The impact of polymer concentration in the aqueous phase of the emulsion was studied 
to assess the ability of the branched copolymer surfactant, DBiB-p(OEGMA50-co-
EGDMA0.8).  A dodecane based o/w emulsion was generated at 1, 3 and 5 mg/mL 
surfactant concentration in the aqueous phase and studied over a 40 day time period. 
It was concluded that emulsions stabilised by 5 mg/mL polymeric surfactant yielded 
the smallest droplet diameter with prolonged levels of stability and least variation in 
droplet size, therefore all further emulsions throughout this work will be generated 
using a 5 mg/mL polymeric surfactant concentration in the aqueous phase. 
Droplet stability was tested through serial dilution of a dodecane based, DBiB-
p(OEGMA50-co-EGDMA0.8) stabilised macroemulsion.  The diameters of the 
emulsion droplets, PdI and optical microscopy to investigate droplet structure were 
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used to determine emulsion stability over a dilution range in water of 50 – 1.56 v/v %. 
It was found that the diameters of the emulsion droplets remain stable to the increased 
volume of the continuous phase and retained their spherical geometry with good 
definition of individual stabilised droplets throughout the entire dilution range. 
Finally the tailoring of size nanoemulsion droplet was studied by varying the 
concentration of volatile co-solvent to non-volatile oil in ratios of: 50:50, 60:40, 70:30, 
80:20, 90:10 and 99:1. Increased volume of volatile oil (ethyl acetate) in the 
nanoemulsion preparation resulted in the droplet diameter being systematically 
reduced and the nanoemulsions becoming more monodisperse.  This ability to  control 
the size of the emulsion droplet will allow further studies to be conducted at specific 
droplet sizes and to determine if size of the droplet contributes to any affects observed. 
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Use of Co-Initiated Branched 
Copolymers as Surfactants 
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3.1. INTRODUCTION 
 
The aim of this investigation was to include a hydrophilic co-initiator into the synthesis 
of amphiphilic branched copolymers and systematically reduce the number of 
hydrophobic chain ends by varying the molar ratio of two initiators DBiB and 
poly(ethylene glycol) 2-bromoisobutyrate (PBiB). It is unclear how many 
hydrophobic chain ends are required for efficient surfactant behaviour, therefore 
identification of the mole percent of hydrophobic chain ends required to form stable 
macroemulsions and nanoemulsions will be determined. This will also provide 
mechanistic information and options for further copolymer design modifications. Co-
initiation is a unique option available to branched copolymerisations and allows chain 
end functionality within the resulting branched copolymers to be controlled by varying 
the molar ratio of initiating groups, see Figure 3.1. This synthetic method for highly 
branched polymers was chosen as previous work in the research group has shown co-
initiation leading to branched copolymers with multi-functional chain ends, for 
example when mixing dendritic and non-dendritic initiator groups.124,125  
In Chapter 2, highly branched amphiphilic polymers were used to successfully 
stabilise both macroemulsions and nanoemulsions as a single emulsifier; all chain ends 
were hydrophobic and the polymer core was hydrophilic. It was hypothesised the 
number of hydrophobic chain ends could be significantly reduced without impacting 
the ability of the branched copolymer to act as a successful single surfactant producing 
droplet diameters similar to those previously seen when using DBiB-p(OEGMA50-co-
EGDMA0.8) as the surfactant. In this study PBiB (~750 g/mol) will be used to act as 
the hydrophilic initiator for model studies; replacing the dodecyl-derived initiator 
systematically to allow for detailed study.  
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Figure 3.1 Schematic representation of a branched copolymeric surfactant, co-
initiated with hydrophilic (green) and hydrophobic (purple) initiator molecules to vary 
the amphiphilic nature of the copolymer. 
Systematic variation of the molar ratio of PBiB:DBiB within the reaction from 0 to 1, 
leads to a theoretical decrease in the number of hydrophobic dodecyl chain ends 
present in the branched material, Figure 3.2. Studies of the resulting copolymers’ 
ability to act as surfactants will be conducted using detailed laser diffraction 
(Mastersizer) for macroemulsions and dynamic light scattering (zetasizer) 
nanoemulsions. Larger emulsions will also be studied using optical microscopy 
analysis to investigate the impact of reducing the number of hydrophobic chain ends 
on the structure of the droplet. It is hypothesised that a critical number of chain ends 
can be determined, at which polymeric surfactants do not forfeit emulsion stability at 
both the macroscale and nanoscale but allow the potential placement of functionality.  
  
 
 
Figure 3.2 Synthesis of linear polymers and branched copolymers using a co-initiation strategy:  OEGMA (blue) based polymers is co-
initiated by initiators derived from DBiB (purple) and PBiB (green) groups and branched when copolymerised with EGDMA (orange) to 
generate copolymers with mixed chain end functionalities.  
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3.2 SYNTHESIS OF OEGMA BASED POLYMERIC 
SURFACTANTS USING CO-INTIATORS 
 
3.2.1 Synthesis of Poly(ethylene glycol) methyl ether 2-bromoisobutyrate 
 
A hydrophilic ATRP macroinitiator, PBiB, was synthesised as shown in Scheme 3.1, 
via a trimethylamine catalysed esterification of poly(ethylene glycol) with 
commercially available α-bromoisobutyryl bromide; Et3NH+Br- salt formed 
immediately on addition of α-bromoisobutyryl bromide. The reaction was left for 24 
hours and the precipitate was removed by filtration, followed by solvent removal in 
vacuo and precipitation of the resulting crude product twice from acetone into 
petroleum ether (30 – 40 oC) to give the purified product. A yellow oil was isolated 
and the purified product was fully characterised by NMR (1H and 13C), shown in 
Figure 3.3 and elemental analysis, see Experimental 7.4.2, all of which were in 
agreement with the desired product. 
 
Scheme 3.1 Synthesis of poly(ethylene glycol) methyl ether 2-bromoisobutyrate 
initiator (PBiB). 
The chain-length of the PEG initiator after purification was confirmed by 1H NMR via 
integration of the multiplet peak at 3.6 ppm assigned to (-O-CH2CH2-), and the singlet 
at approximately 3.3 ppm corresponding to the monomethoxy chain end; as shown in 
the structure assignment, Figure 3.3 A, the number of repeat units in the purified 
initiator was able to be determined as n = 15. Confirmation of this determination is 
also possible through analysis of the protons g (Figure 3.3A) which also leads to a 
calculation of 15 repeat units within the final macroinitiator. The 13C NMR confirmed 
the structure and the lack of impurities within the sample (Figure 3.3B). 
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Figure 3.3 NMR spectra of purified PBiB A) 1H NMR spectrum (D2O, 400 MHz) and 
B) 13C NMR spectrum (D2O, 100 MHz). 
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3.2.2 Synthesis and Characterisation of Linear and Branched Copolymers 
 
3.2.2.1 Kinetic Evaluation of PBiB Initiated and Co-Initiated ATRP of 
OEGMA-derived linear polymers 
 
The synthesis of linear polymers initiated by PBiB or a mixture of DBiB:PBiB in a 
1:1 ratio was investigated to determine whether the polymerisations followed first 
order kinetics with respect to the monomer concentration and whether significant 
differences in initiator efficiency would potentially prevent accurate incorporation into 
the targeted co-initiated branched copolymers.  
ATRP was used to synthesise linear polymers of the commercially available 
hydrophilic monomer, OEGMA, (DPn = 4-5 ethylene glycol units, Mn = 300 g/mol) 
using a 1:2 ratio of CuCl:bpy (with respect to [I]) catalytic system and targeting DPn 
= 50; a mixed IPA/water (92.5/7.5 v/v) solvent was used and polymerisations were 
conducted at 55 % w/v (monomer:solvent) and 40 °C. The development of Mn 
compared to monomer conversion was evaluated by triple-detection GPC and 
OEGMA conversion was monitored by 1H NMR spectroscopy; the decreasing vinyl 
peaks at 6.13 and 5.58 ppm were compared to the CH3-O- chain end of the OEGMA 
pendant chain at 3.4 ppm to determine conversion, as shown in Figure 3.4A. Linear 
polymerisations were sampled every hour for 7 hours for polymerisations either 
initiated by PBiB (forming PBiB-p(OEGMA50)) or co-initiated using a 50:50 
DBiB:PBiB molar ratio (forming a 1:1 mixture of DBiB-p(OEGMA50) and PBiB-
p(OEGMA50)) in the reaction. As observed by 
1H NMR, Figure 3.4 A, the OEGMA 
monomer was completely consumed within 6 hrs for the formation of PBiB-
p(OEGMA50) and within 5 hours for the simultaneous formation of DBiB-
p(OEGMA50) and PBiB-p(OEGMA50)), Figure 3.4 B. The slightly faster reaction 
suggests a small difference in initiation rate for the two initiators but full conversion 
of monomer suggests that this may not present a significant problem in the formation 
of branched copolymers by co-initiation which will combine the resulting polymers 
into mixed copolymer structures. 
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Figure 3.4 1H NMR spectra (CDCl3, 400 MHz) for the ATRP synthesis of A) PBiB-
p(OEGMA50) and B) DBiB-p(OEGMA50) and PBiB-p(OEGMA50) using a co-
initiated simultaneous polymerisation using a 50:50 DBiB:PBiB molar ratio. The loss 
of monomer OEGMA vinyl peaks at 6.13 and 5.58 ppm was monitored for 6-7 hours 
and reactions conducted in an IPA/water (92.5/7.5 v/v) mixed solvent at 55 % w/v 
(monomer:solvent) and 40 °C 
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The kinetics of the different polymerisations was studied to confirm the similarities of 
the two polymerisations, Figure 3.5. This analysis confirms high conversion was 
reached between 4 – 7 hours within each reaction and that the linear polymerisations 
followed first order kinetics as shown by semi-logarithmic plot obtained, whether 
using one or a mixture of two initiators; this provides confidence for the co-initiated 
copolymerisation of OEGMA to form the branched copolymers with varying chain 
end compositions described in Figure 3.2. 
  
Figure 3.5 Kinetic studies for the linear polymerisation of A) PBiB-p(OEGMA50) and 
B) simultaneous formation of DBiB-p(OEGMA50) and PBiB-p(OEGMA50) 
determined by 1H NMR, sampled every hour for 6 - 7 hours.  
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3.2.2.2 Branched Copolymer Synthesis 
 
As shown in Chapter 2, Section 2.2.2, addition of the divinyl monomer EGDMA to a 
linear ATRP forms branched copolymers; an [EGDMA]0/ [I]0 ratio of 0.8:1 was 
therefore incorporated into the polymerisations described in Section 3.2.2.1 to yield 
branched copolymers after an extended reaction time of 24 hrs, see Scheme 3.2. All 
polymerisations were monitored using 1H NMR spectroscopy (Appendix A5) to allow 
analysis of vinyl functionality conversion relative to an internal standard, anisole, and 
all reactions achieved > 99 % conversion. Removal of copper was performed via a 
neutral alumina column and all polymers were purified by precipitation into cold 
petroleum ether (40/60). 
 
Scheme 3.2 Co-initiated branched polymerisation of OEGMA and EGDMA with 
varying ratios of DBiB(x):PBiB(y). The idealised structure of the branched copolymer 
shows three conjoined chains, however larger numbers of chains are incorporated in 
the disperse copolymer sample. 
In this series of co-initiated copolymerisations, the DBiB:PBiB molar ratio  was varied 
systematically from 1:0 through to 0:1, so the final polymer composition can be 
generally described as DBiBxPBiBy-p(OEGMA50-co-EGDMA0.8) where x + y = 1, 
see Figure 3.6. 
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Figure 3.6 Cartoon representation (showing 4 conjoined chains) of the systematic 
change of DBiB:PBiB chain ends derived from varying initiator mole ratios leading 
to varied hydrophobic/hydrophilic chain end compositions. 
The hydrophilic monomer OEGMA was polymerised with DBiB:PBiB in ratios of 
0.9:0.1, 0.75:0.25, 0.5:0.5, 0.25:0.75 and 0.1:0.9, to give a wide range of chain end 
functionality within this library of copolymers. The branched and linear 
homopolymers of OEGMA using the single initiators DBiB or PBiB were also 
synthesised as comparators. 
3.2.2.3 Linear Polymer and Branched Copolymer Characterisation  
 
All polymers and copolymers were characterised by GPC and 1H NMR; the data are 
presented below in Table 3.1 with data from Chapter 2 of DBiB-p(OEGMA50) and 
DBiB-p(OEGMA50-co-EGDMA0.8) included for ease of comparison with copolymers 
synthesised using mixed initiation. 
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Table 3.1 1H NMR and GPC data for linear and branched p(OEGMA).  
 1H NMRb GPCa 
Target Polymer 
Composition 
Conversion  
(%) 
Theoretic
al Mn 
Mw 
(g/mol) 
Mn 
(g/mol) 
Ɖ 
(Mw/Mn) 
DBiB-p(OEGMA50) 
PBiB-p(OEGMA50) 
DBiB-p(OEGMA50-co-
EGDMA0.8) 
DBiB0.90PBiB0.10-
p(OEGMA50-co-EGDMA0.8) 
DBiB0.75PBiB0.25-
p(OEGMA50-co-EGDMA0.8) 
99 
98 
>99 
 
99 
 
99 
15 353 
15 750 
- 
 
- 
 
- 
39 760 
70 350 
235 700 
 
136 100 
 
257 700 
30 750 
38 000 
57 600 
 
22 300 
 
62 500 
 
1.20 
1.85 
4.09 
 
3.60 
 
4.12 
DBiB0.50PBiB0.50-
p(OEGMA50-co-EGDMA0.8) 
DBiB0.25PBiB0.75-
p(OEGMA50-co-EGDMA0.8) 
DBiB0.10PBiB0.90-
p(OEGMA50-co-EGDMA0.8) 
 
PBiB-p(OEGMA50-co-
EGDMA0.8) 
99 
 
99 
 
99 
 
99 
- 
 
- 
 
- 
 
- 
163 700 
 
410 600 
 
303 800 
 
169 800 
54 500 
 
76 400 
 
40 050 
 
63 600 
3.00 
 
5.37 
 
6.74 
 
2.66 
 
aDetermined using GPC (DMF/0.01 M LiBr Eluent 60oC) bDetermined using 1H NMR (CDCl3,400 
MHz) 
 
 
The addition of a 0.8 molar equivalent of EGDMA with respect to initiator groups, led 
to a dramatic increase in Mw and dispersities of all copolymers as characterised by 
double detection GPC (DMF). All polymers synthesised with a mixture of DBiB and 
PBiB initiators reached ≥ 99 % conversion, as determined by the loss of OEGMA vinyl 
peaks at 6.13 and 5.58 ppm in 1H NMR spectrum, Appendix A5, which is known to 
be important to achieve intermolecular branching. As shown in Table 3.1, Mw values 
for co-initiated branched copolymers reached values up to 410,600 g/mol, representing 
a significant increase from the values obtained for DBiB-p(OEGMA50) and PBiB-
p(OEGMA50) linear polymerisations. The variation in the Mw achieved across the 
different co polymers may reflect the slight variations in initiation, with the lowest 
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value obtained as 136,100 g/mol. GPC chromatograms for co-initiated polymers are 
shown in Figure 3.7, where all polymers show significant branching and presence of 
high Mw materials, as further confirmed by right angle light scattering (RALS) 
detection. 
 
 
 
Figure 3.7 GPC (DMF/0.01 M LiBr Eluent 60 oC) chromatogram overlays of A) RI 
and B) RALS signals for p(OEGMA50-co-EGDMA0.8) with varying ratios of 
DBiB:PBiB chain ends; DBiB0.10PBiB0.90 (purple) DBiB0.25PBiB0.75 (red), 
DBiB0.50PBiB0.50 (black), DBiB0.75PBiB0.25 (blue) or DBiB0.90PBiB0.10 (green). 
 
Comparison of GPC analysis of linear analogue polymers (using single initiation) with 
branched materials synthesised in the presence of EGDMA also clearly shows the 
formation of a broader molecular weight distribution, which is typical for branched 
copolymers, Figure 3.8. The statistical nature of the branching process means there 
are both linear chains and branched copolymers of varying composition within the 
final product, with the RALS trace clearly indicating the presence of higher Mw 
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material in the branched copolymer. The RI analysis of the linear polymer PBiB-
p(OEGMA50), Figure 3.8 A, shows the presence of a shoulder at higher molecular 
weight for this linear polymer. This is assigned as products from termination by 
dissociation; a known issue with methacrylate polymers. Such a termination process 
will form reactive macromonomers that may be incorporated into other, non-
terminated chains when reactions are left at high conversion for extended periods. This 
also results in a higher dispersity value of 1.85, in comparison to DBiB-p(OEGMA50) 
of 1.2. This is further confirmed by an observed Mn obtained via GPC analysis of 
38,000 g/mol which is approximately double the theoretical targeted value, Table 3.1. 
 
Figure 3.8 GPC (DMF/0.01 M LiBr Eluent 60 oC) chromatogram overlays of A) RI 
and B) RALS signals for linear PBiB-p(OEGMA50) (black) and branched equivalent 
PBiB-p(OEGMA50-co-EGDMA0.8) (red). 
  Chapter 3 
68 
 
As mentioned earlier, the co-initiated branched copolymers have considerable 
variation in architecture, composition and molecular weight. This is derived from the 
statistical branching between polymer chains that are simultaneously synthesised 
using DBiB and PBiB initiators in varying ratios. The final branched copolymers will 
possess statistical variation in molecular weight within the primary chains, number of 
conjoined chains, ratio of hydrophilic and hydrophobic chain ends and branching 
density.  To investigate the implications of the wide diversity of materials produced, 
the GPC data was analysed to determine the cumulative weight fraction vs molecular 
weight relationship to provide an indication of what weight fraction of each sample 
contained highly branched structures, Figure 3.9.  
 
Figure 3.9 Cumulative weight fraction analysis of branched copolymer 
DBiB0.25PBiB0.75-p(OEGMA50-co-EGDMA0.8) highlighting the  percentage of the 
mass from polymer species with Mw > 500,000 (green), 750,000 (blue) and 1,000,000 
(red) g/mol derived from GPC analysis (DMF/0.01 M LiBr Eluent 60 oC). 
 
Three arbitrary molecular weights 500,000, 750,000 and 1,000,000 g/mol were chosen 
to establish the physical mass of each polymer sample that is present with molecular 
weights above these values, see Table 3.2. In principle, these molecular weight values 
represent structures that have approximately 15, 22 and 29 conjoined primary chains 
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respectively, assuming an average Mn of the primary chains is 34,375 g/mol which is 
the average of the linear polymer Mn values for the p(OEGMA)50 linear polymer 
samples created by single initiation using DBiB or PBiB (Table 3.1). The presence of 
branched copolymers containing large numbers of chain ends is key to the sample 
exhibiting the surface active behaviour observed and discussed in Chapter 2, Section 
2.4 and 2.5. 
 
Table 3.2 Weight fraction of DBiBxPBiBy-p(OEGMA50-co-EGDMA0.8) branched 
copolymers with molecular weights greater than 500,000, 750,000 and 1,000,000 
g/mol.  
Polymer Composition 
Wt% 
>500,000 
g/mol 
Wt% 
>750,000 
g/mol 
Wt% 
>1,000,000 
g/mol 
DBiB-p(OEGMA50-co-
EGDMA0.8) 
11.2 2.47 2.8 
DBiB0.90PBiB0.10-
p(OEGMA50-co-EGDMA0.8) 
14.2 8.5 5.4 
DBiB0.75PBiB0.25-
p(OEGMA50-co-EGDMA0.8) 
15.6 9.1 5.9 
DBiB0.50PBiB0.50-
p(OEGMA50-co-EGDMA0.8) 
5.9 2.19 0.9 
DBiB0.25PBiB0.75-
p(OEGMA50-co-EGDMA0.8) 
21.8 14.8 10.7 
DBiB0.10PBiB0.90-
p(OEGMA50-co-EGDMA0.8) 
33.7 27.19 2.3 
PBiB-p(OEGMA50-co-
EGDMA0.8) 
6.4 2.9 1.4 
 
As a general trend, an increasing PBiB:DBiB ratio (up to 0.9:0.1) within the co-
initiated polymerisations appears to lead to an increasing weight fraction of higher 
molecular weight structures (> 500,000 g/mol; 15 conjoined chains) within the 
samples, Figure 3.10. Interestingly DBiB0.25PBiB0.75-p(OEGMA50-co-EGDMA0.8) 
has the highest weight fraction of branched copolymers with a weight fraction of 
species with a molecular weight >1,000,000 g/mol (>29 primary chains) at nearly 11 
wt %.  
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Figure 3.10 Weight fraction of co-initiated DBiBxPBiBy-p(OEGMA50-co-
EGDMA0.8) branched copolymers with molecular weights greater than A) 500,000, B) 
750,000 and C)  1,000,000 g/mol, plotted against molar percent of PBiB initiator used 
in the co-initiated copolymerisation. 
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Overall, all branched copolymers produced contain species comprising significant 
weight fractions of branched copolymers with molecular weights >500,000 g/mol 
(>15 primary chains) within the complex distribution of structures formed, therefore 
even at co-initiation ratios of 0.9:0.1, a mixture of both chain ends would be expected 
in these high molecular weight structures. 
 
3.2.2.4 Cloud Point Studies 
 
Polymers that contain significant amounts of ethylene oxide repeat units are known to 
have lower critical solution behaviour which manifests itself as a temperature limit 
(the LCST) where uniform, single-phase molecular solutions can be maintained.126,127 
LCST behaviour is understood as being entropically driven, with the considerable 
release of bound water molecules solvating the polymer chains leading to a large 
increase in global entropy, outweighing the loss of entropy during collapse of the 
solvated polymer chains; in many reports, the solvated polymer chains are described 
as “becoming hydrophobic” at the LCST. Due to the use of OEGMA as monomer and 
PEG as a co-initiator, both of which contain ethylene oxide repeat units, cloud point 
studies were undertaken to assess the behaviour of aqueous branched copolymer 
solutions. Aqueous copolymer solutions were prepared at a 1 wt % concentration and 
heated through three cycles using an oil bath until the cloud point was determined, i.e. 
when the transparent solution turned opaque, indicating precipitation of the dissolved 
macromolecules. The change in polymer composition showed little impact on aqueous 
solubility as all branched copolymers were readily water-soluble. However, a 
meaningful decrease in lower critical solution temperatures (LCST) of 6 °C between 
the linear polymers PBiB-p(OEGMA) and DBiB-p(OEGMA50) was observed as may 
be expected from increasing hydrophobicity in the polymer architecture derived from 
the chain end, Figure 3.11.  
The inclusion of the divinyl monomer EGDMA to yield branched copolymers led to 
a decrease in LCST by 3.6 °C even from PBiB-p(OEGMA) to PBiB-p(OEGMA50-co-
EGDMA0.8); further decreases were observed after the inclusion of hydrophobic chain 
ends from the co-initiation and formation of DBiB0.25PBiB0.75-p(OEGMA50-co-
EGDMA0.8) (decrease of 2.0 °C compared to PBiB-p(OEGMA50-co-EGDMA0.8). 
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Figure 3.11 Cloud point studies of DBiB-p(OEGMA50), 
DBiB-p(OEGMA50 -co-EGDMA0.8), DBiB0.25PBiB0.75-p(OEGMA50-co-EGDMA0.8), 
PBiB-p(OEGMA50-co-EGDMA0.8) and PBiB-p(OEGMA50). 
3.2.3 Contact Angle of Liquid on Hydrophobic Surface Determined by Young’s 
Equation 
 
The water contact angle is the angle measured at the point where the liquid-vapour 
interface of a water droplet meets a solid surface. This allows for application of 
Young’s equation,128 Equation 3.1, which quantifies the wettability of a solid surface 
by a  liquid, where the contact angle is derived from the thermodynamic equilibrium 
between the three phases. Young’s equation takes into consideration the tension 
between the liquid-vapour (γLV), solid-vapour (γSV) and solid-liquid (γSL) interfaces, 
Figure 3.12. 
 
Figure 3.12 Contact angle (Ɵ), of a droplet on a solid surface with interfacial tensions 
of solid-vapour = γSV, solid-liquid = γSG and liquid-gas = γLV.129                        
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If the contact angle is above 90 o then the surface is deemed hydrophobic, with contact 
angles above 150 o corresponding to a super hydrophobic surface, while an angle of 
less than 90 o characterises the surface as hydrophilic, Figure 3.12.129 If a surfactant is 
added to the aqueous liquid and progressively increased, the contact angle should 
decrease due to a lessening of surface tension at the liquid-solid interface. 
                                                 𝛾𝑙𝑔𝑐𝑜𝑠𝜃 =  𝛾𝑠𝑣 − 𝛾𝑠𝑙                             (3.1) 
The contact angle determines how well liquids interact with a solid surface, and the 
wettability of a surface can therefore be studied. If the contact angle is > 90 ° there is 
low wettability of the surface, and a contact angle of < 90 ° indicates good surface 
wetting. As shown in Figure 3.13, when a liquid comes into contact with a solid 
surface the lower contact angle means the fluid can spread over a large surface area. 
If the contact angle is high, and interaction is unfavourable the liquid will bead on the 
surface to minimise its contact with the surface. 
 
Figure 3.13 Varying contact angle of liquids on a hydrophobic surface, A) bad 
wetting, θ > 90 °, B) good wetting, θ < 90 ° and C) complete wetting θ = 0 °.  
 
3.2.3.1 Contact Angle Measurement of Linear Polymers and Branched 
Copolymers 
 
Throughout the aqueous contact angle studies employed here, a consistent 
hydrophobic solid surface (PTFE) was used and the aqueous droplet added to the 
surface varied in the dissolved branched copolymer, or linear polymer, that was 
solubilised into distilled water. The impact of the varying end-group composition of 
the branched copolymers was expected to be observed as a systematic change in 
measured aqueous contact angles through alterations of droplet-surface tension. 
Hypothetically, the p(OEGMA) chains that comprise the majority of the polymer and 
copolymer structures will be dissolved into the water and any hydrophobic areas, such 
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as the DBiB chain ends will be displayed at the air-water interface, enabling 
interactions with the hydrophobic surface and an increase in observed wetting (i.e. a 
decrease in contact angle). Variation in chain end composition with increasing DBiB 
or PBiB groups would lead to systematic changes in contact angles observed; a 
decrease indicating the presence of hydrophobic chains at the interface and an increase 
suggesting increasing hydrophilicity.  
In all cases, aqueous polymer solutions of 5 wt % were used and droplets were 
analysed using a drop shape analyser (DSA), using a static sessile drop method. The 
sessile drop method is the standard method of contact angle measurement using drop 
shape analysis and static the angle is measured on a solid surface instead of a dynamic 
sessile drop, where the droplet size is either increased or decreased to measure the 
advancing and receding angle. The high aqueous polymer concentration of 5 wt % was 
selected as packing at the air/water interface, by the branched copolymer emulsifier, 
can be assumed. A hydrophobic polytetrafluoroethylene (PFTE) substrate in tape form 
was applied to a glass slide, and 5 µL droplets of polymer solution were applied and 
the contact angle measured (n = 10). Distilled water was applied to the PTFE substrate, 
which has been previously shown to have a contact angle between 108 – 110 °.130–132 
However, in a subsequent study it was shown that increasing the axial extension ratio 
of the tape, based on initial width and extended width of the tape, the contact angle of 
water can increase from 118 - 165 °.133 The application and stretching of PTFE tape 
on the glass slide explained the measured contact angle for water of 125 ° ± 3.6 °.  
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Figure 3.14 A) Contact angle measurements of aqueous polymer and branched 
copolymer solutions at 5 wt %, n = 10, error bars = standard deviation on a PTFE tape 
substrate. Microscopy images of droplet shapes; B) DBiB-p(OEGMA50), C) DBiB-
p(OEGMA50-co-EGDMA0.8), D) DBiB0.90PBiB0.10-p(OEGMA50-co-EGDMA0.8), E) 
DBiB0.75PBiB0.25-p(OEGMA50-co-EGDMA0.8), F) DBiB0.50PBiB0.50-p(OEGMA50-
co-EGDMA0.8), G) DBiB0.10PBiB0.90-p(OEGMA50-co-EGDMA0.8), H) PBiB-
p(OEGMA50), I)PBiB-p(OEGMA50-co-EGDMA0.8) and J) pure water. 
 
Contact angle measurements (with respect to pure water values of 125 ° ± 3.6 °), Figure 
3.14 A, indicate that the inclusion of PBiB-p(OEGMA50) lowered the contact angle to 
106 ° ± 4.0 °.  As this polymer structure contains no hydrophobic chain ends, this may 
suggest that the hydrophobic methacrylate backbone may align preferentially at the 
  Chapter 3 
76 
 
air/water interface to minimise the interfacial tension and thereby result in a small 
decrease in the observed contact angle through slight spreading of the droplet on the 
PTFE surface. As this linear polymer is chemically near-identical to the branched 
copolymer PBiB-p(OEGMA50-co-EGDMA0.8) it is interesting to observe that the 
measured contact angles are similar (91 ° ± 4.9 °), although the presence of EGDMA 
in the structure and/or restriction of conformational rotation may also offer the 
potential for hydrophobic segments to align at the interface, resulting in the lower 
values than those seen using the linear PBiB-p(OEGMA50). 
 
Addition of the linear DBiB-p(OEGMA50) polymer to the aqueous solution leads to a 
considerable decrease in the observed contact angle to values < 90 ° (84 ° ± 2.3 °) 
which is considered as good wetting; this suggests that the arrangement of the DBiB 
chain ends at the droplet surface does in fact lead to a considerable change in droplet 
surface tension. As seen previously for branched and linear structures derived from 
PBiB initiation, the formation of the chemically near-identical DBiB-p(OEGMA50-co-
EGDMA0.8) led to similar measured contact angles although the branched copolymer 
again showed lower values of 80 ° ± 2.2 o. Inclusion of DBiB-p(OEGMA50-co-
EGDMA0.8) into the aqueous solution displayed the lowest contact angles observed, 
suggesting that this branched copolymer is the most surface active of the library 
synthesised here, including the linear DBiB-p(OEGMA50) and potentially explaining 
the high stability of the emulsions described in Chapter 2, Section 2.4.2.  
 
Across the series of DBiBxPBiBy-p(OEGMA50-co-EGDMA0.8) branched copolymers 
of varying chain end composition, all branched copolymer solutions displayed a higher 
contact angle than DBiB-p(OEGMA50-co-EGDMA0.8), indicating a decrease in 
hydrophobicity (or an increase in surface tension); the branched copolymers from 
DBiB0.90PBiB0.10-p(OEGMA50-co-EGDMA0.8) through to DBiB0.50PBiB0.50-
p(OEGMA50-co-EGDMA0.8) all exhibited a  contact angle of 102 ° suggesting a 
reduced number of hydrophobic chain ends at the air-water interface compared to 
DBiB-p(OEGMA50-co-EGDMA0.8). Assuming packing of polymer structures at the 
interface at this copolymer concentration, it may also suggest that the interface may 
not be tightly packed with hydrophobic chain ends. Interestingly, the inclusion of the 
branched copolymer DBiB0.10PBiB0.90-p(OEGMA50-co-EGDMA0.8) into the aqueous 
solution resulted in a measured contact angle of 87 ° ± 11.4 ° which is (within error) 
  Chapter 3 
77 
 
very similar to the value of the PBiB-p(OEGMA50-co-EGDMA0.8) (91 ° ± 4.9 °), and 
indicating that the low concentration of available DBiB chain ends are still able to 
modify the air-water interface tension over and above the presence of the EGDMA or 
hydrophobic methacrylate backbone – the large error in the measurements for this 
branched copolymer may also indicate the considerable diversity of chain end 
composition.  
 
3.2.4 Theory and Determination of the Critical Micelle Concentration 
 
The critical micelle concentration (CMC) is the concentration of surfactant in solution 
above which additional surfactant or co-surfactants will from micelles.134 The CMC 
is a defining point in emulsion formation, as the interfacial tension changes rapidly up 
to this point with the addition of further surfactants. After the CMC is reached, 
interfacial tension between the two phases remains relatively stable with additional 
surfactant only increasing the concentration of micelles or oil droplets rather than 
further reducing the overall interfacial tension. Below the CMC, interfacial tension is 
linearly dependent on the surfactant concentration and above the CMC the interfacial 
tension is completely independent of the surfactant concentration.  
As shown in Figure 3.15, upon addition of surfactant to water leads to alignment at 
the oil-water interface and a linear decline of surface tension until the interface 
becomes fully saturated. At this point addition of further surfactants does not affect 
the surface tension, but surfactants will self-assemble in the continuous phase to shield 
the hydrophobic chains. Following the CMC point, there is no correlation between 
surface tension and surfactant concentration, as the addition of further surfactants no 
longer has any effect on surface tension but instead increases the concentration of 
micelles. It is at this sharp break point of surface tension plotted against a logarithm 
of surfactant concentration, that CMC value can be determined.135  
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Figure 3.15 Schematic of an idealised CMC measurement representing the change in 
surface tension as surfactant concentration is increased, including micelle formation 
above the CMC and plateau at very low concentrations relating to the surface tension 
of water. 
To increase the stability of an emulsion a co-surfactant can be included to further lower 
surface tension by aligning at the interface between the initial surfactant molecules, 
therefore resulting in a mixed surfactant monolayer.136 
 
3.2.4.1 CMC Measurement of Branched Copolymers and Linear Polymers 
 
Surface tension measurements were conducted on the range of polymers and branched 
copolymers synthesised here, using a Kibron Delta-8 surface tensiometer at 20°C, over 
a serial dilution series. Aqueous polymer solutions were initially prepared at 30 wt % 
and subsequent dilutions gave 30 different concentrations down to 6.9 x 10-9 wt %. 
Use of a 96 well-plate allowed for high throughput analysis of samples; 50 μL of each 
polymeric surfactant (n=8) was used per well and measured against pure water as a 
control. Following measurement, surface tension was plotted against a log 
concentration of surfactant. The CMC value was obtained by calculating the lines of 
best fit for the linear decrease in surface tension (slope) and the lower plateau area, 
and utilising the resulting y=mx+c equation of each section with rearrangement to 
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determine the intercept (x), Figure 3.16. To calculate graphical percentage error for 
CMC measurements, the minimum and maximum gradient was determined by plotting 
the minimum and maximum lines of best fit.  
 
Figure 3.16 Example of CMC calculations by plotting the line of best fit for slope and 
lower plateau region with equations of the line shown for; best fit (black), maximum 
slope (red), minimum slope (green) and lower plateau (purple). 
Surface tension measurements for branched copolymers and linear polymers are 
shown in Figure 3.17 and Figure 3.18. All surface tensiometer measurements observed 
the typical high plateau characteristic for very low concentrations of polymeric 
surfactant, with measurements of pure water at 73 mN/m. However, the traditional 
decrease in surface tension to the CMC did not lead to a steady plateau region as 
expected with a second decrease in surface tension observed in many cases. This 
suggests a complex surface tension behaviour with these materials that is most 
prevalent for branched copolymers with varied chain end composition, Figure 3.17, 
but is also seen to a lesser extent in the measurements of linear and branched 
copolymers containing single chain end chemistry, Figure 3.18. 
  
 
 
Figure 3.17 CMC data for aqueous branched copolymer solutions over a concentration gradient; DBiB0.90PBiB0.10-p(OEGMA50-co-EGDMA0.8)  
( ),DBiB0.75PBiB0.25-p(OEGMA50-co-EGDMA0.8) ( ),DBiB0.50PBiB0..50-p(OEGMA50-co-EGDMA0.8) ( ), and DBiB0.25PBiB0.75-p(OEGMA50-
co-EGDMA0.8) ( ). n=8, error bars = standard deviation. 
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Figure 3.18 CMC data for aqueous linear polymers and branched copolymer solutions; DBiB-p(OEGMA50) ( ), PBiB-p(OEGMA50) ( ), DBiB-
p(OEGMA50-co-EGDMA0.8) ( ), and PBiB-p(OEGMA50-co-EGDMA0.8) ( ), over a concentration gradient. n=8, error bars = standard 
deviation. 
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This complex behaviour is analogous to mixed non-ionic surfactant solutions where 
two time-dependent events occur, causing a dynamic surface tension curve that 
describes assembly at the interface of one surfactant followed by disruption of the 
interface and closer packing as co-assembly of the second surfactant occurs, leading 
to a further decrease in surface tension. Within the branched copolymers, the presence 
of linear, lightly branched structures and highly branched structures is analogous to a 
complex multi-surfactant mixture; where chain end composition also varies, a further 
complexity to the mixture is introduced. Presumably, the linear amphiphilic fraction 
of the distributions are able to pack most efficiently at the interface (as seen for linear 
DBiB-p(OEGMA50) in Figure 3.18) and subsequent rearrangement with the more 
highly branched structures creates the optimised lower surface tension values.  In these 
measurements, the first plateau will be described as the initial CMC value as it is not 
representative of the lowest surface tension measurement, while this minimum 
measured value will be described as STmin, Table 3.3. 
 Table 3.3 CMC and STmin values determined for polymers and branched copolymers 
using a Kibron Delta-8 at 20 oC. Values are expressed as mg/L and errors are expressed 
as a graphical percentage error. 
 
CMC profiles of co-initiated polymeric surfactants were similar, Figure 3.17, and 
branched copolymers which contained a PBiB-derived chain ends appear to have 
Polymer 
Initial CMC 
(mg/L) 
STmin 
(mg/L) 
DBiB-p(OEGMA50) 4.72 x 10-8 (± 8 %) 9.30 x 10-3 
PBiB-p(OEGMA50) 7.4 x 10-8 (± 2 %) 9.30 x 10-3 
DBiB-p(OEGMA50-co-EGDMA0.8) 2.36 x 10
-6 (±10 %) 7.5 x 10-2 
DBiB0.90PBiB0.10-p(OEGMA50-co-
EGDMA0.8) 
2.79 x 10-8 (± 7 %) 7.30 x 10-5 
DBiB0.75PBiB0.25-p(OEGMA50-co-
EGDMA0.8) 
4.74 x 10 -8 (± 2 %) 2.92 x 10-4 
DBiB0.50PBiB0.50-p(OEGMA50-co-
EGDMA0.8) 
1.08 x 10-8 (±16 %) 9.30 x 10-3 
DBiB0.25PBiB0.75-p(OEGMA50-co-
EGDMA0.8) 
2.35 x 10-8 (± 17 %) 1.46 x 10-4 
PBiB-p(OEGMA50-co-EGDMA0.8) 7.25 x 10
-8 (± 0.7 %) 7.5 x 10-2 
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lower CMC values. Overall, it is unclear whether any definitive trends can be reported 
for the CMC or STmin values of the branched copolymers, possibly due to the complex 
heterogeneity of structures within the samples. As a comparison, Sodium dodecyl 
sulphate is a common ionic surfactant and has an experimental CMC 2.6 x10-4 M 
(approximately 57 mg/L) that is nearly identical to Triton X-100, a non-ionic 
surfactant based on the alkyl phenylether of PEG, with a reported CMC of 2.0 x10-4 M 
(approximately 129 mg/L)74; the copolymers presented here appear to be considerably 
more mass efficient than these commonly used commercial surfactants. 
3.3 CO-INITATED POLYMERIC SURFACTANT STABILISED 
MACROEMULSIONS 
 
3.3.1 Macroemulsion Characterisation 
 
Macroemulsions were generated via mechanical shear, using an overhead shear 
homogeniser (Ultra-Turrax 25, IKA) and dodecane as the oil phase due to its high 
compatibility with the hydrophobic chain end functionality of the DBiB-derived 
macromolecules. Aqueous polymer solutions (5 mg/mL) were homogenised with 
dodecane in a 1:1 ratio for 2 minutes at 24,000 rpm and left overnight to equilibrate 
before quantitative analysis by laser diffraction spectroscopy. For example, a typical 
macroemulsion was prepared to a final volume of 6 mL using dodecane (3 mL) as the 
oil (dispersed) phase and aqueous polymer solution (3 mL) for the continuous phase.  
In all emulsions stabilised by branched copolymer surfactants containing DBiB chain 
ends, creaming of the stable emulsion was observed due to the dispersed dodecane oil 
phase having a lower density (0.75 g/mL at 25 °C) than the continuous aqueous phase; 
however, the emulsions were considered stable if no separation of free oil was 
observed and the emulsions appeared characteristically white and opaque. Emulsion 
stability was initially assessed visually due to ease of measurement; Figure 3.19 shows 
an example of the visible breakdown of macroemulsions, characterised by the clear 
separation of oil from the emulsion layer. Unstable oil droplets are subject to 
breakdown during creaming as they are forced together into an oil-rich region of the 
sample and insufficient interfacial stabilisation will not prevent the oil droplets from 
subsequently coalescing.  
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Figure 3.19 Breakdown of dodecane macroemulsion characterised by creaming of oil 
layer and phase separation between emulsion and aqueous polymer solution. Pictured 
is a macroemulsion with PBiB-p(OEGMA50-co-EGDMA0.8) as branched copolymer 
surfactant.  
 
Emulsion instability and release of oil was apparent in emulsions prepared when linear 
DBiB-p(OEGMA50) and PBiB-p(OEGMA50) were used as surfactants. These 
polymers were unable to stabilise macroemulsions and rapid demulsification occurred 
after homogenisation. Although a defined oil layer was visible, a small sample of the 
creamed emulsion layer was able to be sampled and the linear polymer stabilised 
macroemulsions were characterised via laser diffraction. The emulsions that were 
studied contained bimodal droplet distributions Figure 3.20 and all linear polymeric 
surfactant-stabilised emulsions underwent full demulsification after 3 days of storage 
at ambient temperature. 
 
Figure 3.20 Laser diffractograms of linear polymer stabilised dodecane 
macroemulsions A) DBiB-p(OEGMA50) and B) PBiB-p(OEGMA50). 
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Macroemulsions were also prepared using PBiB-p(OEGMA50-co-EGDMA0.8) as the 
branched copolymer surfactant; immediately after homogenisation emulsions were 
formed but after 24 hours storage at ambient temperature, separation of the oil phase 
was apparent and a droplet diameter of 16.9 μm was measured from the remaining 
emulsion layer, Figure 3.21 A and B. Three days later, full separation of the oil and 
water phases had occurred.  
 
Figure 3.21 Studies of emulsion stability: A) Digital images of demulsified PBiB-
p(OEGMA50) and PBiB-p(OEGMA50-co-EGDMA0.8) stabilised dodecane 
macroemulsions with separation of oil layer. B) Average D[4,3] of PBiB-p(OEGMA50-
co-EGDMA0.8) stabilised dodecane macroemulison after 24 hrs storage at ambient 
temperature.  
The poor performance of PBiB-p(OEGMA50) is comparable to that of its branched 
analogue, PBiB-p(OEGMA50-co-EGDMA0.8), and can be expected due to the limited 
hydrophobicity of the polymer. Surprisingly when DBiB-p(OEGMA50) was tested as 
a polymeric surfactant, where all polymer chain ends are the hydrophobic dodecyl 
initiator the macroemulsion is also unstable. This low emulsion stability is likely due 
to the dynamic nature of emulsifiers where reversible desorption of the linear chains 
leads to equilibrium of bound and solution polymer chains, Figure 3.22. As a result 
linear polymers appear to potentially reside more in the aqueous continuous phase, 
rather than bound at the oil-water interface and are not able, therefore, to prevent 
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neighbouring oil droplets from coalescing; the equilibrium appears to lie in favour of 
dissolved unimeric polymer chains. 
 
Figure 3.22 Hypothetical model of desorption of linear polymer chains from the 
oil/water interface, leading to emulsion instability via interaction of neighbouring oil 
droplets. 
 
Macroemulsions stabilised using the range of branched copolymers with varying chain 
end compositions, i.e. DBiB-p(OEGMA50-co-EGDMA0.80), DBIB0.75PBiB0.25-
p(OEGMA50-co-EGDMA0.80), DBiB0.50PBiB0.50-p(OEGMA50-co-EGDMA0.80) and 
DBiB0.25PBiB0.75-p(OEGMA50-co-EGDMA0.80), showed D[4,3]  values of 11.9, 13.0, 
14.5 and 15.3 µm after 24 hours respectively and unimodal size distributions as 
measured by laser diffraction, Figure 3.23. A general increase in droplet diameters is 
observed as the percentage of hydrophobic chain ends is reduced. This is somewhat 
expected due to the decreasing concentration of surface active chain ends, however it 
is surprising that a greater difference is not observed due to the overall four-fold 
decrease in dodecyl chain ends. The laser diffraction of macroemulsions stabilsised by 
PBiB-p(OEGMA50-co-EGDMA0.8) showed a broadening of the distribution and a 
secondary peak at ~ 100 μm was observed, attributed to initial coalescence of the 
droplets and eventual creaming of the dispersed phase was observed after 3 days, 
Figure 3.23 E.  
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Figure 3.23 Laser diffractograms of dodecane macroemulsions stabilised with; A) 
DBiB-p(OEGMA50-co-EGDMA0.8), B) DBiB0.50PBiB0.50-p(OEGMA50-co-
EGDMA0.8), C) DBiB0.75PBiB0.25-p(OEGMA50-co-EGDMA0.8), D) DBiB0.25PBiB0.75-
p(OEGMA50-co-EGDMA0.8) and E) PBiB-p(OEGMA50-co-EGDMA0.8). 
 
To assess the long term stability of the macroemulsions, a study was undertaken to 
assess the impact of storage at ambient temperature on the droplet diameter. After 40 
days of storage under these conditions, the macroemulsions had D[4,3] values of 13.5, 
15.6, 13.8 and 15.1 μm for samples stabilised with DBiB-p(OEGMA50-co-
EGDMA0.80), DBiB0.75PBiB0.25-p(OEGMA50-co-EGDMA0.80),DBiB0.50PBiB0.50-
p(OEGMA50-co-EGDMA0.80) and DBiB0.25PBiB0.75-p(OEGMA50-co-EGDMA0.80) 
respectively i.e. a negligible change in emulsion droplet diameter was seen, Figure 
3.24. Overall, the macroemulsions remained stable over this time period, with samples 
 Chapter 3 
88 
 
stabilised by DBiB-p(OEGMA50-co-EGDMA0.8) and DBiB0.75PBiB0.25-p(OEGMA50-
co-EGDMA0.8) showing the greatest change in D[4,3] with an increase in diameter of ~ 
2 μm. The emulsions stabilised with DBiB0.50PBiB0.50-p(OEGMA50-co-EGDMA0.8) 
and DBiB0.25PBiB0.75-p(OEGMA50-co-EGDMA0.8) showed negligible differences 
over the 40 day storage. A general trend of reduction in hydrophobic chain end 
concentration leading to slight increase in droplet size was observed; for example, 
branched copolymers containing 75 mol % hydrophilic chain ends yielded emulsions 
with droplet diameters ~2 μm larger than DBiB-p(OEGMA50-co-EGDMA0.8). As the 
macroemulsions were stored under ambient conditions, the small differences in 
droplet diameter may be due to variation in temperature and sampling but no 
meaningful difference between samples was observed over the full timescale of the 
study.  
 
Figure 3.24 Storage stability of macroemulsions: D[4,3] values of dodecane 
macroemulsions stabilised by; DBiB-p(OEGMA50-co-EGDMA0.8) (red), 
DBiB0.75PBiB0.25-p(OEGMA50-co-EGDMA0.8) (blue), DBiB0.50PBiB0.50-
p(OEGMA50-co-EGDMA0.8) (green), DBiB0.25PBiB0.75-p(OEGMA50-co-EGDMA0.8) 
(purple). 
A series of macroemulsions were also stored under uncontrolled ambient conditions 
for 3 years, to assess very long term storage stability, Figure 3.25. Macroemulsions 
stabilised with mixed chain end functionality showed no visual creaming or 
coalescence of the oil phase during this time. This remarkable stability is in stark 
 Chapter 3 
89 
 
contrast to PBiB-p(OEGMA50-co-EGDMA0.8) stabilised macroemulsions which 
separated into two well defined phases, with no emulsion layer present. 
 
 
 
Figure 3.25 Dodecane macroemulsions stored at ambient temperature for 3 years 
stabilised with;  A) DBiB-p(OEGMA50-co-EGDMA0.8), B) DBiB0.25PBiB0.75-
p(OEGMA50-co-EGDMA0.8), C) DBiB0.50PBiB0.50-p(OEGMA50-co-EGDMA0.8), D) 
DBiB0.75PBiB0.25-p(OEGMA50-co-EGDMA0.8), E) PBiB-p(OEGMA50-co-
EGDMA0.8). 
 
It is important to fully establish that the beneficial effects of the branched copolymer 
stabilisers is due to the novel branched architectures and not merely a synergistic effect 
of the mixed polymers within the samples; therefore, a control experiment which 
blended aqueous solutions of the linear polymers DBiB-p(OEGMA50) and PBiB-
p(OEGMA50) was performed. The aqueous linear polymer solutions were prepared at 
5 mg/mL and blended to obtain ratios comparable to the molar percentage of PEG and 
dodecyl chain ends within the various branched copolymer structures. The resulting 
macroemulsions prepared with linear polymer blends were not stable; multiple peaks 
were observed in the laser diffraction traces of the emulsion layers which represented 
a large distribution of droplet diameter throughout each sample, Figure 3.26. The 
distribution was progressively more disperse and bimodal with decreasing 
DBiB-p(OEGMA50) content, which was in a marked contrast to the branched 
copolymer-stabilised emulsions with similar ratios of the different chain ends, Figure 
3.21. Full separation of linear polymer blend stabilised macroemulsions was observed 
after approximately 3 days of storage at ambient temperature.  
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Figure 3.26 Laser diffractograms of dodecane macroemulsions stabilised with linear 
blends of polymeric surfactants prepared at 5 mg/mL with ratios of; A) DBiB-
p(OEGMA50)/PBiB-p(OEGMA50) 0.75/0.25, B) DBiB-p(OEGMA50)/PBiB-
p(OEGMA50) 0.50/0.50 and C) DBiB-p(OEGMA50)/PBiB-p(OEGMA50) 0.25/0.75. 
The behaviour of the blended linear polymer solutions clearly demonstrated the crucial 
role that polymeric architectures play within the co-initiated branched copolymer 
emulsifiers. The arrangement of combinations of PEG and dodecyl initiator-derived 
chain ends at the oil droplet surface would not be possible without the branching by 
EGDMA that connects the varying primary chains into the complex branched 
copolymer architectures. Hydrophobic chain ends allow anchoring of polymers at the 
oil/water interface thus reducing high interfacial tensions between the immiscible 
phases and providing emulsion stability via steric stabilisation from the branched 
p(OEGMA) chains. It is also now possible to produce emulsions of comparable size 
and long term stability containing as low as 25 % hydrophobic chain end composition. 
This can be considered the current critical hydrophobic chain end composition at 
which stable o/w macroemulsions can be formed.  
3.3.2 Optical Microscopy of Branched Copolymer Stabilised Macroemulsions 
 
Optical microscopy was used to further analyse the macroemulsion droplets and 
visualise the dispersity of the samples. Following microscopy, image analysis was 
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conducted using FIJI (V 1.51n) software to determine the diameter of individual 
droplets measured per image. After 11 months storage at ambient temperature, a 
concentrated sample was studied and oil droplets retained their near-monodisperse 
distribution with well-defined circular geometry with no sign of coalescence between 
droplets, Figure 3.27.  
 
 
 
Figure 3.27 Optical microscopy images of concentrated dodecane macroemulsion 
after 11 months storage at ambient temperature; A) DBiB-p(OEGMA50-co-
EGDMA0.8), B) DBiB0.75PBiB0.25-p(OEGMA50-co-EGDMA0.8), C) DBiB0.50PBiB0.50-
p(OEGMA50-co-EGDMA0.8), D) DBiB0.25PBiB0.7-5p(OEGMA50-co-EGDMA0.8), 20x 
magnification, scale bar = 100 μm. 
 
Size distribution data from the optical microscopy images showed 11 month old 
emulsions stored at ambient temperature stabilised with DBiB0.50PBiB0.50-
p(OEGMA50-co-EGDMA0.8) had an average droplet diameter of 9 μm, with 90 % of 
droplets present being under 15 μm, whereas the D[4,3] measured by laser diffraction 
after 40 days was 13.8 μm. This highlights the differences of the different analytical 
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techniques; D[4,3] analysis is a volume average mean and a two dimensional diameter 
(number mean) is generated by optical microscopy.  
 
DBiB0.25PBiB0.75-p(OEGMA50-co-EGDMA0.8) stabilised macroemulsions had an 
average droplet diameter of 9.4 μm determined via optical microscopy with 90 % of 
the droplet population under 17 µm, Figure 3.28 A. This was in comparison to droplet 
diameters determined by laser diffraction where the D[4,3] was 15.6 μm after 40 days. 
DBiB0.75PBiB0.25-p(OEGMA50-co-EGDMA0.8) stabilised macroemulsions had a 
lower average diameter at 8.3 µm determined by optical microscopy in comparison to 
Mastersizer analysis, with 90 % of the population size under 14 µm, Figure 3.28 B. 
Overall this showed that the reduction of hydrophobic chain ends caused a minimal 
increase in droplet diameter.  
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Figure 3.28 Example of histogram data of D[1,0] of emulsions with varying 
hydrophobic chain end composition, with cumulative %; A) DBiB0.50PBiB0.50-
p(OEGMA50-co-EGDMA0.8) and B) DBiB0.25PBiB0.75-p(OEGMA50-co-EGDMA0.8). 
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3.4 CO-INITIATED POLYMERIC SURFACTANT STABILISED 
NANOEMULSIONS 
 
As described in Section 2.5, branched copolymer surfactants have been utilised to 
generate nanoemulsions via the removal of a volatile co-solvent from the internal 
dispersed phase. The use of the co-initiated branched copolymers was also studied to 
establish whether the variation in hydrophobic and hydrophilic chain end chemistry 
would impact nanoemulsion formation. Aqueous branched copolymer solutions were 
prepared at a 5 wt % concentration and dissolved overnight. These solutions were used 
as the aqueous phase for a range of nanoemulsions, using overhead shear 
homogenisation followed by solvent evaporation as detailed in Section 2.5. In a typical 
nanoemulsion preparation, a final emulsion volume of approximately 3 mL was 
targeted after evaporation of the co-solvent from an original total emulsion volume of 
6 mL; 3 mL of aqueous polymer solution and 3 mL of the mixed dispersed oil-phase 
with varying ratios of ethyl acetate and castor oil were used across all samples. For 
example, for nanoemulsions prepared using a 99:1 ratio of ethyl acetate:castor oil, the 
oil phase contained  a mixture of 2.97 mL ethyl acetate and 0.03 mL castor oil.  
As expected from previous observations, combinations of linear polymers did not form 
stable nanoemulsions, and rapid demulsification occurred during solvent evaporation. 
PBiB-p(OEGMA50-co-EGDMA0.8) was also unsuccessful as a stabiliser for 
nanoemulsion formation, with no stable emulsion being formed after solvent 
evaporation. In contrast, all branched copolymers containing DBiB-derived chain ends 
successfully stabilised nanoemulsions that were analogous to samples generated using 
DBiB-p(OEGMA50-co-EGDMA0.8) that were described in Chapter 2, Table 3.4. 
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Table 3.4 DLS data for nanoemulsionsa with aqueous branched copolymer solutions 
(5 wt %) with varying chain end composition. 
Polymer Dz  
(nm) 
Dn  
(nm) 
PdI 
DBiB-p(OEGMA50-co-EGDMA0.8) 203 176 0.063 
DBiB0.90PBiB0.10-p(OEGMA50-co-EGDMA0.8) 237 217 0.039 
DBiB0.75PBiB0.25-p(OEGMA50-co-
EGDMA0.8) 
252 236 0.126 
DBiB0.50PBiB0.50-p(OEGMA50-co-
EGDMA0.8) 
253 206 0.147 
DBiB0.25PBiB0.75-p(OEGMA50-co-
EGDMA0.8) 
271 248 
0.104 
DBiB0.10PBiB0.90-p(OEGMA50-co-
EGDMA0.8) 
646 423 0.314 
aNanoemulsions were generated with an oil phase composed of EtOAc:castor oil 
in a 99:1 ratio. 
 
The hydrodynamic diameter (Dz) of the droplets present in the nanoemulsions were 
comparable across the majority of the range of polymeric surfactants with a noticeable, 
but small, trend to increasing diameters with decreasing hydrophobic chain end 
content.  The sizes were maintained below 300 nm across these samples, even when 
the amount of hydrophobic chain ends present was considerably reduced to only 25 
mol %; PdI values remained remarkably low. The exception to this overall trend was 
the stabiliser with the lowest hydrophobic chain end content, DBiB0.10PBiB0.90-
p(OEGMA50-co-EGDMA0.8), which had an large Dz = 667 nm, higher PdI = 0.30 and 
higher number average diameter (Dn) value. Figure 3.29 shows the DLS particle 
diameter distributions for the nanoemulsions also described in Table 3.4. The 
monomodal and narrow nature of the distributions shown is lost when dodecyl chain 
ends present within the branched copolymer emulsifier are significantly decreased; 
nanoemulsions formed using DBiB0.10PBiB0.90-p(OEGMA50-co-EGDMA0.8) exhibit a 
broad and multimodal distribution. 
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Figure 3.29 DLS size distributions for nanoemulsions generated at a 99:1 ratio of ethyl 
acetate:castor oil stabilised with branched copolymers as surfactants; A) DBiB-
p(OEGMA50-co-EGDMA0.8) (black), B) DBiB0.90PBiB0.10-p(OEGMA50-co-
EGDMA0.8) (orange), C) DBiB0.75PBiB0.25-p(OEGMA50-co-EGDMA0.8) (red), D) 
DBiB0.50PBiB0.50-p(OEGMA50-co-EGDMA0.8) (purple) and E) DBiB0.25PBiB0.75-
p(OEGMA50-co-EGDMA0.8) (blue). 
3.4.1 Tailoring of Nanoemulsion Droplet Diameter Stabilised by Co-initiated 
Branched Copolymer 
 
As discussed in the previous chapter, Section 2.5.2, variation of the volatile to non-
volatile oil ratio should allow control of the nanoemulsion droplet size. For this study, 
DBiB0.25PBiB0.75-p(OEGMA50-co-EGDMA0.8) was selected as the branched 
copolymer surfactant, castor oil was again used as the non-volatile oil and ethyl acetate 
as the co-solvent; the volatile:non-volatile oil phase ratios varying from 50:50, 60:50, 
70:30, 80:20, 90:10 to 99:1, Figure 3.28. The ability to reduce the number of dodecyl 
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chains within the branched copolymer surfactant whilst maintaining the ability to 
stabilise nanoemulsions from 2500 nm down to 270 nm was confirmed, Figure 3.30.  
 
Figure 3.30 Nanoemulsion size tailored via solvent evaporation method with 
DBiB0.25PBiB0.75-p(OEGMA50-co-EGDMA0.8) as polymeric surfactant at a 5 wt% 
concentration. Volatile:non-volatile oil phase was composed of ethyl acetate:castor 
oil. 
Interestingly, the use of DBiB-p(OEGMA-co-EGDMA0.8) at a ratio of volatile to non-
volatile oil ratio of 50:50 formed emulsion droplets with diameters less than 1 µm and 
the reduction in hydrophobic chain ends to 25 mole % led to a larger emulsion droplet 
size; this has not been studied in any further detail; however it is plausible that the 
reduction in surface tension modification, as seen in Section 3.2.2.1, results in a higher 
concentration of surfactant required to reduce the surface tension and stabilise a higher 
surface area that would be expected from smaller droplets at the same physical mass 
of oil. Within the series of nanoemulsions shown in Figure 3.29, the PdI values 
decreased from 0.258 for the largest nanoemulsion down to 0.07 for the smallest 
diameter, Table 3.5. 
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Table 3.5 DLS data of tailored nanoemulsions with DBiB0.25PBiB0.75-p(OEGMA50-
co-EGDMA0.8) as the polymeric surfactant. Oil ratio refers to the ratio of volatile:non-
volatile oil blend of Ethyl acetate:castor oil. 
 
DLS analysis of the nanoemulsion size distributions reflect the decreased droplet 
diameter and the lowered polydispersity, Table 3.5. As the amount of ethyl acetate is 
increased, nanoemulsion distributions are consistently monodisperse in concordance 
with the PdI values determined, Figure 3.31.  
 
Figure 3.31 DLS measurements of tailored nanoemulsion droplet size with 
DBiB0.25PBiB0.25-p(OEGMA50-co-EGDMA0.8) as the polymeric surfactant. Oil phase 
ratios of ethyl acetate:castor oil; A) 50:50, B) 60:40, C) 70:30, D) 80:20, E) 90:10 and 
F) 99:1.  
Oil Ratio Dz (nm) PdI 
50:50 2500 0.258 
60:40 1290 0.242 
70:30 960 0.244 
80:20 820 0.194 
90:10 540 0.119 
99:1 270 0.07 
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3.5 CONCLUSIONS 
 
The hypothesis tested within this Chapter attempted to extend the value of the 
branched copolymer surfactants described in Chapter 2 by taking advantage of the 
joining of chains during the branching process. In principle, it was believed that a 
branched polymerisation containing mixed initiators would controllably and 
systematically allow control of the overall chain end composition of the surfactants. 
To test this hypothesis, a PEG-derived macroinitiator was substituted into the 
branching ATRP polymerisation of OEGMA at varying levels and in combination 
with a dodecyl-derived initiator and the variation of behaviour of the amphiphilic 
branched copolymers was studied. All studies, showed variations of behaviour that 
could be attributed to the varying chain end composition of the complex 
macromolecular samples. 
 
The ability of the branched amphiphilic copolymers, and the failure of all linear 
polymers and mixtures of linear polymers, to stabilise emulsions is hypothesised to be 
due to manipulation of a fine balance of the solution equilibrium of adsorbed and 
desorbed molecules at macro and nanoemulsion interfaces. The branched copolymer 
PBiB-p(OEGMA50-co-EGDMA0.8) was also unsuccessful in forming stable 
emulsions, presumably due to the lack of hydrophobic chain ends as hypothesised 
when designing this study. The removal of up to 75 mole % of hydrophobic chain 
ends, whilst still providing excellent emulsifier behaviour, is remarkable; comparative 
droplet sizes to DBiB-p(OEGMA50-co-EGDMA0.8) studied in Chapter 2, at both the 
macro- and nanoscale were observed.  
 
The results discussed in this chapter highlight the impact of the branched architecture 
on the copolymers’ ability to act as an efficient surfactant. The branched architecture 
appears to provide multiple hydrophobic chain ends per macromolecule thus creating 
a multiple anchoring effect at the oil/water interface and promoting rapid re-adsorption 
of hydrophobic chain ends following individual desorption, Figure 3.32; the desorbed 
primary chain ends are held in close proximity to the oil droplet surface and prevented 
from releasing into solution. In essence, to desorb the entire surfactant molecule would 
require the concerted and simultaneous desorption of multiple chain ends which is 
highly unlikely. It is important to recognise the slight changes that are seen between 
emulsions stabilised with branched copolymers of relatively low hydrophobic chain 
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end content. The Dz and Dn values are subtly higher for nanoemulsions formed under 
identical conditions and the packing of hydrophobic chains at interfaces may be less 
dense than materials with higher contents of hydrophobic chain ends; this may be of 
interest when considering the behaviour of materials in later Chapters. 
 
Figure 3.32 Effect of branched architecture on anchoring polymer chains near to the 
oil/water interface for ready readsorption.  
The anchoring of branched polymer emulsifiers to the oil/water interface is a key 
factor influencing the long term stability of the o/w emulsions. This was further shown 
by blending of linear polymers in statistical ratios to match the branched polymer 
counterparts. Blending of linear polymers led to multimodal laser diffraction traces, 
with multiple droplets being present in the emulsions spanning 1 – 20 µm and low 
levels of stability.  
 
The branched copolymer surfactants draw comparisons to Pickering emulsifiers which 
are stabilised by solid particles, as discussed in Section 1.6.3., due to the high 
molecular weights as well as their ability to stabilise macroemulsions and 
nanoemulsions over long periods of time. Pickering emulsifiers act by adsorbing onto 
the interface and preventing coalescence by the solid particles forming a rigid 
mechanical barrier.137 It is thought that the branched copolymers discussed in this 
investigation are preventing coalescence in a similar manner, where the highly 
branched structure with multiple hydrophobic anchoring points creates a dense coating 
as the polymer arranges itself at the interface. This provides a strong barrier further 
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reducing the chance of neighbouring droplets coalescing and cause emulsion phase 
separation.  
 
As it has been determined that a safe minimum of 25 mol % of the chain ends are 
required to be hydrophobic, the incorporation of a functional initiator group instead of 
PBiB can be explored and will be the subject of Chapter 4. This allows for tailoring of 
not only the emulsion droplet diameters but also the amount of functionality that is 
present at the surface of the oil droplet.  
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Effect of Thiol-functionalised 
Copolymer Surfactants within 
Mucoadhesive Emulsions 
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4.1 INTRODUCTION 
 
In Chapter 3, branched copolymers with a reduced number of hydrophobic chain ends 
were successfully used as surfactants to form o/w stabilised emulsions at both the 
macro- and nano-scale. It was shown that a) branched copolymers with as few as 10 
mole percent hydrophobic chain ends were able to produce stable macroemulsions, 
and b) branched macromolecules with just 25 mole percent of their chain ends bearing 
hydrophobic dodecyl groups were able to stabilise nanoemulsions with comparative 
droplet sizes to systems stabilised with DBiB-p(OEGMA50-co-EGDMA0.8); 
containing 100 % of its chain ends as hydrophobic alkyl groups. Further reduction to 
just 10 mole percent of the chain ends bearing dodecyl groups also formed potentially 
biologically-relevant nanoemulsions below 700 nm. Here, we hypothesise that the 
non-stabilising hydrophilic chain ends of these branched copolymers, derived in 
Chapter 3 from PEG-based macroinitiators, can be replaced with functional groups 
such as thiols, Figure 4.1, which may provide useful interaction with mucus-lined 
surfaces and resultant mucoadhesion.  
 
Figure 4.1 Inclusion of thiol functionality at the chain ends of branched copolymer 
surfactants. General polymer composition; SHxDBiBy-p(OEGMA50-co-EGDMA0.8). 
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4.1.1 Development of Masked-Thiol Functionalised ATRP Initiators 
 
Previously published work, from within the group, has shown masked thiol groups can 
be incorporated into a range of polymers by the use of xanthate-based initiators, 
including dendritic initiators, with the control expected from an ATRP reaction and 
the formation of linear and branched copolymers with high Mw at high monomer 
conversion, Figure 4.2.108  The dendritic initiator molecules have also been shown to 
successfully co-initiate an ATRP reaction in combination with a relatively short 
macroinitiators derived from PEG.109,125  Xanthate groups have been shown to be 
relatively easily de-protected to expose the masked thiol functionality post-
polymerisation; this approach avoids complications such as the laboratory use of thiols 
and oxidation or disulphide formation during storage. 
 
Figure 4.2 Dendritic initiator groups as previously used, with thiol groups masked by 
xanthate protecting groups. 1,2  
 
For the functional-emulsions targeted here, a small molecule ATRP initiator XanBiB, 
Figure 4.3, previously referred to as a generation zero dendritic initiator in literature 
reports,108 will be used in conjunction with DBiB to form a range of branched 
copolymer stabilisers containing varying thiol functionality after deprotection. This 
will subsequently target one thiol group per polymer chain end and the molar ratio of 
XanBiB:DBiB will be varied using the co-initiated polymerisation method described 
in Chapter 3.  
 
Figure 4.3 First generation xanthate initiator, Xan-G0-BiB, referred to as XanBiB in 
this study. 
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The scope of the target polymers is highlighted in Figure 4.4. As shown a large range 
of functionality may be achieved and varied within the polymer architecture. Emulsion 
characterisation using laser diffraction, optical microscopy and DLS will allow direct 
comparison of functional emulsions formed through this strategy and 
macroemulsions/nanoemulsions formed using the non-functional and mixed 
hydrophilic/hydrophobic branched copolymer emulsifiers described in Chapters 2 
and 3. The aim of this study was to determine whether thiolated chain end 
functionalised branched copolymers were able to stabilise macro- and nanoemulsions, 
whether such systems would be stable and, if so, whether variation of thiol content 
within the polymeric surfactant would direct the subsequent behaviour of the samples.  
This methodology could thereby potentially provide a route to tailor the properties and 
behaviour of macro- and nanoemulsions and offer benefits for future applications. 
As mentioned earlier, modified mucus-penetration and mucoadhesion is the main goal 
of the research, therefore, both quantitative and qualitative approaches to determine 
mucus interactions of these novel emulsions will be required. Taking a lead from 
literature reports, flow-through and static models of liquids will be evaluated, 
including the use of biosimilar (synthetic representations) and ex vivo mucus samples 
to assess emulsion behaviour with varying functionality.  
  
 
 
 
Figure 4.4 Schematic representation of masked-thiol functional branched copolymer emulsifiers targeted within this Chapter; OEGMA derived 
primary chains (blue), with branching derived from copolymerisation of EGDMA (orange) and co-initiation to include mucoadhesive character at 
different ratios by varying the molar ratios of XanBiB (pink) and DBiB (purple) initiators. 
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4.1.2 Quantification of Mucoadhesion  
 
The variety of methods used to assess mucoadhesion has led to wide diversity in the 
quantification and reporting of adhesion properties for different materials. For 
example, solid adhesives, tablets or hydrogels, can be assessed by the force required 
to detach them from an ex vivo mucosal surface.139 Force-detachment curves can 
subsequently be produced to determine adhesion; however, for liquid-based dosage 
systems such as emulsions, a more appropriate model is required. In the previous 
reports, methods such as rheology140, flow-through model combined with HPLC141 or 
fluorescently labelling of mucoadhesives have been utilised.142,143  
A ‘gutter’ flow-through model has been reported widely and a “typical” example is 
shown in Figure 4.5. Sections of ex vivo mucosal tissue are placed within the gutter 
and a liquid/semi-solid mucoadhesive is dosed to the tissue; flow of simulated 
biological fluid is then pumped to the top of a gradient and allowed to flow over the 
surface. If the mucoadhesive sample is drug-loaded, the amount of drug removed by 
the simulated biological fluid can be quantified via HPLC. Alternatively, the mucosal 
surface can be imaged post-flow, to visually assess the remaining sample and asses 
adhesion to the tissue substrate.35 
 
Figure 4.5 Schematic of a typical ‘gutter’ model for studies of mucoadhesives in 
liquid form; ex vivo mucosal tissue is often used for testing. Adapted from: M. T. Cook 
and V. V. Khutoryanskiy.35 
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An issue with many of the currently reported mucoadhesion studies is that they require 
the use of ex vivo tissue, where animals have been sacrificed specifically for their 
mucosal tissue. However, recently there has been a greater use of biosimilar mucosal 
mimics, which avoid the use of animal tissue as well as providing a readily accessible 
and reproducible method for adhesion studies within non-biological laboratories. 
4.2 SYNTHESIS OF CO-INTIATED THIOLATED POLYMERS 
FOR USE AS SURFACTANTS 
 
To synthesise the functional ATRP initiator XanBiB, two precursors 
2-((ethoxycarbonothioyl)thio) acetic acid, XanCOOH, and 2-hydroxyethyl 
bromoisobutyrate, HBiB, were required, Scheme 4.1.  
 
Scheme 4.1 Synthesis of i) 2-((ethoxycarbonothioyl)thio) acetic acid (XanCOOH), ii) 
2-hydroxyethyl bromoisobutyrate (HBiB) and iii) first generation xanthate 
bromoisobutyrate (XanBiB). 
XanCOOH was synthesised following reported methods, by reacting potassium ethyl 
xanthogenate with 2-bromoacetic acid for 16 hours, Scheme 4.1i, followed by 
isolatation by filtration and purification using liquid-liquid extraction to yield a white 
solid. The purified product was fully characterised by NMR (1H and 13C), Figure 4.6, 
and mass spectrometry (Appendix A7). HBiB synthesis also followed previous reports 
and required a TEA-catalysed mono-esterification of ethylene glycol with 
α-bromoisobutyryl bromide, Scheme 4.1ii. The reaction was also left for 16 hrs, and 
the purified product was isolated by a simple liquid-liquid extraction to yield a yellow 
oil; full characterisation was achieved by NMR (1H and 13C), Figure 4.7, and mass 
spectrometry (Appendix A8).  
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Figure 4.6 A) 1H NMR (CDCl3, 400 MHz) and B) 
13C NMR (CDCl3, 100 MHz) of 
HBiB. 
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Figure 4.7 A) 1H NMR (CDCl3, 400 MHz) and B) 
13C NMR (CDCl3, 100 MHz) of 
XanCOOH. 
The formation of the XanBiB ATRP initiator was accomplished by an esterification 
between these molecules (HBiB and XanCOOH), Scheme 4.1iii, using N,N’-
dicyclohexylcarbodiimide/4-(dimethylamino)pyridinium p-toluenesulfonate 
(DCC/DPTS) coupling. Removal of the N,N’-dicyclohexylurea by-product by 
filtration was followed by liquid-liquid extraction. The crude product was further 
purified by column chromatography, eluting ethyl acetate:hexane (30:70). A yellow 
oil was recovered and fully characterised by NMR (1H and 13C), Figure 4.8 A-B and 
mass spectrometry, Figure 4.9. 
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Figure 4.8 A) 1H NMR (CDCl3, 400 MHz) and B) 
13C NMR (CDCl3, 100 MHz) of 
XanBiB. 
The 1H NMR spectrum of a purified XanBiB is presented in Figure 4.8A, with the 
presence of some residual DCM which was later removed in vacuo. Reaction of HBiB 
with XanCOOH is shown to be completed via the appearance of a multiplet peak at 
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4.41 ppm attributed to CH2CH2 (labelled d). This peak is the merging of two well 
resolved triplets from HBiB attributed to HO-CH2 and CH2OC=O at 3.87 and 4.31 
ppm respectively, Figure 4.6A. The loss of a broad singlet at 6.4 ppm –OH, Figure 
4.7A, from XanCOOH is also observed.  Electrospray (ES) mass spectrometry was in 
agreement with the desired product, where XanBiB exact mass = 372 and the ES mass 
spectrometry experimentally determined [M+Na]+ m/z = 395. 
 
Figure 4.9 MS-ES (MeOH) analysis of XanBiB.  
4.2.1 Linear Polymer and Branched Copolymer Synthesis 
 
Linear polymers were synthesised from OEGMA using XanBiB by employing the 
same ATRP conditions as the linear polymers initiated by DBiB and PBiB detailed in 
Chapters 2 and 3. Again, a CuCl:bpy catalytic system (1:2:1 ratio with initiator group) 
was used and linear polymerisations targeted DPn = 50 monomer units were conducted 
in a IPA/water (92.5/7.5 % v/v) co-solvent mixture at 55 % w/v (monomer:solvent) at 
40 °C, Scheme 4.2.  Polymer reactions were monitored via 1H NMR, analysing the 
conversion of vinyl monomer peaks in reference to an internal standard (anisole) and 
all reactions were considered successful if very high monomer conversion (> 99 %) 
was achieved.  Removal of copper catalyst was performed in all cases via a neutral 
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alumina column and the polymers were purified by precipitation into petroleum ether 
(40/60). 
Scheme 4.2 Synthesis of a linear p(OEGMA) polymer initiated with XanBiB, 
targeting DPn = 50. 
As with previous studies reported in Chapters 2 and 3, branched XanBiB-initiated 
copolymers were also synthesised under the same conditions described above with 
addition of an EGDMA branching monomer at a ratio of 0.80:1.00 ([EGDMA]0 / [I]0 
= 0.80) to yield branched copolymers after 24 hours reaction time.  
Again, following the procedures and strategy for branched copolymer co-initiation 
described in Chapter 3, branched copolymers were synthesised by varying the molar 
ratio of initiator groups DBiB and XanBiB. Across the series of co-initiated branched 
copolymers, the molar ratio of DBiB:XanBiB was varied over a wide range spanning 
1:0 and 0:1, Scheme 4.3, yielding final polymer compositions of 
DBiBxXanBiByp(OEGMA50-co-EGDMA0.8) where x + y = 1; the resulting copolymer 
library, therefore, represents complex macromolecules with systematically varying 
molar ratios of hydrophobic and functional chain ends whilst maintaining the same 
hydrophilic OEGMA based polymer core, Figure 4.4. The specific DBiB:XanBiB 
co-initiation ratios employed here were: 0.92:0.08, 0.75:0.25, 0.5:0.5, 0.25:0.75, 
0.1:0.9 and 0.05:0.95.  
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Scheme 4.3 Co-initiated branched copolymerisation of OEGMA and EGDMA with 
varying ratios of DBiB:XanBiB. 
4.2.2 Post-polymerisation Functionalisation of Co-Initiated Branched 
Copolymers  
 
Post-polymerisation deprotection/functionalisation was carried out on the 
xanthate-containing linear and branched macromolecules via a one-pot removal of the 
xanthate group with 10:1 excess of n-butylamine with respect to xanthate groups, as 
previously reported, Scheme 4.4.108,138,144 Thiolated polymer samples were isolated by 
precipitation of crude polymer samples twice into cold hexane.  
 
Scheme 4.4 Deprotection of XanBiBxDBiBy-p(OEGMA50-co-EGDMA0.8) in the 
presence of n-butylamine (anhydrous THF, room temperature, 1.5 hrs) to yield 
SHxDBiBy-p(OEGMA50-co-EGDMA0.8) where x+y = 1 = [I]. 
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Removal of the protecting group was characterised and confirmed by 1H NMR, Figure 
4.10. Loss of the quartet at 4.65 ppm attributed to CH3CH2-O (labelled a) is observed, 
which is characteristic of the deprotection of all polymers.  
 
Figure 4.10 1H NMR (400 MHz, CDCl3) A) XanBiB0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8) and SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) showing loss of 
xanthate protecting group. 
4.2.3 Polymer Characterisation 
 
As with the polymers synthesised in Chapters 2 and 3, all xanthate linear and branched 
copolymers were characterised by GPC and 1H NMR to determine success of each 
polymerisation, Table 4.1. 1H NMR end-group analysis allows number average 
molecular weight to be determined for linear polymer samples, but provides little 
useful information for co-initiated branched copolymers. 
 
 
 
 
 
ppm 
 Chapter 4 
116 
 
Table 4.1 GPC and 1H NMR characterisation of OEGMA-derived polymers co-
initiated with XanBiB:DBiB in varying molar ratios. 
  1H NMRb GPCa 
Target Polymer Composition Conversion 
(%) 
Theoretical 
Mn 
Mw 
(g/mol) 
Mn 
(g/mol) 
Ɖ 
 
XanBiB-p(OEGMA50) 99 15, 373 39,300 22,800 
 
1.7 
DBiB0.92XanBiB0.08-p(OEGMA50-
co-EGDMA0.8) 
>99 - 297,024 45,856 6.3 
DBiB0.75XanBiB0.25-p(OEGMA50-
co-EGDMA0.8) 
>99 - 147,522 38,240 3.8 
DBiB0.50XanBiB0.50-p(OEGMA50-
co-EGDMA0.8) 
>99 - 401,500 52,000 7.7 
DBiB0.25XanBiB 0.75-p(OEGMA50-
co-EGDMA0.8) 
>99 - 281,893 70,749 3.9 
DBiB0.10XanBiB 0.90-p(OEGMA50-
co-EGDMA0.8) 
>99 - 134,501 37,151 3.6 
DBiB0.05XanBiB 0.95-p(OEGMA50-
co-EGDMA0.8) 
>99 - 367,200 64,800 5.7 
XanBiB-p(OEGMA50-co-
EGDMA0.8) 
99 - 50,818 23,824 2.1 
a GPC (DMF/0.01 M LiBr Eluent 60oC); b 1H NMR (CDCl3,400 MHz) 
 
As shown in previous Chapters, the inclusion of a low concentration of EGDMA leads 
to a broadening of dispersity and considerable increase in weight average molecular 
weight. This can be readily seen in the refractive index and right angle light scattering 
chromatograms of the branched copolymers, Figure 4.11, and was previously seen for 
the branched copolymers of Chapters 2 and 3. All polymers co-initiated with 
DBiB:XanBiB reached 99 % or greater conversion which is important for 
intramolecular branching in these copolymerisation strategies. 
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Figure 4.11 Overlay of RI (black) and RALS (blue) chromatograms of A) 
DBiB0.92XanBiB0.08-p(OEGMA50-co-EGDMA0.8), B) DBiB0.75XanBiB0.25-
p(OEGMA50-co-EGDMA0.8), C) DBiB0.50XanBiB0.50-p(OEGMA50-co-EGDMA0.8), 
D) DBiB0.75XanBiB0.25-p(OEGMA50-co-EGDMA0.8), E) DBiB0.10XanBiB0.90-
p(OEGMA50-co-EGDMA0.8) and F) DBiB0.05XanBiB0.95-p(OEGMA50-co-
EGDMA0.8). 
Interestingly, comparison of the linear XanBiB-p(OEGMA50) and branched XanBiB-
p(OEGMA50-co-EGDMA0.8), Figure 4.12, did not display the same dramatic and 
characteristic increase in Mw and Mn as expected for the inclusion of a EGDMA into 
the copolymerisation. The linear polymer contained a high molecular weight shoulder 
on the RI chromatogram, showing a small amount of intermolecular coupling during 
the polymerisation, as discussed in Section 2.2.2 resulting in the higher than expected 
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dispersity value of 1.7 and the higher Mw value of 39,370 g/mol. The lack of branching 
in this copolymerisation, utilising just the single XanBiB initiator is unclear, but these 
polymers were not studied for emulsion formation. 
 
Figure 4.12 Overlay of RI (black) and RALS (blue) traces of A) XanBiB-
p(OEGMA50) and B) XanBiB-p(OEGMA50-co-EGDMA0.8). 
As described in Chapter 3 Section 3.2.2, the data collected by the GPC analysis allows 
the determination of the cumulative weight fraction vs. molecular weight relationship 
for each polymer studied. This analysis was conducted for the xanthate containing 
branched copolymers and the three same nominal molecular weights of 500,000, 
750,000 and 1,000,000 g/mol were chosen to illustrate the fraction of very highly 
branched material in each sample, Table 4.2. These molecular weight values represent 
structures that have approximately 19, 28 and 37 conjoined primary chains assuming 
an average Mn of the primary chains as 26,775 g/mol (average of the linear polymer 
primary chain Mn values for XanBiB-p(OEGMA)50 and DBiB-p(OEGMA)50).  
Unfortunately, no direct trend was observed for the branched copolymers, however a 
range of values from 5.6 wt % (DBiB0.10XanBiB0.90-p(OEGMA50-co-EGDMA0.8)) to 
18.9 wt % (DBiB0.50XanBiB0.50-p(OEGMA50-co-EGDMA0.8)) of the samples were 
shown to contain a minimum of 19 conjoined chains and statistically, these high 
molecular weight species would be bearing at least one thiol group, even at the lowest 
ratio of XanBiB used within the co-initiated copolymerisations (8 mol %).  
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Table 4.2 Percentage of polymer weight fraction above 500,000, 750,000 and 
1,000,000 g/mol analysed from cumulative weight fraction graph plotted from GPC 
data (DMF/0.01 M LiBr Eluent 60 oC, 1 mL/min). 
Polymer Composition Weight % 
>500,000 
(g/mol) 
Weight % 
>750,000 
(g/mol) 
Weight % 
>1,000,000 
(g/mol) 
DBiB0.92XanBiB0.08-
p(OEGMA50-co-
EGDMA0.8) 
17.7 11.6 8 
DBiB0.75XanBiB0.25-
p(OEGMA50-co-
EGDMA0.8) 
7.7 3.4 1.7 
DBiB0.50XanBiB0.50-
p(OEGMA50-co-
EGDMA0.8) 
18.9 13 9.4 
DBiB0.25XanBiB0.75-
p(OEGMA50-co-
EGDMA0.8) 
7.7 3.9 2.1 
DBiB0.10XanBiB0.90-
p(OEGMA50-co-
EGDMA0.8) 
5.6 2.1 0.9 
DBiB0.05XanBiB0.95-
p(OEGMA50-co-
EGDMA0.8) 
15.6 9.9 6.6 
 
The lack of any discernible trends is further exemplified in Figure 4.13. The polymer 
containing the highest weight of high molecular weight species, fraction across all of 
the nominal molecular weights, is DBiB0.50XanBiB0.50-p(OEGMA50-co-EGDMA0.8), 
where the weight fraction of the polymer  >1,000,000 g/mol (> 37 primary chains) was 
9 %. 
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Figure 4.13 Weight fraction of co-initiated XanBiBxDBiBy-p(OEGMA50-co-
EGDMA0.8) branched copolymers with molecular weights greater than A) 500,000, B) 
750,000 and C)  1,000,000 g/mol, plotted against molar percent of XanBiB initiator 
used in the co-initiated copolymerisation. 
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4.2.2 Kinetic Evaluation of Singly Initiated and Coinitiated Linear 
Polymerisations of OEGMA. 
 
The kinetics of a XanBiB initiated linear polymerisation of OEGMA was compared 
with the formation of a mixture of linear polymers through the simultaneous co-
initiation of OEGMA using a 1:1 ratio of DBiB and XanBiB. The polymerisations 
were monitored by 1H NMR, Figure 4.14, and monomer conversion was determined 
by the ratio between OEGMA vinyl peaks at 6.13 and 5.58 ppm and p(OEGMA) 
pendant chain at 3.4 ppm.  
Polymerisations were studied over 7 hours, with samples taken and studied hourly. As 
shown by the 1H NMR spectra, vinyl peaks could not be distinguished after 6 hours 
for the reaction forming XanBiB-p(OEGMA); after 5 hours reaction within the co-
initiated polymerisation, only a very weak signal for the vinyl protons was observable 
and no residual vinyl bonds were detectable after 6 hours. The similarity of the 
consumption of monomer in these reactions suggests that the polymerisations are not 
affected by the mixture of initiators and that the two initiators appear to lead to similar 
overall rates of polymerisation. 
The 1H NMR data may also be plotted to generate a kinetic plot showing both 
conversion vs time and the semi-logarithmic plot that is regularly used to confirm a 
consistent concentration of radicals within the ATRP reaction, Figure 4.15. 
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Figure 4.14 Kinetic analysis of ATRP polymerisations using xanthate-functional 
initiators: 1H NMR (CDCl3, 400 MHz) spectra for the synthesis of A) XanBiB-
p(OEGMA50) and B) the simultaneous formation of  DBiB-p(OEGMA50) and 
XanBiB0.5-p(OEGMA50)  (1:1 molar ratio).  
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The graphical representations of the kinetic studies are shown in Figure 4.15. First 
order reactions are indicated in both cases, with high conversion being achieved at a 
similar time and comparable rates of monomer consumption.  
 
Figure 4.15 Kinetic analysis of A) XanBiB-p(OEGMA50) synthesis and B) the 
simultaneous formation of DBiB-p(OEGMA50) and XanBiB0.5-p(OEGMA50). 
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4.2.4 Critical Micelle Concentration Measurements of Thiol-functional 
Branched Copolymers 
 
As the thiol-functional branched copolymers were designed to be utilised as functional 
stabilisers for macro- and nano-emulsions, the study of the aqueous solutions of the 
copolymers was conducted to determine self-assembly behaviour and critical micelle 
concentrations as detailed in Section 3.2.4.1, for the analogous copolymers that were 
co-initiated by DBiB and PBiB. The CMC values were obtained by calculating the 
intercept between the lines of best fit for the linear decrease in surface tension and the 
first plateau area, Figure 4.16.  
All, surface tension measurements were conducted as outlined in Chapter 3, Section 
3.2.4.1 using a Kibron Delta-8 surface tensiometer at 20 °C. Aqueous polymer 
solutions were prepared at 30 wt % and subsequent dilutions gave 30 different 
concentrations down to 6.9 x 10-9 wt %. Use of a 96 well-plate allowed for high 
throughput analysis of samples after 50 μL of each copolymer surfactant (n=8) was 
added to each well, with pure water as a control. The measured surface tension values 
were plotted against the surfactant concentration (logarithmic scale). 
Interestingly, the thiol-functional branched copolymer solutions also showed the same 
multiple plateau regions as copolymer concentrations were increased. This complex 
surfactant behaviour was previously interpreted in Chapter 3 as potentially resulting 
from the diverse mixture of macromolecular architectures, molecular weights and 
chain end compositions within each sample containing both PBiB and DBiB initiator 
residues; it is rational to assume the same behaviour would be seen here. 
 
 
 
 
 
  
 
Figure 4.16 CMC data for thiol-functional branched copolymers; SH0.05DBiB0.95-p(OEGMA50-co-EGDMA0.8) ( ), SH0.25DBiB0.75-p(OEGMA50-
co-EGDMA0.8) ( ), SH0.50DBiB0.50-p(OEGMA50-co-EGDMA0.8) ( ), and SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) ( ). n = 8, error bars = 
standard deviation. 
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The range of thiol functional SHxDBiBy-p(OEGMA50-co-EGDMA0.8) branched 
copolymer emulsifiers, studied here, show remarkably similar surface tension 
behaviour with nearly identical STmin values and a narrow range of observed CMC 
values. STmin is a relatively arbitrary and non-standard value that is reported here for 
completeness and, as can be seen in Figure 4.16, the behaviour at higher copolymer 
concentrations is difficult to interpret. The CMC values of these macromolecules, 
ranging between 9.12 x10-6 and 1.83 x10-5 mg/L are in marked contrast to those 
determined in Chapter 3 for DBiBxPBiBy-p(OEGMA50-co-EGDMA0.8) branched 
copolymers (1.08 x10-8 to 4.74 x10-8 mg/L); nearly three orders of magnitude in 
concentration difference is seen. This would indicate the DBiBxPBiBy-p(OEGMA50-
co-EGDMA0.8) copolymers are a more surface active series of materials, and are 
potentially more able to align the hydrophobic chain ends at the air-water interface. 
Table 4.3 CMC measurements determined from surface tensiometer measurements 
for branched thiol-functional copolymers and concentration where surface tension is 
lowest (STmin). Error = graphical percentage error.  
Polymer CMC  
(mg/L) 
STmin 
(mg/L) 
SH0.25DBiB0.75-p(OEGMA50-co-EGDMA0.8) 9.12 x 10
-6 (± 8.7 %) 1.46 x 10-4 
SH0.50DBiB0.50-p(OEGMA50-co-EGDMA0.8) 9.13 x 10
-6 (± 8.4 %) 1.50 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) 1.55 x 10
-5 (± 16.2 %) 1.50 
SH0.95DBiB0.05-p(OEGMA50-co-EGDMA0.8) 1.83 x 10
-5 (± 2.0 %) 1.50  
 
4.2.5 Contact Angle Measurements of Thiol-functional Branched Copolymers 
 
Contact angle measurements of aqueous thiol-functional branched copolymer 
solutions (5 wt % concentration) were taken using the same DSA instrument and static 
sessile drop method as described in Chapter 3. Also, as previously described, a 
hydrophobic PTFE substrate in tape form was applied to a glass slide, and 5 µL 
droplets of polymer solution were applied and the contact angle measured (n = 10), 
Figure 4.17. 
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Figure 4.17 A) Contact angle measurements of thiol-functional branched copolymers 
and pictures of contact angle on PTFE substrate of B) SH0.05DBiB0.95-p(OEGMA50-
co-EGDMA0.8), C) SH0.25DBiB0.75-p(OEGMA50-co-EGDMA0.8),  D) SH0.50DBiB0.50-
p(OEGMA50-co-EGDMA0.8),  and E) SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8). 
The contact angle values obtained for solutions of thiol-functional branched 
copolymers, Table 4.5, are all below the observed value of pure water of 125° ± 3.6°, 
described in Chapter 3, suggesting improved wetting of the PTFE surface and 
presentation of hydrophobic groups to the air/water interface. The lowest contact angle 
was observed for SH0.05DBiB0.95-p(OEGMA50-co-EGDMA0.8) as expected (median 
value = 85.03°), and this is highly comparable to the value obtained for the fully 
hydrophobic DBiB-p(OEGMA50-co-EGDMA0.8) of 79.38 ° (median). Additionally, 
contact angle values for solutions containing branched copolymers with nominally 
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identical 75 mole percent DBiB-derived chain ends, namely SH0.25DBiB0.75-
p(OEGMA50-co-EGDMA0.8) and DBiB0.75PBiB0.25-p(OEGMA50-co-EGDMA0.8), are 
also correspondingly higher than their counterparts at approximately 108 ° and 102 ° 
(median) showing a reduction in wetting with a reduced number of hydrophobic chain 
ends as expected.  
Table 4.5 Contact angles measured for aqueous solutions of thiol-functional branched 
copolymer surfactants. 
 Contact Angle (°) 
Branched Copolymer Mean Median Std. Dev. 
(±) 
DBiB-p(OEGMA50-co-EGDMA0.8) 79.59 79.38 2.16 
SH0.05DBiB0.95-p(OEGMA50-co-
EGDMA0.8) 
85.28 85.03 6.39 
SH0.25DBiB0.75-p(OEGMA50-co-
EGDMA0.8) 
107.95 108.36 9.09 
SH0.50DBiB0.50-p(OEGMA50-co-
EGDMA0.8) 
93.71 93.62 6.66 
SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8) 
104.33 104.26 4.72 
 
Despite the significant difference in CMC values, reported in Section 4.2.4., the two 
libraries of branched copolymer surfactants derived from mixtures of DBiB with either 
PBiB or the deprotected XanBiB (thiol functionality) were clearly surface active and 
comparable within their chemistry and solution behaviour. Studies of emulsification 
were therefore conducted to establish the potential to form thiol-functional 
macroemulsions and nanoemulsions. 
4.3 MUCOADHESIVE MACROEMULSIONS 
 
The targeted mucoadhesive macroemulsions and nanoemulsions must contain 
biologically relevant oil phases and therefore all studies using the SHxDBiBy-
p(OEGMA50-co-EGDMA0.8) branched copolymer surfactants as emulsifiers were 
conducted using either squalene or castor oil, Figure 4.18.  
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Figure 4.18 Chemical structures of A) Squalene and B) Castor oil.  
4.3.1 Macroemulsion Formation using Mucoadhesive Branched Copolymer 
Emulsifiers 
 
Macroemulsions were generated via mechanical shear using an overhead homogeniser 
(Ultra-Turrax 25, IKA) and aqueous branched copolymer polymer solutions 
(5 mg/mL) and squalene in a 1:1 volume ratio for 2 minutes at 24,000 rpm in a 
procedure identical to previous emulsion studies reported in Chapter 3. The resulting 
emulsions were left to stand overnight and equilibrate before quantitative analysis by 
laser diffraction spectroscopy. The SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) 
branched copolymer was selected for detailed study as this polymer had shown to have 
a good overall balance of molecular weight, thiol functionality and significant weight 
fractions of highly branched species, Tables 4.1 and 4.2.  
For completeness, and as seen for linear PBiB-initiated materials, linear 
SH-p(OEGMA50) did not form stable macroemulsions, with the minimal emulsion 
layer that could be retrieved after 24 hours displaying a bimodal distribution 
determined from laser diffraction analysis, Figure 4.19. The samples rapidly creamed 
and separated and, after 3 days of storage, full separation of the oil and aqueous phases 
was observed.  
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Figure 4.19 D[4,3] trace of SH-p(OEGMA50) stabilised squalene macroemulsion layer 
present within a rapidly separating sample. 
4.3.2 Mucoadhesive Branched Copolymer Stabilised Macroemulsion 
Characterisation 
 
As stated above, SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) branched copolymer 
stabilised squalene macroemulsions were selected for detailed study; the samples were 
characteristically white and opaque in appearance, with creaming of the emulsion but 
no apparent separation of the oil phase. Laser diffraction spectroscopy was used to 
assess the long term stability of the emulsion when stored at ambient temperature. The 
volume weighted D[4,3] after 24 hrs of equilibration was 15.4 μm and maintained a very 
similar size when measured repeatedly over 5 days, 2, 3 and 4 weeks ( D[4,3] = 15.2, 
15.8, 15.9 and 16.2 μm respectively), Figure 4.20.  
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Figure 4.20 Overlay of D[4,3] traces showing stability of thiolated branched  
copolymer, SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8), stabilised squalene 
macroemulsions stored at ambient temperature for up to 4 weeks.  
The stability of these macroemulsions was somewhat surprising due to the potential 
for thiol-thiol coupling reactions to occur under these conditions and the lack of 
oxygen exclusion within the stored samples. The apparent lack of disulphide 
formation, expected to lead to considerable emulsion droplet growth, is indicative of 
considerable steric repulsions between the emulsion droplets derived from the 
branched copolymer emulsifiers. This is noteworthy as it also suggests that the thiol 
groups are somewhat hidden from each other and do not readily come into contact.  
Intra-droplet disulphide bonds cannot be ruled out, however, and the resulting increase 
in branched copolymer molecular weight may lead to increased macroemulsion 
emulsion stability. This possibility would also lead to loss of surface thiol functionality 
and potential diminishing of mucoadhesive properties. Although the D[4,3] values did 
increase slightly over time, the emulsion measurements consistently gave a 
monomodal distribution with no observable oil release. 
For subsequent studies of mucoadhesion, SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8) stabilised macroemulsions were loaded with one of two hydrophobic 
dyes; Oil red O or Oil blue A. The dyes were incorporated into emulsions at 0.1 wt % 
for ease of visualisation on the mucosal surface, as shown in Figure 4.20. Dye-loaded 
macroemulsions stabilised by DBiB-p(OEGMA50-co-EGDMA0.8) were also 
generated to allow comparison with thiol-functional macroemulsions, Figure 4.21 B. 
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Figure 4.21 Optical microscopy images of various squalene macroemulsions at 20x 
zoom magnification; A) blank emulsion stabilised with SH0.75DBiB0.25-p(OEGMA50-
co-EGDMA0.8), B) oil blue A-loaded (0.1 wt %) emulsion stabilised with DBiB-
p(OEGMA50-co-EGDMA0.8), and C) Oil red O-loaded (0.1 wt %) emulsion stabilised 
with SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8). 
In these experiments, and probably due to slight experimental variation, the resulting 
macroemulsions had a D[4,3] value of 13 μm, compared to that of the blank emulsion 
which was 15.2 μm. The optical images were analysed by FIJI (V 1.51n) to generate 
number distributions of droplet diameters, plotted as histograms to provide an 
indication of the breadth and frequency within each sample, Appendix A12-15. Oil 
red O and Oil blue A containing macroemulsions showed comparable distributions, 
indicating that approximately 90 and 95 % of the droplet populations were of 
diameters below 15 μm for Oil blue A and Oil red O respectively, Figure 4.22. 
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Figure 4.22 Histogram representation of optical microscopy analysed by FIJI (V 
1.51n) data for A) Oil blue A and B) Oil red O encapsulated squalene macroemulsion 
stabilised with the SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) branched copolymer 
surfactant.  
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4.3.3 Thiol-functional Macroemulsion Muco-interactive Studies 
 
The assessment of muco-interactions, including mucoadhesion, requires either 
biological mucus samples or synthetic equivalents of natural mucus. Several 
biosimilar mucus preparations have been reported and a preparation outlined by Boegh 
et al.145 was selected for these studies as the rheological profile of this synthetic 
equivalent was reportedly optimised to strongly resemble natural porcine intestinal 
mucus. As previously discussed in Chapter 1, mucins are high molecular weight, 
heavily glycosylated natural molecules which are responsible for the rheological 
properties of mucus. Commercially available mucins are limited to those sourced from 
porcine stomach or bovine submaxillary glands and purification leads to large 
reduction in the molecular weight of the mucins146. Boegh et al. determined that the 
inclusion of the high molecular weight poly(acrylic acid), Carbopol 940, led to 
modification of the biosimilar mucus to mimic the rheological shear-thinning 
dominant elastic behaviour of porcine intestinal mucus with similar viscosity. The 
resulting biosimilar mucus, Figure 4.23,  contained porcine mucin (5 % w/v), 
poly(acrylic acid) (0.9 % w/v), bovine serum albumin (BSA) (0.65 w/v %) and a lipid 
mixture (0.46 % cholesterol, 0.18 % phosphatidylchloine and 0.11 % linoleic acid) 
with polysorbate 80 (0.16 %). 
 Figure 4.23 Synthetic biosimilar mucus mimicking porcine intestinal secretions.  
To establish the potential for thiol-functional macroemulsions to demonstrate varying 
behaviour in the presence of mucus, two stable macroemulsions were generated using 
either the non-functional branched copolymer DBiB-p(OEGMA50-co-EGDMA0.8), 
described in Chapter 3, or the heavily thiol-functionalised SH0.75DBiB0.25-
p(OEGMA50-co-EGDMA0.8). 
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These initial muco-interactive studies were conducted via optical microscopy using 
biosimilar mucus (500 μL) spread across a glass side and additional of a concentrated 
emulsion (100 μL) to the mucosal surface. The sample were viewed immediately by 
optical microscopy and monitored over a 10-minute time period, Figure 4.23. Non-
functional DBiB-p(OEGMA50-co-EGDMA0.8) stabilised macroemulsions appeared to 
spread evenly across the mucus, with individual droplets easily observed, 
Figure 4.23A, and no observable aggregation of droplets or emulsion instability. This 
was in stark contrast to the thiol-functionalised macroemulsion, which upon contact 
with the mucus showed aggregation of droplets, Figure 4.24 B and C, and rupture of 
dye-loaded oil at several points over the 10-minute time period; additionally, no 
migration of emulsion droplets was observed across the sample.  
 
Figure 4.24 Optical microscopy images of branched copolymer stabilised emulsions 
in contact with biosimilar mucus; A) Oil blue A-loaded DBiB-p(OEGMA50-co-
EGDMA0.8) stabilised squalene macroemulsion after 10 minutes; and Oil red O-loaded 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) stabilised squalene macroemulsions 
after B) immediate application and C) 10 minutes in contact with the substrate. 10x 
zoom magnification, scale bars = 200 μm. 
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The lack of motion within the thiol-functionalised macroemulsion suggested strong 
mucoadhesive behaviour, potentially through rapid oxidative disulphide bond 
formation between the cysteine regions of the biosimilar mucus and the thiolated 
branched copolymer surfactant. Furthermore, the general theory of mucoadhesion 
involves two stages which are loosely defined as the contact and consolidation stages. 
Chemical bond formation during the consolidation stage is characteristic of the so-
called “second generation” mucoadhesive materials and disulphide bond formation is 
the basis of most thiolated mucoadhesive macromolecules. Here, we hypothesise that 
the formation of disulphide bonds at the contact point leads to a disturbance of the 
macroemulsion stabilisation, affecting the contact angle at the mucus-emulsion 
interface and causing the droplet to rupture with subsequent release of encapsulated 
material. This was further probed by the addition of SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8) stabilised squalene macroemulsions loaded with Oil red O and Oil blue 
A to biosimilar mucus, where again the triggered release of dye was observed, Figure 
4.25 A and B. The demulsification of macroemulsion droplets was readily visualised 
with consequent blending of the dye loaded oil droplets creating a third purple oil 
phase while still maintaining individual blue and red areas. This behaviour opens up 
the possibility for these macroemulsions to be used as a dual treatment system which 
could be studied further in the future.  
 
Figure 4.25 Burst release studies visualised by optical microscopy of Oil red O and 
Oil blue A loaded SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) stabilised squalene 
macroemulsions in the presence of biosimilar mucus at time intervals of A) 0 mins 
and B) 10 mins. A = 10x zoom magnification, scale bar = 200 μm, B = 20x zoom 
magnification, scale bar = 100 μm. 
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This dramatic mucus-interacting behaviour of the thiol-functional macroemulsions 
was unexpected as the 4-week storage study suggested no instability or thiol-thiol 
coupling between polymer chains. Furthermore, the non-functional macroemulsion 
behaviour suggested no stability issues following interaction with the biosimilar 
mucus surface, although as full recovery of the emulsion from the mucus surface was 
not possible this could not be fully established. Previous reports of mucoadhesive 
thiomers did not suggest mucus-triggered release may occur in these systems, 
however, the potential for a triggered/mucus-interacting drug delivery system was 
considered as particularly useful for delivery to sites such as the eye, where the mucus 
turnover time is rapid and long term stability of commercial therapies is a known issue, 
see Chapter 5.  
The potential for similar behaviour from thiol-functionalised nanoemulsions led to 
similar studies. A range of adhesive and release behaviour would be ideal, to allow 
targeting of specific benefits as required by different disease states or administration 
routes; for example, increasing the retention time of orally-dosed drug delivery 
systems, without immediate release, may improve absorption of drug molecules into 
the blood stream.  
4.4 MUCOADHESIVE STUDIES OF THIOL-FUNCTIONAL 
BRANCHED COPOLYMER STABILISED NANOEMULSIONS  
 
4.4.1 Nanoemulsion Formation 
 
For this study SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) was again selected as the 
branched copolymer stabiliser to directly compare behaviour with similar 
macroemulsions and nanoemulsions stabilised with this macromolecule. O/w 
nanoemulsions were generated using the same solvent evaporation methodology 
described in Chapter 3, where the ratio of volatile:non-volatile oil was varied to tailor 
the droplet size. In this study, castor oil was selected as the non-volatile oil phase due 
to previous research published within the group showing successful nanoemulsion size 
tailoring;107 castor oil is also known to be non-toxic and a safe drug delivery vehicle 
within the body. Nanoemulsions were left at ambient temperature following 
homogenisation, allowing for full removal of volatile co-solvent by evaporation which 
was monitored gravimetrically. Similar observations were made for macroemulsions 
generated using linear homopolymer showed that, stable nanoemulsions were not able 
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to be formed using SH-p(OEGMA50) and rapid demulsification was observed. As 
expected, SH-p(OEGMA50-co-EGDMA0.8) was also unsuccessful as an emulsifier for 
nanoemulsion formation. 
4.4.2 Nanoemulsion Characterisation 
 
A study was undertaken to evaluate whether SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8) stabilised nanoemulsions would exhibit the triggered demulsification 
seen for macroemulsions stabilised by the same branched copolymer. A 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) stabilised nanoemulsion was generated 
using the methodology outlined in Chapter 3, utilising ethyl acetate:castor oil in a 99:1 
ratio incorporating Oil red O (0.05 wt % loading) for ease of observation against a 
biosimilar mucus substrate, Figure 4.26.  
 
Figure 4.26 DLS nanoemulsion size distributions of castor oil-based nanoemulsions: 
A) loaded with Oil red O (0.05 wt %) and with SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8) as polymeric surfactant and B) SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8) as polymeric surfactant, unloaded. 
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DLS analysis of the SH0.25DBiB0.75-p(OEGMA50-co-EGDMA0.8) stabilised castor oil 
nanoemulsion with Oil red O yielded a Dz value of 250 nm and a low PdI of 0.10, 
Table 4.4. No visual indication of instability was observed during storage before 
evaluation for mucus-interacting properties with biosimilar mucus. Characterisation 
of the nanoemulsion containing Oil red O was almost indistinguishable an analogous 
nanoemulsion generated in the absence of Oil red O, showing a lack of influence from 
the encapsulated dye on the nanoemulsion formation process or the branched 
copolymer surfactant. 
Table 4.4 DLS analysis of castor oil nanoemulsion with SH0.75DBiB0.25-p(OEGMA50-
co-EGDMA0.8) as polymeric surfactant, loaded with Oil red O (0.05 wt %) or 
unloaded. 
Polymer Oil Red O 
wt % 
Dz  
(nm) 
Dn  
(nm) 
PdI 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) 
 
0.05  250 230 0.10 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) - 249 230 0.10 
 
A sample of the Oil red O containing nanoemulsion (10 μL) was applied to the 
biosimilar mucus and monitored visually for any triggered release of oil and dye, 
which may indicate similar behaviour to the thiol-functional macroemulsion; no 
release of dye-containing oil was observed visually over 10 minutes, with the 
nanoemulsion appearing to be predominantly static on the mucosal surface 
throughout. Figure 4.27 shows the behaviour of the thiol-functional nanoemulsion 
following immediate addition to biosimilar mucus and after 10 minutes. The thiol-
functionalised nanoemulsions appeared, therefore, to display mucoadhesive behaviour 
but no triggering of demuslification. This may be due to the reduced droplet diameter 
limiting the number of disulphide bonds formed between polymer stabiliser and the 
mucus surface and a lack of sufficient perturbation of the oil/water interface which 
would lead to rupturing of the oil droplets.  
 Chapter 4 
140 
 
 
Figure 4.27 Mucus-interaction studies of SH0.25DBiB0.75-p(OEGMA50-co-
EGDMA0.8) nanoemulsion on biosimilar mucus after A) 0 minutes and B) 10 minutes. 
 
As no triggered release was shown by a 250 nm SH0.25DBiB0.75-p(OEGMA50-co-
EGDMA0.8) stabilised nanoemulsion, in stark contrast to the corresponding 
macroemulsion (13 µm), the relationship of release behaviour and droplet diameter 
would be an interesting area of future research. Tailoring of nanoemulsion droplet size 
was evaluated to establish whether thiol functional emulsifiers were able to act 
similarly to the non-thiol containing branched copolymers. SH0.75DBiB0.25-
p(OEGMA50-co-EGDMA0.8) was used to stabilise nanoemulsions with varying ratios 
of volatile solvent to non-volatile solvent leading to tailored droplet sizes, as outlined 
in Chapter 3. To tailor droplet diameters the ratio of ethyl acetate:castor oil was varied 
in ratios of 50:50, 60:40, 70:30, 80:20, 90:10 and 99:1, Figure 4.28, Appendix Table 
A1. These nanoemulsions were studied for mucus-triggered release but no such 
behaviour was seen in this size range. 
 
Figure 4.28 Tailored droplet size (Dz) of thiol-functional copolymer SH0.75DBiB0.25-
p(OEGMA50-co-EGDMA0.8) stabilised nanoemulsions were varying ethyl 
acetate:castor oil ratios. 
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The trend seen in Figure 4.28 is highly analogous to the previous tailoring of 
nanoemulsion droplet size presented in Chapters 2 and 3 for analogous branched 
copolymer stabilisers. It is important to compare and contrast the tailoring of 
nanoemulsion droplet size to establish if clear trends can be seen and insight into the 
mechanism of branched copolymer emulsifiers can be determined. As detailed in 
Table 4.5, thiol-functional droplet diameters were able to be tailored from 1300 nm to 
270 nm by increasing the amount of volatile solvent present in the oil phase/decreasing 
the amount of non-volatile oil.  
Table 4.5 DLS analysis of tailored nanoemulsion droplets by varying the ratio of 
volatile:non-volatile oil and varying branched block copolymer stabiliser. 
 Nanoemulsion hydrodynamic diameter using different branched 
copolymer stabilisers 
Dz (nm) 
EtOAc:castor 
oil volume 
ratio 
DBiB0.25PBiB0.75-
p(OEGMA50-co-
EGDMA0.8) 
SH0.75DBiB0.25-
p(OEGMA50-co-
EGDMA0.8) 
DBiB-
p(OEGMA50-co-
EGDMA0.8) 
50:50 2500 1370 1036 
60:40 1290 960 766 
70:30 960 706 635 
80:20 820 620 481 
90:10 540 530 486 
99:1 270 280 211 
 
Comparison with data generated from similar tailoring using DBiB0.25PBiB0.75-
p(OEGMA50-co-EGDMA0.8) and DBiB-p(OEGMA50-co-EGDMA0.8) showed an 
interesting trend where DBiB-p(OEGMA50-co-EGDMA0.8) stabilised nanoemulsions 
consistently exhibited the smallest hydrodynamic diameters across all ratios of volatile 
and non-volatile oil; DBiB0.25PBiB0.75-p(OEGMA50-co-EGDMA0.8) stabilised 
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nanoemulsions were consistently the largest with SH0.25DBiB0.75-p(OEGMA50-co-
EGDMA0.8) stabilised nanoemulsions remaining intermediate at all ratios, Figure 4.29 
 
Figure 4.29 Comparison of Dz values for nanoemulsions with different volume 
fraction of volatile oil (ethyl acetate). Nanoemulsions stabilised with branched 
copolymers; DBiB0.25PBiB0.75-p(OEGMA50-co-EGDMA0.8), (SH0.75DBiB0.25-
p(OEGMA50-co-EGDMA0.8) and DBiB-p(OEGMA50-co-EGDMA0.8). 
This trend suggests that the high density of hydrophobic DBiB-derived chain ends 
within DBiB-p(OEGMA50-co-EGDMA0.8) are most efficient at stabilising the 
interfacial tension of the remaining non-volatile oil phase. The same volume of non-
volatile oil is present in each sample derived from identical volatile/non-volatile oil 
ratios in each series, therefore, the thiol-functional branched copolymer stabiliser is 
more closely aligned to the behaviour of branched copolymers containing high ratios 
of DBoB-derived chain ends. This may be due to the lack of steric crowding at the 
chain end when compared to the PBiB initiator residue but may also point to a 
difference in the arrangement of chains at the surface of the oil droplets; for example, 
the presence of dangling chains or density of packing of hydrophobic chain ends, 
which may have implications for interpretation of data from later studies.  
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4.5 MUCOADHESIVE BEHAVIOUR OF NANOEMULSIONS AS 
DETERMINED BY FLOW THROUGH MODEL WITH 
BIOSIMILAR MUCUS 
 
The ‘gutter’ model previously described in Section 4.1.2, is a valid experimental 
design for liquid dosing systems, however it is more commonly used to test the 
adhesive strength of semi-solid dosing systems. Typically, an ex vivo sample of 
mucosal tissue is treated with simulated biological fluids that flow over the sample to 
‘wash’ the adhesive substrate. As the ‘gutter’ model design requires the use of ex vivo 
tissues, it is somewhat inaccessible for research groups working outside of a biological 
laboratory. It is also suffers from tissue sample-to-sample variation, as with any 
evaluation utilising biological samples, and does not lend itself to rapid evaluation of 
a range of material options without multiple repeated experiments.  
For the studies reported here, a model was therefore designed to incorporate the 
‘gutter’ flow model concepts but utilising biosimilar mucus to replace tissue samples, 
and allowing for ease of studies within non-biological laboratories and without the 
requirement for tissue sampling. The model design aimed to study the flow of 
nanoemulsion samples over a biosimilar mucus surface and allow the quantification 
of adhesion through gravimetric analysis of the liquids passing across the surface; a 
reduction in mass would equate to loss of nanoemulsion from the flow and therefore 
be directly interpreted as mucoadhesion. By selecting a sealed system, rather than the 
typical open gutter model, repeatable coverage of the biosimilar mucosal surface could 
be accomplished and the potential for the nanoemulsion to flow outside of the tissue 
boundaries was avoided. 
The “flow-through” mucoadhesion model was, therefore, adapted from a novel flow-
through cell culture chamber (Kirstall QV500), Figure 4.30A and C. The model is 
made up of four components; an inlet chamber, a sealed chamber, an outlet chamber 
and a peristaltic pump. The inlet chamber is attached via tubing to the peristaltic pump, 
which is in turn attached to the sealed chamber. The pump is set at the desired speed 
for flow (mL/min), and then the system flows the inlet liquid over the sealed chamber 
and back into the inlet chamber in a ‘recycling’ mode. As the model has various joints 
throughout the tubing, they can be easily detached to allow for flow into an outlet 
vessel, allowing for collection of the inlet liquid and ultimately quantification.  
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Figure 4.30 Flow through mucoadhesive model: A) Diagrammatic representation of 
the model showing inlet, outlet and sealed chamber containing biosimilar mucus with 
attachment to peristaltic pump. B) Validation of pump settings by flow of water over 
biosimilar mucus at 3 speed settings. C) Photograph of sealed chamber set up. 
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In this study biosimilar mucus (1 mL) was placed in the sealed chamber and weighed 
before attachment to the pump. The inlet chamber was also pre-weighed and weighed 
again upon addition of nanoemulsion (2 mL); the inlet, sealed chamber and pump are 
then attached together. Once the pump setting is selected, the nanoemulsion will flow 
from the inlet over the biosimilar mucus at a rate of 1 mL/min, and repeated. Upon the 
second flow the sealed chamber was detached from the system and fed into a pre-
weighed outlet chamber, thereby allowing for quantification of mucoadhesion by 
gravimetric measurements of nanoemulsion regained from the model in comparison 
to the amount originally added to the inlet. The weight of the biosimilar mucus plus 
emulsion was also taken to account for adhesion; the inlet chamber was also weighed 
to account for any loss of emulsion due to experimental error.  
A validation study was initially conducted to check that any loss of emulsion during 
flow can be attributed solely to the potential adhesive behaviour of the nanoemulsions 
and not due to swelling of the mucus in the presence of water.  Pure water (1 mL) was 
flowed over the biosimilar mucus at 3 different speed settings for 1 minute each to 
create a three-point calibration. The peristaltic pump was able to administer flow rates 
of 100 μL/min to 1000 μL/min; for this study flow rates of 300 μL/min, 700 μL/min 
and 1000 μL/min were used. Water was collected via an outlet chamber, and the 
amount of water regained from the model monitored gravimetrically. As shown in 
Figure 4.30 B, the study confirmed that the amount of water recovered from the model 
was consistent with the pump speed settings, therefore showing that the biosimilar 
mucus did not have an adverse effect on the amount of mass of liquid flowing through 
the cell; if the weight had increased, the flow may be diluting and removing biosimilar 
mucus into solution/suspension, and if the weight had decreased, the biosimilar mucus 
would be potentially swelling and removing water from the flow. Validation prior to 
the mucoadhesive study was important as the expected mass differences between 
nanoemulsions are small, and any loss of emulsion due to mucus swelling would 
nullify the experiment.  
4.5.1 Impact of Droplet Diameter on Mucoadhesive Behaviour of Nanoemulsions 
 
As stated above, the flow-through method required the nanoemulsion to be flowed 
directly over a known volume of biosimilar mucus, with quantification of adhesion 
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measured gravimetrically by the reduction of mass of the sample; a so-called “mass-
loss” experiment.   
A series of different nanoemulsions (2 mL) stabilised with the same branched 
copolymer surfactant, SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8), but created with 
varying droplet sizes, Table 4.6, were flowed over the biosimilar mucus using 
methodology as described above in Section 4.5 and results are shown in Figure 4.31.  
 
Figure 4.31 Extent of mucoadhesion (%) of tailored nanoemulsions with 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) as polymeric surfactant. 
As shown in Figure 4.28, nanoemulsions stabilised by SH0.75DBiB0.25-p(OEGMA50-
co-EGDMA0.8) with droplet diameters between 1300 and 700 nm showed no apparent 
difference in mucoadhesive behaviour (approximately 95 % mass recovery). 
However, nanoemulsion droplet diameters < 600 nm showed a measurable and 
increasing mucoadhesion. The smallest nanoemulsions (530 nm and 280 nm) 
exhibited 19 and 42 % adhesion respectively. This initial investigation utilised 
nanoemulsions of varying size but stabilised with the same thiol-functional branched 
copolymer, therefore the same number of thiols were spread over a varying surface 
area.  
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Table 4.6 Extent of mucoadhesion (%) of tailored nanoemulsions stabilised with 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8). 
Polymer Dz  
(nm) 
Extent of 
Adhesion 
(%) 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) 
 
1370 5.2 
960 5.8 
706 4.1 
620 13.4 
530 18.5 
280 42.0 
 
The collected (post-flow) nanoemulsion samples were analysed by DLS to assess the 
effect of mucosal contact on the size distributions to assess whether a particular droplet 
size within each sample was preferentially adhering to the biosimilar mucus. With the 
exception of largest nanoemulsion droplets, a general trend of slightly increased 
droplet Dz values diameters was observed post flow-through, Figure 4.32 This increase 
is most probably derived from the preferential adherence of the smallest droplets 
within each distribution leading to a larger hydrodynamic diameter being measured 
for the samples; the considerable difference between the mucoadhesion of the tailored 
nanoemulsions, Figure 4.31, would support this assumption and the largest samples 
would not have a distribution that extends very far into 500 nm range.  
 
Figure 4.32 DLS traces of SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) stabilised 
nanoemulsions initial (black) and post-flow (red) at ethyl acetate:castor oil ratios of 
A) 50:50 and B) 60:40. 
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Figure 4.33 Comparison of Dz (nm) of tailored nanoemulsions with SH0.75DBiB0.25-
p(OEGMA50-co-EGDMA0.8) as branched copolymer stabiliser with castor oil as non-
volatile oil, pre- and post-mucoadhesive studies with flow-through model. 
The variation of nanoemulsion sizes within the tailored droplet experiments does 
utilise varying oil volumes and, therefore, the amount of oil within each flow-through 
experiment varies by a factor of 50 for any given sample volume. Typically, reports 
of nanoparticles strongly refer to the considerable increase in surface area at the 
nanoscale but this is only true for comparative materials at equal mass. 
Nanoemulsions would also exhibit a considerable increase in surface area as the 
droplet size decreases for any fixed mass; however, the decrease in oil volume used to 
generate each tailored nanoemulsion sample does lead to a systematically decreasing 
oil volume (1.5 mL to 0.03 mL) and potentially, fewer actual droplets although this 
has not been established; a simple “increased surface area” explanation of the 
increased mucoadhesion as size decreases is not applicable. To understand the impact 
of size on the observed mucoadhesion, the packing of spheres onto surfaces was also 
considered, however, this is known to be radius independent and has a theoretical 
maximum packing density of 0.9069 on a Euclidean surface. 
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The DLS analysis of the tailored nanoemulsions provides hydrodynamic diameter (Dz) 
data for the average droplet within each sample. This may be used to calculate the 
surface area of the average droplet, if we assume that the droplets are perfectly 
spherical, Equation 4.1.  
              𝐴 = 4𝜋𝑟2                            (4.1) 
The percentage of the total surface area of each nanoemulsion droplet that contacts the 
emulsion is governed by the evenness of the biosimilar mucus surface, but assuming 
a flat surface and non-deformable oil droplets, the actual surface area of contact may 
be assumed to be relatively similar (approximates to a point contact) and independent 
of oil droplet diameter. If we also assume a statistical distribution of thiols at the 
surface of all oil droplets, a comparative interaction of different sized nanoemulsion 
droplets may be envisaged as shown in Figure 4.34. This would suggest that a 
considerably higher fraction of the thiols present are available for surface interactions 
with decreasing droplet diameter and this may explain the improved mucoadhesion of 
smaller nanoemulsion droplets. 
 
Figure 4.34 Comparative interaction between nanoemulsion oil droplets at two 
different diameters and biosimilar mucus surface, where a statistical distribution of 
thiols (pink spheres) leads to a higher fraction of thiols present at droplet surface for 
interaction at a smaller droplet diameter. Schematically pictured is the distribution of 
15 chain ends over nanoemulsion droplet diameters of; A) 1370 nm and B) 280 nm.  
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An alternative explanation is that the biosimilar mucus is flexible, uneven and the 
nanoemulsion droplets are slightly deformable. This would lead to a contact area that 
is considerably higher than a point-contact and potentially involving increased 
numbers of thiols per nanoemulsion droplet. One complication is that smaller droplets 
would potentially be able to access more of the available surface area of an uneven 
biosimilar mucous due to size exclusion of the larger droplets, however, if we assume 
the contact area is considerably larger than a point contact and discount any size 
exclusion effects, the interaction with the mucosal substrate may be represented as 
shown in Figure 4.35. 
 
Figure 4.35 Hypothetical contact area of nanoemulsion droplet with biosimilar 
mucosal surface. 
If we assume a circular contact area with a diameter of 25 nm, a surface area of contact 
is calculated to be 1960 nm2. Different contact areas can also be considered, however 
this large contact area is taken as an extreme value; for context, the excluded surface 
area of a PEG chain with an Mn = 2000 g/mol tethered to a nanoparticle surface has 
been reported as 12.25 nm2. The Dz value measured by DLS also allows the calculation 
of average droplet volume which may be used to determine the relative number of 
droplets in each nanoemulsion sample as the amount of oil used to create each sample 
at tailored diameters is known.  
For example, the nanoemulsion created using a 50:50 ratio of ethyl acetate:castor oil 
displayed a Dz value of 1370 nm, and therefore a radius of 685 nm, surface area per 
droplet of 5.96x106 nm2 and a volume per droplet of 1.35x109 nm3; similarly the Dz = 
280 nm nanoemulsion created from the 99:1 ethyl acetate:castor oil ratio has a radius 
of 140 nm,  a subsequent droplet surface area of 2.46x105 nm2 and droplet volume of 
1.15x107 nm3, Table 4.7 The volume of each droplet, or the relative number of 
droplets, is not critical to the consideration of the individual droplet contact, however, 
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it is interesting to note that there are nearly 120 droplets with a Dz = 280 nm for each 
Dz = 1370 nm droplet.  
Table 4.7 Variation in droplet volume (nm3), droplet surface area (nm2) and droplet 
consumed by a set area (%) with change in Dz (nm). 
Dz  
(nm) 
Droplet volume  
(nm3) 
Droplet surface  
Area (nm2) 
 Droplet area  
consumed by 1960nm2 (%) 
1370 1.35x109 5.96x106 0.03 
960 4.63x108 2.90x106 0.07 
706 1.84x108 1.57x106 0.13 
620 1.25x108 1.21x106 0.16 
530 7.80x107 8.82x105 0.22 
280 1.15x107 2.46x105 0.81 
 
When considering the percentage of each individual droplet surface area that does 
contact the surface, the relationship that can be derived is particularly illuminating. If 
we accept a contact surface area of 1960 nm2 per droplet, the fraction of the droplet 
surface area that is in contact with the surface scales by 24-fold, Table 4.7. The actual 
surface area of contact is not important for this relative ratio as the values scale 
accordingly; for example, if a 500 nm2 contact area is considered as more 
representative, the droplet area consumed by contact with the biosimilar mucus for the 
1370 nm diameter nanoemulsion droplets is 0.03 % and a value of 0.81 % is derived 
for the 280 nm sample (a 24-fold difference). This is graphically represented in Figure 
4.36 where the mucoadhesion data and relative percentage of individual droplet 
surface area utilised for mucoadhesion contact are plotted against nanoemulsion 
hydrodynamic diameter. 
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Figure 4.36 Relative increase in droplet area (%) in contact with mucus ( ) against 
the percentage mucoadhesion determined by flow through model as nanoemulsion 
droplet diameter (Dz) increases ( ).  
4.5.2 Impact of Increasing Thiol-Functionality on Mucoadhesive Behaviour of 
Nanoemulsions 
 
The size of nanoemulsion droplets clearly has an impact on the mucoadhesion of thiol-
functional samples stabilised by branched copolymer stabilisers. The library of 
branched copolymers synthesised with varying thiol-functionalities provides an 
opportunity to study the impact of the concentration of thiols on the mucoadhesion of 
nanoemulsions of similar sizes. In order to generate a systematically varying 
nanoemulsion library, samples were generated using the same aqueous polymer 
concentration of each thiol functional branched copolymer (5 wt %) at two 
volatile:non-volatile oil volume ratios (ethyl acetate:castor oil) of 90:10 and 99:1, 
Table 4.7. 
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Table 4.7 Tailored nanoemulsions using varying ethyl acetate:castor oil ratios and 
different thiol-functional branched copolymer stabilisers. 
Polymer EtOAc:castor 
oil ratio 
Dz  
(nm) 
Dn  
(nm) 
PdI 
DBiB-p(OEGMA50-co-EGDMA0.8) 
90.10 351 305 0.06 
99:1 228 209 0.07 
SH0.08DBiB0.92-p(OEGMA50-co-EGDMA0.8) 
90:10 530 209 0.19 
99:1 241 217 0.05 
SH0.25DBiB0.75-p(OEGMA50-co-EGDMA0.8) 
90:10 - - - 
99:1 260 221 0.14 
SH0.50DBiB0.50-p(OEGMA50-co-EGDMA0.8) 
90:10 460 221 0.08 
99:1 251 218 0.05 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) 
90:10 530 480 0.12 
99:1 280 270 0.13 
SH0.90DBiB0.10-p(OEGMA50-co-EGDMA0.8) 
90:10 660 634 0.02 
99:1 345 290 0.16 
 
At the higher ratio of volatile ethyl acetate (99% v/v), the branched copolymer 
SH0.08DBiB0.92-p(OEGMA50-co-EGDMA0.8), SH0.50DBiB0.50-p(OEGMA50-co-
EGDMA0.8) and SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) generated comparable 
nanoemulsions of 240 – 250 nm; however, the use of SH0.90DBiB0.10-p(OEGMA50-co-
EGDMA0.8) led to a larger nanoemulsion of Dz = 345 nm. As expected from previous 
observations, variation in the branched copolymer stabiliser at higher castor oil content 
(10 % v/v) showed a greater variance of droplet diameter and Dz varying from 460 nm 
to 750 nm.  Nanoemulsions generated using SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8) and SH0.90DBiB0.10-p(OEGMA50-co-EGDMA0.8) at this ratio led to Dz 
values ~200 nm greater than that of nanoemulsions with lower thiol content. This 
again would suggest that the increase in thiol chain ends, or lack of hydrophobic chain 
ends, changes the packing of the polymer at the oil interface; a greater number of DBiB 
chain ends on the branched copolymer may be able to facilitate a more dense packing 
around the oil droplet, creating a p(OEGMA) interfacial layer that is held closer to the 
droplet surface resulting in lower hydrodynamic diameters. Importantly, DLS 
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measures the hydrodynamic diameter of the swept volume of the entire entity, Figure 
4.37, not the specific diameter of the oil droplet itself that is surrounded by the tethered 
branched p(OEGMA) stabiliser. 
 
Figure 4.37 DLS traces for SHxDBiBy-p(OEGMA50-co-EGDMA0.8) stabilised 
nanoemulsions formulated with a 99:1 ratio of EtOAc:castor oil; A) SH0.08DBiB0.92-
p(OEGMA50-co-EGDMA0.8), B) SH0.25DBiB0.75-p(OEGMA50-co-EGDMA0.8), C) 
SH0.50DBiB0.50-p(OEGMA50-co-EGDMA0.8), D) SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8) and E) SH0.90DBiB0.10-p(OEGMA50-co-EGDMA0.8). 
Due to the consistent Dz values (Dz = 228-260 nm; one sample at Dz = 345 nm as 
described above) of the nanoemulsions derived from a 99:1 ratio of ethyl acetate and 
castor oil, Table 3.8, these samples with varying thiol content were selected for the 
flow-through mucoadhesion investigation. The nanoemulsions (2 mL) were flowed 
over the previously described biosimilar mucus at a rate of 1 mL/min, with the extent 
of mucoadhesion again monitored by the mass loss calculation. A non-functional 
nanoemulsion stabilised with polymeric surfactant, DBiB-p(OEGMA50-co-
EGDMA0.8), was also included as a control which theoretically should not interact 
with the mucus. 
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Figure 4.38 shows the results of the flow-through model experiment; the number of 
thiol-functional chain ends within the branched copolymer stabiliser is clearly 
correlated with the observed mucoadhesive behaviour of these nanoemulsions with 
substantially similar Dz values. A sigmoidal relationship is observed with a significant 
increase from 3 % of the nanoemulsion being retained when no thiol functionality is 
present, to 42 % retention when SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) is used 
as the stabiliser. A small additional increase to 43% retention is seen when 
SH0.90DBiB0.10-p(OEGMA50-co-EGDMA0.8) is used but this appears to be a plateu of 
retention that may be derived from saturation of the mucosal surface. Interestingly, no 
meaningful change in retained nanoemulsion was seen between nanoemsulsions 
stabilised with either the non-functional DBiB-p(OEGMA50-co-EGDMA0.8) or the 
SH0.25DBiB0.75-p(OEGMA50-co-EGDMA0.8) lightly functional branched copolymer. 
This may be due to the stochastic nature of the adhesion and the probability of a 
nanoemulsion presenting a statistically placed thiol at the contact point and at the time 
of contact, Figure 4.34. 
 
Figure 4.38 Mucoadhesive behaviour of nanoemulsions stabilised with polymeric 
surfactants DBiB-p(OEGMA50-co-EGDMA0.8), SH0.25DBiB0.75-p(OEGMA50-co-
EGDMA0.8), SH0.50DBiB0.50-p(OEGMA50-co-EGDMA0.8), SH0.75DBiB0.25-
p(OEGMA50-co-EGDMA0.8) and SH0.90DBiB0.10-p(OEGMA50-co-EGDMA0.8) as 
determined by a flow of nanoemulsion over biosimilar mucus, measuring the amount 
of mucoadhesion (%).     
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DBiB-p(OEGMA50-co-EGDMA0.8) surprisingly showed very slight mucoadhesive 
behaviour which could be attributed to the mesh nature of mucus, where some 
entrapment of particles can be noted. When 50 % of the chain ends of the branched 
copolymer are thiol-bearing, statistically half of the droplet is coated in thiol functional 
chains which are more likely to successfully bind to the mucus. As the functionality 
of the particles is changed from no thiol to SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8) the probability of binding to the cysteine rich areas of the mucus is 
increased. The actual values of mucoadhesion are presented in Table 4.8. 
Table 4.8 Extent of mucoadhesion (%) by non-functional and thiol-functional 
branched copolymer surfactant stabilised nanoemulsions formulated with a 99:1 ratio 
of EtOAc:castor oil. 
Polymer Dz  
(nm) 
Mucoadhesion 
(%) 
DBiB-p(OEGMA50-co-EGDMA0.8) 228 3.0 
SH0.25DBiB0.75-p(OEGMA50-co-EGDMA0.8) 
 
288 3.4 
SH0.50DBiB0.50-p(OEGMA50-co-EGDMA0.8) 251 14.5 
   
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) 249 42.0 
   
SH0.90DBiB0.10-p(OEGMA50-co-EGDMA0.8) 
 
345 43.0 
 
4.6 EX VIVO MULTIPLE PARTICLE TRACKING 
To probe the mucoadhesive properties of the nanoemulsions further, an ex vivo 
multiple particle tracking (MPT) study was conducted to detail their diffusive or 
adhesive behaviour through biologically-derived mucus. The studies  were carried out 
in collaboration with the Gumbleton group in the School of Pharmacy and 
Pharmacology at Cardiff University, with the procedure detailed in preceding 
publications39 and previously described mathematical methods detailed below.147–149  
A fluorescent dye, Lumogen Red 305 (BASF), was encapsulated into nanoemulsions 
stabilised with the branched copolymer surfactants containing a varying amount of 
thiol functionality: DBiB-p(OEGMA50-co-EGDMA0.8), SH0.25DBiB0.75-p(OEGMA50-
co-EGDMA0.8), SH0.50DBiB0.50-p(OEGMA50-co-EGDMA0.8), SH0.75DBiB0.25-
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p(OEGMA50-co-EGDMA0.8) and SH0.90DBiB0.10-p(OEGMA50-co-EGDMA0.8) at 
0.1 wt % concentration, with respect to the final nanoemulsion volume. 
Nanoemulsions were formulated as described above using homogenisation (24,000 
rpm for 2 minutes) of a 1:1 ratio of each aqueous polymer solution (5 wt %) to oil 
phase and a 99:1 v/v ratio of ethyl acetate:castor oil. Following overnight solvent 
evaporation of the volatile solvent, luminous pink emulsions were produced and 
characterised via DLS, Table 4.9 the nanoemulsions were stored at ambient 
temperature away from direct light. For MPT studies, porcine intestinal ileum (2 m) 
was obtained from a local abattoir and stored in ice-cold oxygenated phosphate 
buffered saline (PBS) prior to sample processing. The ileum was processed into 25 cm 
lengths and incised longitudinally to allow for waste to be gently rinsed away using 
ice-cold PBS. The mucus layer was subsequently harvested by gentle scraping, to 
increase the yield of the loose mucus layer but also include a high content of the 
adhered layer.150 Previous reports have shown that the structure of mucus can be 
significantly damaged if gentle handling is not employed. The harvested mucus was 
divided into aliquots (0.5 g) and stored at -20 °C until required for use.151,152 
Table 4.9 DLS analysis of lumogen red loaded nanoemulsions with varying polymeric 
surfactants. All nanoemulsions were formulated with an oil phase in a ratio of 99:1 
EtOAc:Castor Oil. 
Polymer Dz  
(nm) 
Dn  
(nm) 
PdI ζ 
(mV) 
DBiB-p(OEGMA50-co-EGDMA0.8) 226 187 0.129 -19 
 
SH0.25DBiB0.75-p(OEGMA50-co-EGDMA0.8) 
 
203 156 0.148 -16 
SH0.50DBiB0.50-p(OEGMA50-co-EGDMA0.8) 363 336 0.238 -8 
     
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) 479 371 0.330 -18 
     
SH0.90DBiB0.10-p(OEGMA50-co-EGDMA0.8) 
 
568 466 0.321 -16 
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The fluorescently labelled nanoemulsions were inoculated into a sample of mucus 
(0.5 g) at a concentration confirmed not to cause particle aggregation (0.001 %). This 
concentration was confirmed by inoculating porcine intestinal mucus with three 
volumes of nanoemulsions (0.05, 0.02 and 0.001 %) and conducting MPT studies 
where individual droplets could not be easily defined at concentrations of 0.05 and 
0.02 %. 
All samples were incubated for 2 hours at 37°C before particle tracking was studied, 
to ensure a good particle distribution throughout the sample. 2-dimensional imaging 
(Lecia DM IRB wide-field epi-fluorescence microscope, x63 magnification oil 
immersion lens) using a high speed camera (Allied Vision Technologies, UK), 
allowed video capture at a frame rate of 33 ms (30 frames/s), and each resulting video 
contained 300 frames. For each sample of mucus containing nanoemulsion, approx. 
120 individual particles were tracked; each sample was repeated three times, therefore 
360 nanoemulsion particles were tracked over 3 separate mucus samples. Fluorescent 
dye that appeared to dissociate from the nanoemulsions did not detract from individual 
droplet tracking, but was part of the background fluorescence. Videos were processed 
using Fiji ImageJ plugin mosaic to track individual droplet trajectories through the 
mucus sample.  
The 10 second videos were reduced to 30 frame videos (1 second) where individually 
tracked particles were continuously maintained within the X-Y focal plane throughout 
the 30 frames, (see supporting USB). Limiting videos to 30 frames minimises the 
impact of mucin movement on particle diffusive calculations.147 Individual particle 
trajectories were converted into numeric pixel data also using the Mosaic Particle 
Tracker plugin within Fiji ImageJ, which was able to be converted into metric distance 
based on microscope and video capture settings.  
Distance moved by an individual particle over a selected time interval (Δt) in the X-Y 
trajectory is expressed as a squared displacement (SD). The mean squared 
displacement (MSD)153, detailed in equation 4.2 of any particle (n) is the geometric 
mean of the particles SD through the 30-frame period. 
                           MSD(n) = (XΔ)
2 + (YΔ)
2                              (4.2) 
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MSD was calculated for the 360 particles over the three mucus samples and the 
Effective Diffusion Coefficient (Deff), equation 4.3 for each nanoemulsion was 
calculated: 
                              Deff = MSD/ (4*Δt)                       (4.3) 
where 4 is a constant relating to the 2D mode of video, and Δt known.  
The particle diffusion across various time intervals can therefore be measured; and the 
number of particles that are diffusive through the mucus evaluated.147 A diffusivity 
factor (DF), equation 4.4 expresses the Deff across time intervals chosen to be 1 s and 
0.2 s. 
                            DF = DeffΔt=1s / DeffΔt=0.2s                     (4.4) 
From this calculation, a particle with a DF value of over 0.9 was determined to be 
diffusive, this is then further expressed as a percentage of diffusive particles. The 
diffusion in mucus is compared against that of particle diffusion in water (Do), 
equation 4.5 which is calculated using the Stokes-Einstein equation at 37°C. 
                                  Do = kT/ 6πηr                               (4.5) 
Where k is the Boltzmann constant, T is absolute temperature, η is water 
viscosity and r the radius of the particles.  
This also allows for diffusion of all particles to be expressed as the parameter 
percentage ratio of Deff/Do. 
Lumogen Red stability in the nanoemulsions appeared to decrease as the thiol content 
within the branched copolymer stabiliser increased and measured Dz values ranged 
from 226 to 568 nm across the samples, with PdI values increasing with the apparent 
released dye seeming to interfere with the DLS measurements slightly, Figure 4.39, 
and the formation of additional peaks which were not seen in the absence of the 
encapsulated dye.  
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Figure 4.39 DLS traces of lumogen red nanoemulsions stabilised with A) DBiB-
p(OEGMA50-co-EGDMA0.8) (red), B) SH0.25DBiB0.75-p(OEGMA50-co-EGDMA0.8) 
(green), C) SH0.50DBiB0.50-p(OEGMA50-co-EGDMA0.8) (purple), D) SH0.75DBiB0.25-
p(OEGMA50-co-EGDMA0.8) (pink) and overlay of E) SH0.25DBiB0.75-p(OEGMA50-
co-EGDMA0.8) (orange) with SH0.90DBiB0.10-p(OEGMA50-co-EGDMA0.8) (blue).  
As mentioned above MPT is not affected by background fluorescence and individual 
nanoemulsion droplets were readily observed. Images taken from MPT videos, Figure 
4.40, show the individual fluorescently labelled particles of similar diameters in the 
mucosal tissue. In Figure 4.34B, clouds of lumogen red are visible, most noticeably in 
the top left hand corner coinciding with the aggregation shown within DLS traces.  
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Figure 4.40 Images taken from MPT videos, of nanoemulsion with polymeric 
surfactants A) DBiB-p(OEGMA50-co-EGDMA0.8) and B) SH0.90DBiB0.10-
p(OEGMA50-co-EGDMA0.8). 
Following video capture of MPT, the individual nanoemulsion droplet trajectories are 
able to be visualised as shown in Figure 4.41, (video capture included on supporting 
disk). DBiB-p(OEGMA50-co-EGDMA0.8) and SH0.25DBiB0.75-p(OEGMA50-co-
EGDMA0.8) stabilised nanoemulsions were readily able to diffuse through the mucus, 
Figure 4.35A and B, but increasing the thiol content of the branched copolymer 
stabiliser, using SH0.50DBiB0.50-p(OEGMA50-co-EGDMA0.8), led to a higher 
percentage of fully adhered and poorly diffusing nanoemulsion droplets in the mucus. 
 
Figure 4.41 Typical MPT trajectories taken from Mosaic individual particle trajectory 
plugin on FIJI. Trajectories of nanoemulsions with polymeric surfactants; A) DBiB-
p(OEGMA50-co-EGDMA0.8), B) SH0.25DBiB0.75-p(OEGMA50-co-EGDMA0.8) and 
SH0.90DBiB0.10-p(OEGMA50-co-EGDMA0.8) 
For each nanoemulsion a Deff value was calculated for each of the 360 particles, over 
a time interval of 1 second. Diffusion kinetics are detailed in Table 4.10 
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Table 4.10 Diffusion kinetics of nanoemulsions stabilised with polymeric surfactants 
with general composition SHxDBiBy-p(OEGMA50-co-EGDMA0.8) where x+y = 1 and 
DBiB-p(OEGMA50-co-EGDMA0.8), through native porcine mucus, n = 3, ± standard 
deviation. 
Polymer Dz 
(nm) 
Diffusion 
in water D° 
(cm2/sec 
*10-9) 
Diffusio
n in 
Mucus 
Deff 
(cm2/sec 
*10-9) 
Deff/
D° 
(%) 
Diffusive 
particles 
(%) 
DBiB-p(OEGMA50-co-
EGDMA0.8) 
228 19.71 0.22390 
(±0.0496) 
 
1.1359 42 
SH0.25DBiB0.75-p(OEGMA50-
co-EGDMA0.8) 
 
203 22.14 0.12148 
(±0.0363) 
0.5487 31 
SH0.50DBiB0.50-p(OEGMA50-
co-EGDMA0.8) 
 
363 12.38 0.05074 
(±0.0234) 
0.4099 21 
SH0.75DBiB0.25-p(OEGMA50-
co-EGDMA0.8) 
 
479 9.38 0.00244 
(±0.0005) 
0.0261 14 
SH0.90DBiB0.10-p(OEGMA50-
co-EGDMA0.8) 
 
568 7.91 0.00085 
(±0.0002) 
0.0107 6 
      
The DBiB-p(OEGMA50-co-EGDMA0.8) stabilised nanoemulsion showed significant 
diffusion through the mucus, with 42 % of particles diffusing rapidly, twice as fast as 
a nanoemulsion stabilised with SH0.25DBiB0.75-p(OEGMA50-co-EGDMA0.8) which 
also sees an 11 % drop in diffusive nanoemulsion droplets. The rate of diffusion in 
mucus continues to drop by half as the thiol chain end content is increased to 50 and 
75 mole %. The SH0.90DBiB0.10-p(OEGMA50-co-EGDMA0.8) stabilised nanoemulsion 
has the most dramatic increase in mucoadhesion, with only 6 % of the particles 
showing diffusive behaviour and these nanoemulsion droplets only diffusing at a rate 
of 0.00085x10-9 cm2/sec .  
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Heterogenity of particle diffusion is calculated to assess the diffusive properties of 
each individual particle. This means that outliers to the population can be determined, 
which may follow alternative pathways through the mucus. For the percentile data 
shown in Figure 4.42, the effective diffusion coefficient values, Deff, were calculated 
for n = 360 particles over 1 second, DeffΔt=1s, and ranked; the 90
th percentile shows 
the Deff value below which 90 % of the nanoemulsion droplet reside.   
 
Figure 4.42 Heterogenity of movement through mucus of nanoemulsions over a range 
of different thiolated polymers. Deff was calculated over n = 360 particles over 1 
second, percentiles ranked from the 10th to the 90th, where the 90th percentile shows 
the Deff value within which 90 % of the particles are below. A) DBiB-p(OEGMA-co-
EGDMA0.8), B) SH0.25DBiB0.75-p(OEGMA50-co-EGDMA0.8), C) SH0.50DBiB0.50-
p(OEGMA50-co-EGDMA0.8), D) SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) and E) 
SH0.90DBiB0.10-p(OEGMA50-co-EGDMA0.8) 
Heterogenity of particle diffusion shows the distinct difference between the diffusive 
behaviour of DBiB-p(OEGMA50-co-EGDMA0.8) and SH0.90DBiB0.10-p(OEGMA50-
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co-EGDMA0.8) where the 90
th percentile Deff values are 2.5 x10-9 and 
0.05x10-9 cm2 S-1 respectively. This highlights not only the difference in diffusive 
speed between nanoemulsions stabilised with branched copolymers containing 0 and 
90 mole% thiol functional chain ends but also aligns with the trend showing decreasing 
diffusion speed in the 90th percentile as the amount of thiol is increased.  
4.7 OIL BLUE A RELEASE FROM NON-FUNCTIONAL AND 
THIOL-FUNCTIONAL NANOEMULSIONS 
 
MPT studies have shown that by increasing the number of thiol chain ends present in 
the branched copolymer stabilisers, the rate of diffusion through mucus steadily 
declines, and the amount of particles showing diffusive character is reduced, Table 
4.10; this correlates strongly with the results seen using the flow-through 
mucoadhesion model. DBiB-p(OEGMA50-co-EGDMA0.8) showed rapid diffusion and 
limited mucoadehsion whilst the thiol-containing branched copolymer stabilisers 
created nanoemulsions with carrying properties. 
A clear indication of the density of packing and the physical conformations of the 
varying branched copolymer surfactants has been building with each study. It appears 
that decreasing the number of DBiB chain ends within the stabilising branched 
copolymers leads to a variation in the homogeneity of the hydrophilic branched 
p(OEGMA) chains.  
When all chain ends of the branched copolymer are hydrophobic, the stabilised 
nanoemulsion droplets can be considered as being stabilised by a dense arranegement 
of close-packed DBiB chains at the oil water interface and, therefore, each primary 
chain of the branched stabiliser is held within a limited distance from the oil droplet 
surface, Figure 4.43A.  This allows the droplets to pass quickly through the mucus due 
to the stealth like qualities of p(OEGMA),48 with 58 % of the particles showing limited 
diffuse probably due to the mesh like nature of mucus (200+ nm particles would be 
expected to be trapped to some extent) and the distribution of pore sizes being 
heterogeneous. 
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Figure 4.43 Potential arrangement of thiol-functional branched copolymers around an 
oil droplet; A) DBiB-p(OEGMA50-co-EGDMA0.8), B) SH0.50DBiB0.50-p(OEGMA50-
co-EGDMA0.8) and C) SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8). 
SH0.25DBiB0.75-p(OEGMA50-co-EGDMA0.8) stabilised nanoemulsions have a slight 
decrease in particle diffusion which can be attributed to disulphide bonds being formed 
between the free thiol groups on the droplet surface and the cysteine rich areas of 
mucus; this correlates with the slight, but limited mucoadhesion observed.  
Further increases in thiol functionality within the branched copolymers leads to a 
subsequent decrease in the number of hydrophobic chain ends and therefore the 
number and density of anchoring points for the branched copolymers at the oil droplet 
interface. Hypothetically, this would also lead to an expansion of the hydrodynamic 
diameter as the branched copolymer primary chains are more able to extend into the 
aqueous surrounding medium, Figure 4.43 B and C. A decrease in diffusion would be 
expected (ie those nanoemulsions that are diffusing would diffuse slower as they have 
a larger hydrodynamic diameter) and the increased concentration of thiols would lead 
to an increase in mucoadehesion (as observed in the flow-through experiment) and a 
decrease in the number of diffusing nanoemulsion droplet. 
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The apparent release of Lumogen red from the nanoemulsions with higher thiol 
functionality, seen during the MPT studies, also suggested that the decreasing density 
of DBiB-derived chain ends may lead to “leaky” nanoemulsion droplet interfaces. This 
is schematically shown in Figure 4.43 where the thiol functional branched copolymers 
are extending into the aqueous continuous phase and the density of DBiB chain ends 
decreases. If this is occurring, the hydrophobic dye may be able to release from the oil 
droplet and release would be expected to be mediated by DBiB content in the branched 
copolymer stabiliser.  
To investigate this hypothesis, a radiochemical dialysis experiment was undertaken to 
monitor release of a hydrophobic dye from nanoemulsions stabilised with either 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) or DBiB-p(OEGMA50-co-EGDMA0.8). 
Nanoemulsions were generated as described previously (1:1 ratio of aqueous polymer 
solution (5 wt %), 99:1 ratio of EtOAc:castor oil),  yielding a final emulsion volume 
of 1.5 mL. Table 4.12 and Figure 4.44. The nanoemulsions were loaded with tritiated 
Oil blue A (0.1 wt %) as a radiolabelled hydrophobic dye, rather than Lumogen red, 
as Oil blue A has a very low water-solubility and therefore was expected to accentuate 
any differences in release; radiological studies were chosen as detection and 
quantification is very sensitive and may be adjusted without changing the 
concentrations of materials used.  DLS evaluations showed Dz values of 230 nm for 
nanoemulsions generated using DBiB-p(OEGMA50-co-EGDMA0.8) Dz = 353 nm 
when using the SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) stabiliser. This 
difference is consistent with the size increases previously described in this chapter and 
the rationale explained above. 
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Table 4.12 Comparison of hydrophobic dye loaded nanoemulsions compared to blank 
nanoemulsions, with the oil phase composed of 99:1ethyl acetate:castor oil. 
Polymer 
Dye Loaded D
z
 
(nm) 
D
n
 
(nm) 
PdI 
DBiB-p(OEGMA
50
-co-EGDMA
0.8
) 3H Oil blue 230 206 0.066 
SH
0.75
DBiB
0.25
-p(OEGMA
50
-co-EGDMA
0.8
) 3H Oil blue 353 248 0.244 
DBiB-p(OEGMA
50
-co-EGDMA
0.8
) Oil blue 225 195 0.057 
DBiB-p(OEGMA
50
-co-EGDMA
0.8
) Lumogen 226 187 0.129 
SH
0.75
DBiB
0.25
-p(OEGMA
50
-co-EGDMA
0.8
) Lumogen 479 371 0.330 
DBiB-p(OEGMA
50
-co-EGDMA
0.8
) - 228 209 0.079 
SH
0.75
DBiB
0.25
-p(OEGMA
50
-co-EGDMA
0.8
) - 249 230 0.100 
 
 
Figure 4.44 A) DLS trace of DBiB-p(OEGMA
50
-co-EGDMA
0.8
) (blue) and 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) (red) stabilised nanoemulsions with 
tritiated Oil blue A (0.1 wt %) and B) DBiB-p(OEGMA
50
-co-EGDMA
0.8
) stabilised 
nanoemulsion loaded with oil blue A (0.1 wt %). 
A schematic of the dialysis experimental is shown in Figure 4.45, where a 3.5 kDa 
molecular weight cut off membrane was used and distilled water was employed as the 
reservoir solvent. Release of Oil blue A was monitored for 24 hrs with 1 mL sampled 
at t = 0.5 hrs and 1 hr, then subsequent 1 hr time points for 8 hrs. After each sample, 
the full reservoir was replaced to maintain sink conditions throughout the experiment. 
Quantification of dye release was conducted using liquid scintillation counting.  
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Figure 4.45 Diagram of dialysis experimental set-up, with distilled water as 
reservoir.   
The dialysis study described above appears to confirm the previously described 
hypothesis; when using SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) as the 
nanoemulsion stabiliser, an increase rate of dye release was observed in comparison 
to the non-functional nanoemulsion stabilised with DBiB-p(OEGMA
50
-co-
EGDMA
0.8
). After 24 hrs the thiol functionalised nanoemulsion had released 26 % 
more dye, Figure 4.46, compared to the un-functionalised counterpart. 
The lack of anchoring DBiB chain ends does seem to lead to a “leaky” interface which 
is consistent with the Lumogen red loading observations and many of the observations 
described during this Chapter including contact angle studies and varying DLS 
measurements over systematically varying nanoemulsions.   
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Figure 4.46 Cumulative release (percentage) of oil blue A (0.1 wt %) from 
nanoemulsions stabilised with DBiB-p(OEGMA
50
-co-EGDMA
0.8
) (green) and 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) (red). 
4.8 CONCLUSIONS 
In this study, branched copolymers with the general composition XanBiBxDBiBy-
p(OEGMA50-co-EGDMA0.8) have been synthesised with variation of x and y varying 
systematically from 0:1 through to 1:0 respectively. Deprotection of the copolymers 
exposed the thiol groups and yielded branched copolymers with the general 
composition SHxDBiBy-p(OEGMA50-co-EGDMA0.8). The library of materials 
successfully generated macroemulsions and nanoemulsions which demonstrated 
interactions with biosimilar and biologically-derived mucus samples. The instability 
of the macroemulsions when presented to mucus substrates appears to offer the 
potential for triggered release from samples that are very stable in the absence of the 
mucosal surface. 
The ability to modify the number of thiols within the branched copolymer stabilisers 
and resulting macro and nanoemulsions has been substantially demonstrated with 
variations of behaviour being observed in a number of different studies. Very 
interestingly, the strategy presented here allows both control over the size of emulsion 
droplets at constant thiol content and the number of thiols present at constant emulsion 
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droplet size, with the subsequent control of emulsion droplet behaviour. 
Unexpectedly, the influence of droplet diameter on mucoadhesion at constant thiol 
content, also allows a tailoring of behaviour in mucosal environments. 
Mucoadhesive studies using MPT and ex vivo porcine mucus also identified DBiB-
p(OEGMA50-co-EGDMA0.8) stabilised nanoemulsions as extremely diffusive with a 
demonstrated 263-fold difference between the diffusion speed of DBiB-p(OEGMA50-
co-EGDMA0.8) stabilised nanoemulsions and nanoemulsions formed using the high 
thiol counterpart SH0.90DBiB0.10-p(OEGMA50-co-EGDMA0.8). The Cardiff 
University team commented that these nanoemulsions were amongst the fastest 
diffusing particles they have studied. 
Overall, this investigation has shown that the increase in thiol chain ends within the 
branched copolymers leads to a controllable increase in mucoadhesive behaviour. 
However, the impact of reducing the number of hydrophobic chain ends on the 
hydrodynamic diameter of the nanoemulsions and the potential robustness of the oil-
water interface, has also become apparent. This suggests that the thiol-content, where 
mucoadhesion is maintained, may need to be balanced by the ability to retain 
hydrophobic guest molecules in any drug delivery applications. Following 
confirmation that these emulsions do indeed exhibit mucoadhesive properties, the 
potential for them to be used as for drug delivery requires biological evaluation and 
this will be the subject of the next Chapter. 
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5.1 INTRODUCTION 
 
The aim of this chapter is to evaluate the benefits of mucoadhesive emulsions for drug 
delivery via two routes of administration; ophthalmic topical application and in vivo 
oral delivery. In Chapter 4 the successful mucoadhesive characteristics of the 
polymeric surfactant SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) was determined 
therefore this polymer was chosen to formulate a mucoadhesive emulsion for further 
study as a drug delivery vehicle. DBiB-p(OEGMA50-co-EGDMA0.8) will be used to 
compare the efficacy between a fully diffusive and mostly mucoadhesive emulsion. 
Both mucoadhesive and non-mucoadhesive emulsions at the nano- and macro-scale 
will be biologically evaluated using two cell lines, human corneal epithelial cells 
(HCE-T) and human conjunctival epithelial cells (HCjE-Gi). In previous studies 
HCjE-Gi cells have shown to secrete mucus, MUC5AC, once a monolayer of cells has 
been established.154 The structure of intestinal mucus is well documented and covers 
the epithelial cell layer in the gut.1,155 Mucoadhesive properties of emulsions will be 
assessed in order to overcome mucus binding inefficiencies and penetration of 
emulsion through mucus layers will be studied. Emulsions will be loaded with relevant 
drugs for ophthalmic diseases, Amphotericin B and Cyclosporin A, as well as FTC-
prodrug a poorly water soluble drug compound to be absorbed through the gut to 
understand loading, stability, delivery and finally release. 
 
5.1.1 Structure of the Eye 
The human eye (Figure 5.1) consists of two regions: the anterior section including 
cornea to lens and posterior section, lens to optic nerve. The cornea is the eye’s 
outermost layer and a transparent structural part of the eye that allows light into the 
lens and acts as a barrier against dirt and germs, and has been extensively reviewed 
elsewhere for these properties.156 The cornea consists of five layers, of which three are 
cellular; epithelium, stroma and endothelium and two interface layers; Bowman 
membrane and Descement membrane.157 The human tear film coats the surface of the 
eye and works to regulate the health of the eye as well as maintaining the surface. The 
tear film coats the anterior surface of the eye and is composed of three layers and is 
discussed in greater detail below in Section 5.1.2. The lacrimal gland supplies the 
aqueous layer158, while the lipid layer is supplied by the meibomian glands159 and the 
mucus layer by the goblet cells in the conjunctiva, which all make up the tear film. 
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However, studies have also highlighted that the lacrimal gland also supplies mucins to 
the tear film layer as well.160 The meiboman glands are sebaceous glands located in 
the upper and lower eyelids, while the lacrimal glands are situated in upper lateral 
section of the eye orbit.  
 
Figure 5.1 Structure of the human eye. 
 
5.1.2 Mucus Production in the Eye 
 
Mucus is produced via two pathways in the eye: 1) Conjunctival goblet cells located 
within the conjunctiva, Figure 5.1 secrete mucins which spread over the surface of the 
cornea and conjunctiva, 2) Epithelial cells secrete mucins which form a gel-like 
matrix, binding loosely to the surface of the microvilli of the epithelium as a stationary 
layer.10  
The mucin layer secreted directly by epithelial cells has a thickness of 0.035 μm9, but 
the tear film has been shown to vary in thickness from 5 – 40 μm,9–11 with the middle 
aqueous layer being ~ 7 µm thick.161,162 The tear film is composed of three layers; the 
mucin, aqueous and lipid layers,10 Figure 5.2. For normal vision to occur the tear film 
must form a smooth even layer over the surface of the cornea. The phenomena of 
blinking is used not only to clear the eye of any foreign bodies, but also acts to spread 
the tear film and mucins over the surface of the cornea. Every time blinking occurs, 
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the tear film is reformed, mucus layer is resurfaced and the lipid layer redistributed 
across the preocular surface.11 The mucus layer helps form and maintain the tear film 
layer, making the epithelial surface wettable by tears therefore further helping trap 
contamination.  
 
Figure 5.2 Tear film structure consists of three layers: lipid, aqueous and mucin.  The 
mucins are secreted by epithelium cells and stick to the microvilli forming a gel-like 
matrix.  
5.1.3 Corneal Diseases and Current Treatments 
 
There are a variety of conditions which can affect the cornea, including injuries which 
can heal on their own or cause deep scarring, allergies such as hayfever and corneal 
dystrophies, where the cornea loses its normal clarity due to a build-up of material.  In 
this investigation two of the most common corneal diseases will be focused on; fungal 
keratitis and kertaconjuctivitis sicca (dry eye syndrome). 
Fungal keratitis is a condition more commonly found in tropical countries and is a 
potentially blinding condition if not properly treated. Symptoms include blurred 
vision, redness as well as pain and are a significant cause of ocular morbidity and 
unilateral blindness globally. Fungal keratitis is an infection of the cornea that can 
develop quickly from eye injury or even contact lens use; it can be caused by 
filamentous fungi such as Fusarium or Aspergillus species or non-filamentous yeasts 
candida species. Fungal keratitis is a common cause of corneal ulcers in developing 
countries, in India the estimated incidence is 113 in 100,000.163 In less economically 
developed countries ocular trauma is common among agricultural workers and is the 
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most common site of infection of fungal keratitis.163 Fungal spores within the 
environment enter through epithelia defects, often caused by the trauma but can also 
be due to contact lens wear or ocular surgery. In the US fungal keratitis is a rare 
condition, however it is found more typically in the southern states with Candida being 
the more prevalent cause with 30,000 new cases reported annually.163 Due to the 
prevalence of contact lens use and the reduction of agriculture in the US there is a risk 
factor of 37 % for people who wear contact lenses and a 25 % risk factor for ocular 
trauma.163 Candida usually causes keratitis in eyes which have a pre-existing ocular 
surface disease, previous treatment with topical steroids or systemic illnesses.164  
Amphotericin B (Amp B), Figure 5.3, is an antifungal drug used to treat fungal 
keratitis;165 it is applied as a topical solution and has previously shown good activity 
against Aspergillus and Candida strains and continues to be the first choice of 
treatment against Candida.163 Amp B works by binding to the fungal cell membrane, 
forming pores causing rapid ion leakage and therefore fungal cell death with the 
mechanism well studied elsewhere.166,167 
 
Figure 5.3 Chemical structure of Amphotericin B an anti-fungal agent used to treat 
keratitis.  
Cyclosporin A (CsA), see Figure 5.4, is an anti-inflammatory and immunosuppressant 
which can be used to treat a number of ocular conditions including uveitis 
(inflammation of the middle layer of the eye), corneal healing, vernal 
keratoconjunctivitis (an allergic response) as well as helping prevent rejections of 
corneal transplants.168–171 
Another disease which affects the cornea is keraticonjunctivitis sicca, or as more 
commonly referred to, dry eye syndrome. This is a common condition which affects 
the tear film causing either a lack of formation of tears or rapid evaporation of tears 
from the ocular surface.172 Patients who have dry eye syndrome are prone to 
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potentially blinding infections as well as increased risk of complications following 
procedures. Dry eye syndrome is associated with a variety of causes including 
environmental conditions, hormone imbalance and contact lenses.173 Previous 
treatments for dry eye syndrome included the use of artificial tears, ointments and 
environmental control, however research concluded that dry eye syndrome could 
successfully be treated by an anti-inflammatory agent. Studies showed that decreased 
tear secretion, turnover and desiccation promote inflammation on the ocular surface.174 
CsA in an emulsion form was the first FDA approved anti-inflammatory treatment for 
dry eye syndrome in 2002. Through multiple clinical trials175,176 CsA was shown to be 
able to treat dry eye syndrome via stimulating the production of aqueous tears as well 
as reducing the symptoms of blurred vision and reducing the need for artificial tears. 
Through these studies it was shown that ocular surface and lacrimal gland 
inflammation had been identified which play a role in the pathogenesis of dry eye 
syndrome.172  
 
Figure 5.4 Chemical structure of Cyclosporin A an immunosuppressant used to treat 
a variety of ocular conditions including dry eye syndrome.  
The most common topical administration of ophthalmic treatments is eye drops, 
providing patients with ease of application as well as being a non-invasive system. 
However, a drawback to the use of eye drops is that they are rapidly cleared from the 
site of administration by the eyes defensive mechanisms; blinking, tear drainage and 
tear formation.156 This leads to poor penetration for drugs applied topically, with 
contact time with the ocular surface being low, leading to less than 5 % of the applied 
dose reaching the intraocular tissues.177,178 Due to this rapid clearance alongside the 
low levels of permeation across the cornea, the efficacy of eye droplets is low, leading 
to repetitive dosing. Further issues with eye drops include that the volume 
administered typically exceeds the capacity of the conjunctival sac, leading to 
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overspill onto the cheeks.179 There is potential to mitigate these effects by utilising a 
mucoadhesive system as a topical ophthalmic treatment, increasing the retention time 
of the drug at the site of administration due to bonding of the mucoadhesive system to 
the mucins present in the tear film. 
CsA is currently administered as an ophthalmic emulsion for topical dosing (0.05 %, 
Restasis®), which is composed of glycerin, castor oil, polysorbate 80, carbomer 
copolymer type A in water to improve the solubility and adjusted to pH using 
NaOH.158 Restasis® as an eye drop treatment has the same issues with retention time 
at the target site. Amp B was previously formulated as Fungizone®, a micellar 
formulation of the drug, however this formulation contained deoxycholate to improve 
the solubility of Amp B which was shown to be an irritant for the cornea.156 Eye drops 
have recently been produced from the liposomal Amp B (AmBisome®), however this 
also has formulation problems as it is stated to only have a one week shelf life after 
reconstitution.165 
5.1.4 In-vitro Cytoxicity Assays 
 
In-vitro assays were performed on two cell lines, human corneal epithelial cells (HCE-
T) and human conjunctival epithelial cells (HCjE-Gi) to determine the cytotoxic 
effects of both mucoadhesive and non-mucoadhesive emulsions at the nanoscale. 
HCE-T cells are a transformed cell line from a 49 year old female donor  which were 
donated by JCHO Hohigaoka Medical Centre and HCjE-Gi are a human immortalised 
cell line which were donated by Gibson laboratory to the University of Liverpool. 
Both cell lines were used as they are well established and have similar structural and 
functional properties of corneal cells in vivo as well as having an active role in mucus 
production.  
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Figure 5.5 Optical microscopy image example of A) HCE-T and B) HCjE-Gi cells 
after 7 days of growth, scale bar = 100 μm. 
There are many assays that can be carried out to evaluate the cytotoxic effects of a 
drug and/or an emulsion to a cell.  In this section the assays used to biologically 
evaluate blank emulsions (emulsion not containing a drug payload) and loaded 
emulsions (emulsion containing drug) are discussed. It is important to perform 
multiple cytotoxicity assays on cells to confirm cytotoxic responses due to different 
criteria of cells being assessed.  
5.1.4.1 Resazurin Assay 
 
The resazurin assay measures the mitochondrial activity of a cell and is therefore 
indicative of cytotoxicity. The mitochondria have many functions within the cell, the 
most prominent being energy conversion and regulation of cell metabolism.180 In this 
assay the mitochondria reduce resazurin to fluorescently active resorufin, see Scheme 
5.1, which can be measured on a fluorescent plate reader. An advantage of this assay 
over the common MTT assay is that the cells remain alive after the assay, allowing for 
further studies on the same samples, including staining.  
 
Scheme 5.1 Resazurin reduction to resorufin. 
As mentioned it is important to perform multiple cytotoxicity assays on cells to 
confirm cytotoxic responses, for example a resazurin assay may indicate that there is 
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no cytotoxic response if the mitochondria of cells are not affected, however other 
components of the cell may be being affected. 
5.1.4.2 Phalloidin Assay 
 
Phalloidin is conjugated to a fluorophore and used to stain the F-actin of the cellular 
cytoskeleton so the structural integrity of the cell can be determined by fluorescent 
microscopy. Alongside phalloidin, the nuclei of the cells are also stained with 4′,6-
diamidino-2-phenylindole (DAPI). DAPI is a fluorescent DNA stain, which binds to 
adenine-thymine rich areas making it an ideal stain for nuclei.181 Figure 5.6 shows an 
image of HCE-T cells stained with phalloidin (green) and DAPI (blue), after 7 day 
growth to reach confluency. This is defined as the percentage at which the surface of 
the culture dish is covered in adherent cells. 
 
Figure 5.6 Phalloidin staining of HCE-T cells. DAPI staining of the nuclei (blue) and 
phalloidin staining of the cell cytoskeleton (green). 20 x zoom magnification, scale 
bar = 100 µm. 
5.1.4.3 Live/Dead Assay  
 
The live/dead assay determines cell viability in response to treatment, compared to the 
resazurin assay and phalloidin staining the number of dead cells can also be 
determined. In this assay live cells are distinguished from dead cells by the presence 
of intracellular esterase activity, shown by the enzymatic conversion of non-
fluorescent calcein AM to intensely fluorescent calcein.  The calcein dye is well 
retained within live cells, yielding an intense green fluorescence (ex/em ~495/~515 
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nm). Ethidium homodimer-1 (EthD-1) enters cells with damaged membranes and 
undergoes a 40-fold enhancement of fluorescence upon binding to the nucleic acids. 
This thereby produces a bright red fluorescence in dead cells (excitation/emission 
~495/~635 nm), see Figure 5.7. EthD-1 is excluded from the live cells by the intact 
plasma membrane. Live/dead cell count was completed post-experimentation using an 
image processing package for unstitching of cell images and cell counting (FIJI, 
ImageJ 1.51n).  
 
Figure 5.7 Live/dead assay performed on HCjE-Gi cell line. Live cells stained by 
enzyme activated calcein AM (green), dead cells by EthD-1 (red) and nuclei by DAPI 
(blue). 10 x zoom magnification, scale bar = 100 µm. 
5.2 GENERATION OF DRUG LOADED MACROEMULSIONS 
 
As discussed two drugs currently used to treat ophthalmic conditions were selected for 
encapsulation into emulsions: Amphotericin B (Amp B) an antifungal drug used to 
treat fungal keratitis165 and Cyclosporin A (CsA) an immunosuppressant used to treat 
keratoconjunctivitis sicca (Dry Eye Syndrome).  
Currently formulations of Amp B have stability issues leading to a short shelf life as 
well as low solubility in a range of solvent systems being problematic. Amp B has 
partial solubility in water at low pH values of 2-3 at approximately 0.1 mg/mL.182 A 
variety of oils were tested to determine which could successfully solubilise Amp B 
and CsA to the greatest extent. Solubility was tested by blending drugs into the oils at 
a known mass and left for 3 days to stir. For castor, peanut, sesame, soybean and 
squalene, partial solubility at 7 mg/ mL was observed, however, as previously reported 
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Amp B has a critical aggregation concentration of (1 μg/mL)183 so the presence of 
insoluble aggregates was noted in all oils tested. Squalene was selected as the oil phase 
for all drug loaded macroemulsion formulations due to its natural presence in the 
human eyelid lipid,184 and also within the tears.185 CsA has known aqueous solubility 
of 27.67 μg/mL186 and was determined to be soluble in castor, peanut, soybean, sesame 
and squalene oils at 7 mg/mL. The drugs were loaded at topical dose concentrations 
into the emulsions via blending with the oil phase.  As discussed earlier, Section 5.1.2., 
the current clinical formulations include concentrations of: Amp B at 0.15 % w/v165 
and CsA at 0.05 % w/v.154 
Initially macroemulsions were formulated with the clinically relevant drug 
concentrations for biological evaluation, due to the interesting behaviour shown in 
Chapter 4, Section 4.3 where macroemulsions produced a burst release effect of 
encapsulated hydrophobic dye when in contact with a mucosal surface. This would be 
an interesting dynamic to explore as a topical ophthalmic treatment system with 
potential rapid release to the target site.  
Macroemulsions were formulated via mechanical shearing, using an overhead shear 
homogeniser (Ultra-Turrax 25, IKA). Aqueous polymer solutions (5 mg/mL) were 
homogenised with squalene in a 1:1 ratio for 2 minutes at 24,000 rpm and left 
overnight to equilibrate before quantitative analysis by laser diffraction spectroscopy. 
Six macroemulsions were generated, unloaded or drug loaded with Amp B or CsA 
using unfuctionalised, DBiB-p(OEGMA50-co-EGDMA0.8) and thiol functionalised, 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) polymers for mucoadhesion.  
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Figure 5.8 Laser diffraction measurements of A) non-mucoadhesive, DBiB-
p(OEGMA50-co-EGDMA0.8) with B) mucoadhesive SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8) macroemulsions loaded with AmpB (green), CsA (blue) and a blank 
emulsion (red) and C) Optical microscopy image of Amphotericin B loaded 
macroemulsion stabilised with DBiB-p(OEGMA50-co-EGDMA0.8), 20 x zoom 
magnification, scale bar = 100 μm. 
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As shown in Figure 5.8 and Table 5.1, inclusion of CsA and Amp B in non-
mucoadhesive, DBiB-p(OEGMA50-co-EGDMA0.8), emulsions produced 
monodispersed droplets with  the same D[4,3] for both drug loaded and blank 
emulsions. Mucoadhesive, SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8), 
macroemulsions also had the same D[4,3] following encapsulation of both drugs 
compared to the unloaded emulsion analogue. Optical microscopy further confirmed 
the presence of well-defined oil droplets, with no drug aggregates able to be observed. 
 
Table 5.1 Comparison of the volume mean diameter of macroemulsions loaded with 
Amphotericin B, Cyclosporin A and an unloaded emulsion. Emulsions were stabilised 
with either SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) (mucoadhesive) or DBiB-
p(OEGMA50-co-EGDMA0.8) (non-mucoadhesive). 
Polymer           Loading D[4,3] (μm) 
SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8
) 
 
 
 
DBiB-p(OEGMA50-co-
EGDMA0.8) 
Blank 
Amp B 
CsA 
 
 
Blank 
Amp B 
CsA 
 
14.6 
16.0 
15.9 
 
 
11.4 
13.2 
13.2 
 
 
Macroemulsions were generated for completeness of the study, where encapsulation 
of Amp B and CsA at topical dose concentrations was possible. However, as 
macroemulsions were shown to demulsify in contact with a mucosal surface as seen 
in Chapter 4, releasing the drug payload rapidly, it was decided to only proceed with 
nanoemulsions for biological evaluation.  
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5.3. BIOLOGICAL EVALUATION OF NANOEMULSIONS 
 
5.3.1. Cytotoxicity of Unloaded Nanoemulsions 
 
Aqueous polymer solutions at 5 wt% of both DBiB-p(OEGMA50-co-EGDMA0.8) 
(non-mucoadhesive) and SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) 
(mucoadhesive) were prepared for nanoemulsion formulations. These polymers were 
selected following the multiple particle tracking studies in Chapter 4 to reflect a highly 
adhesive system and a highly mucous penetrating one. These potentially provide 
alternative drug delivery routes, permeation through the mucus layer and epithelial 
cells to deliver drugs to the underlying cells or complete adhesion to the ocular surface, 
which would improve the retention time of ocular topical administration routes such 
as eye drops. As these nanoemulsions have been shown to have long term stability in 
previous chapters, there is potential to increase the shelf life of an Amp B treatment 
from one week as discussed in Section 5.1.2. 
Nanoemulsions were generated in a 1:1 ratio of oil:aqueous polymer solution; the oil 
phase was a mixture of volatile solvent and non-volatile oil. In this instance, the non-
volatile oil was biologically relevant castor oil mixed with ethyl acetate as the volatile 
solvent in a 99:1 ratio. Castor oil was selected as it has previously been shown to be a 
good vehicle for CsA ophthalmic emulsions (0.05 %, Restasis®, Allergan), where it is 
thought that upon release of the oil it interacts with the tear film lipid layer187, 
stabilising the tear film and reducing tear evaporation.188 In one study, castor oil was 
shown to decrease tear evaporation after two weeks of treatment.189 Similar to 
macroemulsions, nanoemulsions were also formulated via over-head shear 
homogenisation for 2 minutes at 24,000 rpm, utilising a solvent evaporation method. 
Emulsions were left at ambient temperature following homogenisation, allowing for 
full removal of the volatile oil phase which was monitored gravimetrically. The DLS 
traces for blank nanoemulsions stabilised with SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8) and DBiB-p(OEGMA50-co-EGDMA0.8) is shown in Figure 5.9, with full 
characterisation outlined in Table 5.2. This therefore allows for the evaluation of a 
system which could potentially permeate through the mucus layer and towards the 
underlying epithelial cells as well as one which could provide complete adhesion to 
the ocular surface, improving the retention time of a dosing system such as eye drops.  
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Figure 5.9 Overlay of DLS traces for nanoemulsions stabilised with SH0.75DBiB0.25-
p(OEGMA50-co-EGDMA0.8) (blue) and DBiB-p(OEGMA50-co-EGDMA0.8) (red), 
generated with a 99:1 ratio of ethyl acetate:castor oil. 
Table 5.2 Comparison of Dz and PdI of castor oil nanoemulsions. Emulsions stabilised 
with either SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) (mucoadhesive) or DBiB-
p(OEGMA50-co-EGDMA0.8) (non-mucoadhesive). 
Polymer                  Dz  (nm)         PdI 
SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8
) 
 
DBiB-p(OEGMA50-coEGDMA0.8) 
277 
 
 
250 
 
0.13 
 
 
0.06 
 
 
As discussed in section 5.1, the assays used to determine cytotoxicity of blank 
nanoemulsions stabilised with DBiB-p(OEGMA50-co-EGDMA0.8) (non-
mucoadhesive) and SH0.75DBiB-p(OEGMA50-co-EGDMA0.8) (mucoadhesive) were 
resazurin, phalloidin staining and live/dead. HCE-T and HCjE-Gi cells were treated 
with non-mucoadhesive and mucoadhesive nanoemulsions and exposure time was 
varied between 1, 4 and 24 hours. This time points were selected to reflect potential 
treatment times for topical dosing to the eye, with 24 hours being the maximum time 
for dosing. Cells were cultured for 7 days and monitored by optical microscopy to 
assure approximately 80 % confluency and a monolayer had been established prior to 
treatment with each nanoemulsion. It is important that cells reached this level of 
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confluency to ensure they are able to communicate successfully but do not inhibit cell 
growth due to being over-confluent.   
Nanoemulsions were successfully diluted in culture media to obtain concentrations of 
50.0, 25.0, 10.0, 9.1, 8.3, 7.7, 7.1, 5.0 and 3.3 v/v % (nanoemulsion in media) for 
exposure to cells. Following previous research within the group it was determined that 
dilution of nanoemulsions stabilised with copolymers analogous to DBiB-
p(OEGMA50-co-EGDMA0.8) from a 2 – 4096 fold dilution in distilled water did not 
cause nanoemulsion instability or change in droplet diameter.107 
For each treatment the same material was tested on the same cell line of same passage 
number in triplicate, alongside controls to confirm the assay was working correctly 
and ensure validity of the experiment. The two controls were: 
 Negative Control – represents healthy, confluent cells treated with culture 
media only, expected to observe no adverse effects 
 Positive Control – cells treated with 10 % DMSO to induce cell death. A high 
DMSO concentration was used to adverse effects within 1 hr. 
For the reszaurin assay, the above controls were studied, alongside wells with media 
and media with cells so background signals detected by the fluorescent plate reader 
could be removed. 
Results from resazurin assays are shown in Figure 5.10 for HCjE-Gi cells and Figure 
5.11 for HCE-T cell line. Statistical analyses were carried out on SPSS Statistics V22 
software; one-way test of homogeneity of variances and analysis of variance 
(ANOVA) as well as Dunnett’s T3 post-hoc evaluation were conducted, p≤0.05 was 
regarded to be statistically significant. 
The assay was deemed to be working correctly as a significant difference between the 
negative and positive controls for both cell lines was observed, therefore cytotoxicity 
was clearly observed with the positive control and no adverse effects were observed 
with the negative control. Overall no significant difference was observed between the 
negative control and all concentrations of nanoemulsions gained by diluting with 
media. Therefore no cytotoxicity was observed for all concentrations of both 
mucoadhesive and non-mucoadhesive nanoemulsions tested.  
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Figure 5.10 Overall cytotoxicity of nanoemulsions stabilised with A) DBiB-
p(OEGMA50-co-EGDMA0.8) (non-mucoadhesive) and B) SH0.75DBiB0.25-
p(OEGMA50-co-EGDMA0.8) (mucoadhesive) determined from resazurin assays. 
HCjE-Gi cells were exposed to different concentrations of blank castor oil emulsions 
50 - 3.3 v/v %, grown and treated for different time scales. Confluent cells (grown for 
7 days) were exposed to emulsions for 1 hour (red), 4 hours (blue) and 24 hours 
(green). (mean error bars represent ± 1 standard deviation); n=3. *, Significance by 
ANOVA and Dunnett’s T3 post-hoc evaluation (p ≤ 0.05). 
Mucoadhesive emulsions tested on HCE-T cells observed cytotoxicity after 24 hrs at 
a 50 v/v % concentration, however dilutions of 25.0 – 3.3 v/v % mucoadhesive 
emulsion had no cytotoxic effect on the cells, however, non-mucoadhesive emulsions 
showed cytotoxic effects after 24 hours at concentrations of 50 – 12.5 v/v %. 10.0 v/v 
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% dilution showed no significant difference from the negative control, however due 
to this concentration having a greater cytotoxic impact, a 9.1 v/v % emulsion 
concentration was taken forward for future studies.  
 
Figure 5.11 Overall cytotoxicity of nanoemulsions stabilised with A) SH0.75DBiB0.25-
p(OEGMA50-co-EGDMA0.8) (mucoadhesive) and B) DBiB-p(OEGMA50-co-
EGDMA0.8) (non-mucoadhesive) polymeric surfactants determined from resazurin 
assays. HCE-T cells were exposed to different concentrations of blank castor oil 
emulsions, 100 % emulsion – 3.3 v/v %, grown and treated for different time scales. 
Confluent cells (grown for 7 days) were exposed to emulsions for 1 hr (red), 4 hrs 
(blue) and 24 hrs (green). (mean error bars represent ± 1 standard deviation); n=3. *, 
Significance by ANOVA and Dunnett’s T3 post-hoc evaluation (p ≤ 0.05). 
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As discussed previously it is important to perform numerous assays to confirm 
cytotoxicity.  A live/dead assay was performed on the HCjE-Gi cell line for 
mucoadhesive emulsion and for non-mucoadhesive emulsions, see Figure 5.12 A and 
B respectively. Emulsions were dosed at dilutions of 12.5 – 5.0 v/v %, a smaller range 
than the resazurin as this had indicated cytotoxicity at higher concentrations.  Cells 
were exposed to emulsions for 1, 24 and 48 hour time points and run in technical 
triplicates. As cells exposed to a 9.1 v/v % and above dilution of nanoemulsions were 
shown to be non-toxic over a 24 hr exposure time, a 48 hr time point was included as 
an extreme condition. Mucoadhesive emulsions showed no cytotoxic effect on cells, 
with 24 and 48 hour time points yielding increased cell growth in comparison to the 
negative control. At 24 hours there was significant difference between the negative 
control and 9.1 v/v %, with the cells treated with emulsion showing an increased live 
cell number but cell death was not induced.  
Non-mucoadhesive emulsions were dosed again at a smaller range of dilutions than 
resazurin, 12.5 – 5.0 v/v % over 1, 24 and 48 hour time points and run in technical 
triplicates. Non-mucoadhesive emulsions showed no cytotoxic effect on cells after 1, 
24 and 48 hr time points yielding no significant difference between the negative 
control and all emulsion concentrations. Therefore this confirmed that concentrations 
of emulsions at 9.1 v/v % had no toxic effect on the cells.   
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Figure 5.12 Overall cytotoxicity of nanoemulsions stabilised with polymeric 
surfactants A) SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) (mucoadhesive) and B) 
DBiB-p(OEGMA50-co-EGDMA0.8) (non-mucoadhesive) determined by live/dead 
assays. HCjE-Gi cells were exposed to different concentrations of blank emulsions, 
12.5 – 5.0 v/v %, grown and treated for different time scales. Confluent cells (grown 
for 7 days) were exposed to blank castor oil emulsions for 1 hour (red), 24 hours (blue) 
and 48 hours (green). (mean error bars = ± 1 standard deviation), n = 3. *, Significance 
by ANOVA and Dunnett’s T3 post-hoc evaluation (p ≤ 0.05). 
 191 
 
5.4 DRUG LOADED NANOEMULSIONS FOR BIOLOGICAL 
EVALUATION 
 
5.4.1 Loading emulsions with Amphotericin B  
 
To determine the need for an oil phase to encapsulate Amp B and eliminate the 
potential of a purely aqueous polymer solution stabilising Amp B particles, Amp B 
(0.15 w/v %) was homogenised with an aqueous polymer solution of DBiB-
p(OEGMA50-co-EGDMA0.8) (5 wt %) for 2 minutes at 24,000 rpm analogous to the 
emulsion formulation method. An Amp B (0.15 w/v %) and water solution was also 
homogenised to assess Amp B behaviour without the presence of branched copolymer 
surfactants. As shown in Figure 5.13, DLS studies for Amp B and an aqueous polymer 
solution of DBiB-p(OEGMA50-co-EGDMA0.8)  (5 wt %), produced a bimodal 
distribution, whereas the DLS trace for Amp B in water produced a multimodal 
distribution. Therefore, the presence of an oil phase as well as a branched copolymer 
stabiliser in the formulation is key for the loading and stabilisation of Amp B.  
 
Figure 5.13 Overlay of DLS traces of homogenised suspensions of Amp B and 
aqueous polymer solution of DBiB-p(OEGMA50-co-EGDMA0.8)  (5 wt %) (green) 
and Amp B in pure water (orange).   
As discussed in Section 5.2., the use of Amp B led to some fundamental encapsulation 
issues. Nanoemulsions were generated in a 99:1 ratio of ethyl acetate:castor oil with 
DBiB-p(OEGMA50-co-EGDMA0.8) as polymeric surfactant and following solvent 
evaporation, sedimentation of a small amount of  Amp B aggregates was observed. 
However, following gentle agitation of the emulsion, resuspension of Amp B sediment 
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was observed. The emulsion was characterised via DLS, see Table 5.3, and a 290 nm 
emulsion was successfully formulated, with no secondary population to coincide with 
free aggregates in the sample.  
To further investigate this issue, Amp B nanoemulsion with DBiB-p(OEGMA50-co-
EGDMA0.8) as polymeric surfactant was centrifuged for 15 minutes at 5000 G to 
remove the aggregates and assess the effect of this on the formulation. As shown in 
Figure 5.14, DBiB-p(OEGMA50-co-EGDMA0.8) stabilised Amp B nanoemulsion both 
before and after centrifugation produce a singular peak which overlays fully showing 
no breakdown of emulsion.  Post centrifugation a pellet of what was suspected to be 
unencapsulated Amp B was collected and 1H NMR was used. This confirmed the 
presence of pure Amp B recovered post-centrifugation (Appendix 16).This indicates 
that unencapsulated Amp B may be suspended within the nanoemulsion. 
 
Figure 5.14 Overlay of DLS traces for DBiB-p(OEGMA50-co-EGDMA0.8) stabilised 
Amp B nanoemulsions (0.15 w/v %) with castor oil as non-volatile oil, for 15 mins at 
5000 G. 
Nanoemulsions were generated with an aqueous solution of SH0.75DBiB0.25-
p(OEGMA50-co-EGDMA0.8) or DBiB-p(OEGMA50-co-EGDMA0.8) as branched 
copolymer surfactants (5 wt %) and a 99:1 ratio of ethyl acetate:castor oil.  The 
mixtures were homogenised for 2 minutes at 24,000 rpm and the volatile solvent left 
to evaporate. Amp B and CsA were loaded into the emulsions by solubilising the drugs 
in castor oil overnight at topical dose concentrations of 0.15 and 0.05 w/v % 
respectively. A small amount of Amp B aggregates were present at this concentration, 
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however as it was shown that Amp B could be successfully suspended these 
nanoemulsions were used without centrifugation. Figure 5.15 shows the overlay of 
DLS trace for Amp B loaded non-mucoadhesive and mucoadhesive nanoemulsions, 
where both nanoemulsions yielded Dz sizes of 290 nm, with PdIs of 0.15 and 0.17 
respectively. The inclusion of drug into the emulsion led to a slight increase in 
diameter, from 250 nm for both blank emulsions made using the different polymeric 
surfactants.  
 
Figure 5.15 Comparison of nanoemulsion droplet diameters stabilised with non-
mucoadhesive, DBiB-p(OEGMA50-co-EGDMA0.8) (red) and mucoadhesive, 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) (blue) branched copolymers with castor 
oil as non-volatile oil. A) Blank emulsions, B) Amp B at topical dose concentration 
(0.15 w/v %) and C) CsA at topical dose concentration (0.05 w/v %). 
CsA nanoemulsion formulated with a non-mucoadhesive polymeric surfactant DBiB-
p(OEGMA50-co-EGDMA0.8) with castor oil as non-volatile oil, produced droplets 
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with larger Dz values of 370 nm compared to the previously formulated unloaded 
emulsion, of 250 nm, however the PdI remained low at 0.08. The mucoadhesive castor 
oil based nanoemulsion with SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) as 
branched copolymer surfactant showed an increase to 260 nm from 250 nm of the 
unloaded emulsion, with the inclusion of CsA but still maintaining a low PdI value at 
0.07, as detailed in Table 5.3. 
Table 5.3 Comparison of Dz and PdI of nanoemulsions loaded with Amphotericin B, 
Cyclosporin A and an unloaded emulsion. Emulsions stabilised with either 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) (mucoadhesive) or DBiB-p(OEGMA50-
co-EGDMA0.8) (non-mucoadhesive) with castor oil as non-volatile oil. 
Polymer           Loading Dz (nm) PdI 
SH0.75DBiB0.25-
p(OEGMA50-co-
EGDMA0.8
) 
 
 
DBiB-p(OEGMA50-co-
EGDMA0.8) 
Blank 
AmpB 
CsA 
 
Blank 
AmpB 
CsA 
 
277 
290 
264 
 
250 
290 
371 
0.13 
0.15 
0.07 
 
0.06 
0.17 
0.08 
 
5.4.2 HCjE-Gi Secretion of Mucus  
 
As described in section 5.1, HCjE-Gi cells were chosen because after a monolayer of 
cells is established, MUC5AC mucins are secreted and allow the mucoadhesive 
properties of the nanoemulsions formulated with the thiol functionalised polymers to 
be tested. To determine the mucoadhesive properties of the thiol-functionalised 
branched copolymer surfactants, a series of nanoemulsions were generated 
incorporating Oil red O into the castor oil phase as described below.  The dye then 
allowed a fluorescent plate reader to be used to quantify nanoemulsions. 
Two nanoemulsions were formulated using SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8) and DBiB-p(OEGMA50-co-EGDMA0.8) as polymeric surfactants. Oil red 
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o (0.1 w/v %) was solubilised in castor oil over night and nanoemulsions formulated 
in a 1:1 ratio of aqueous polymer solution (5 wt %) to oil phase, where the oil phase 
was a 99:1 ratio of ethyl acetate:castor oil. Following homogenisation and volatile oil 
evaporation DLS analysis of the two nanoemulsions was carried out: Dz diameters of 
280 nm, with PdIs of 0.11 – 0.13, as detailed in Table 5.4, Figure 5.16. HCjE-Gi cells 
were treated with non-mucoadhesive, DBiB-p(OEGMA50-co-EGDMA0.8) and 
mucoadhesive SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) stabilised oil red O 
loaded nanoemulsions (9.1 v/v %) for 24 hrs, and cells analysed using a fluorescent 
plate reader,  following removal of the nanoemulsion. It was hypothesised that due to 
the presence of mucins the mucoadhesive emulsions would adhere to the cell surface 
and the non-functionalised emulsion would not and this would be reflected by the 
fluorescence readings taken using a fluorescence plate reader.  
Table 5.4 DLS analysis of nanoemulsions loaded with oil red O (0.1 wt %). 
Polymer Oil Red O 
Conc. (wt %) 
Dz 
(nm) 
Dn 
(nm) 
PdI 
SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8) 
0 250 230 0.100 
SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8) 
0.1 280 260 0.11 
DBiB-p(OEGMA50-co-EGDMA0.8) 0 228 209 0.07 
DBiB-p(OEGMA50-co-EGDMA0.8) 0.1 280 260 0.13 
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Figure 5.16 DLS traces of oil red O (0.1 wt %) nanoemulsions stabilised with A) 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) and B) DBiB-p(OEGMA50-co-
EGDMA0.8) branched copolymers with castor oil as non-volatile oil. 
Nanoemulsions were also dosed to HCjE-Gi cells in the presence of commercially 
available contrived tears (Ursa Bioscience), which contain mucins found naturally in 
the tear film. It was hoped that the inclusion of biosimilar tears would increase the 
concentration of mucins present in the sample and induce mucoadhesion. As shown in 
Figure 5.17, the mucoadhesive emulsions showed no preferential absorbance to that 
of a non-mucoadhesive emulsion. The addition of tears to the cells also did not affect 
the absorbance, with again no difference between a non-mucoadhesive and 
mucoadhesive emulsion. 
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Figure 5.17 HCjE-Gi cells treated with oil red O (0.1 wt %) castor oil based 
nanoemulsions, stabilised with DBiB-p(OEGMA50-co-EGDMA0.8) (grey) and 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) (blue) branched copolymers to assess 
their adhesive properties. Cells were treated with nanoemulsions only and in the 
presence of biosimilar tears, n = 2.  
Due to the lack of adhesion shown to HCjE-Gi, the amount of mucus secreted by the 
cells in this cell culture was not deemed to be sufficient to test for adhesive properties 
of emulsions. Following this it was decided the, DBiB-p(OEGMA50-co-EGDMA0.8) 
system and its potential ability to permeate through mucus and epithelium cells to treat 
the two ocular diseases highlighted in Section 5.1.2. would be focused on.  HCE-T 
cells was therefore used for the remainder of the biological evaluation studies 
described below, as these cells replicate the drug delivery route i.e. permeation through 
the epithelial cells lining the corneal surface for increased drug delivery and efficacy.  
5.4.3 Phalloidin Staining of Drug Loaded Nanoemulsions 
 
Phalloidin staining was carried out on HCE-T cells using negative (media only) and 
positive controls (10 % DMSO) as well as DBiB-p(OEGMA50-co-EGDMA0.8) 
stabilised nanoemulsions of castor oil with varying concentrations of Amp B and CsA. 
As described in Section 5.1.2. nanoemulsions were formulated with Amp B and CsA 
at topical doses of 0.15 and 0.05 w/v % respectively using castor oil as the non-volatile 
oil phase. HCE-T cells were exposed to 100 % nanoemulsion with either Amp B or 
CsA i.e. no culture media, and subsequent dilutions of nanoemulsion in media 
reflecting the blank nanoemulsion concentrations used in the previous resazurin study, 
50.0 – 3.3 v/v %. Staining confirmed that the cytoskeleton and cellular structure was 
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the correct morphology for HCE-T cells in the negative control, and as expected the 
positive control of 10% DMSO was unable to be stained as cells had detached from 
the well due to cell death. Figure 5.18, shows the results of Amp B loaded 
nanoemulsions dosed to confluent HCE-T cells for 24 hrs at concentrations of 100 % 
nanoemulsion – 3.3 v/v % diluted in culture media, with relevant drug concentrations 
stated in Table 5.5. Cells exposed to 100 % emulsion lead to cell death i.e. cells lifted 
from the well; cells still present were stained and could be seen to be rounded and/or 
not resembling a healthy cell. Cells exposed from emulsion dilution of 25.0 v/v % in 
media (184 µg Amp B or 62 µg CsA), concentrations onwards are comparable to the 
negative control. 
Table 5.5 Nanoemulsion dilutions (v/v % in media) and their relevant Amp B and 
CsA concentrations in µg as dosed to HCE-T cells. 
Emulsion Dilution 
(v/v %) 
Amp B Concentration 
(µg) 
CsA Concentration 
(µg) 
100 735 250 
50.0 367 125 
25.0 184 62 
16.7 123 42 
12.5 92 31 
10.0 73 25 
9.1 67 23 
8.3 68 23 
7.8 57 19 
7.1 52 18 
5.0 37 13 
3.3 24 8 
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Figure 5.18 Phalloidin staining of HCE-T cells treated with Amp B loaded DBiB-
p(OEGMA50-co-EGDMA0.8) stabilised nanoemulsions with castor oil as non-volatile 
oil at concentrations of: A) 100 % nanoemulsion, B) 25.0 v/v %, C) 16.7 v/v %, D) 
12.5 v/v %, E) 10.0 v/v % , F) 9.1 v/v %, G) 8.3 v/v %, H) 7.8 v/v %, I) 7.1 v/v %, J) 
5.0 v/v %, K) 3.3 v/v % and L) negative control. 20x zoom magnification, 
scale bars = 100 µm. 
Figure 5.19 shows phalloidin staining of HCE-T cells exposed to CsA loaded 
nanoemulsions from 100 % nanoemulsion to 3.3 v/v % diluted in culture media i.e. 
250 µg – 8 µg CsA. 100 % nanoemulsion led to cell death; cells round and lift from 
the baseplate through a process called mesenchymal transition, meaning few cells 
were remaining to be imaged. Those cells that were imaged appeared unhealthy and 
rounded in comparison to the negative control (unexposed cells). Cells exposed to 50.0 
v/v %, 125 µg CsA nanoemulsion and subsequent dilutions were comparable to the 
negative control.  
These results combined with resazurin and live/dead assay, confirms that a 9.1 v/v % 
concentration of nanoemulsion to media is viable for further biological testing with 
drug loading of CsA (23 µg) and Amp B (67 µg) as dosed to HCE-T cells or 46 µg/mL 
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and 137 µg /mL respectively.   Phalloidin staining also confirms that the inclusion of 
CsA and Amp B does not induce cell death at higher nanoemulsion concentrations of 
50.0 (125 µg CsA) and 25.0 (184 µg Amp B) v/v %.  
 
 
 
Figure 5.19 Phalloidin staining of HCE-T cells treated with CsA loaded 
nanoemulsions stabilised DBiB-p(OEGMA50-co-EGDMA0.8) with castor oil as non-
volatile oil at concentrations of: A) 100 % nanoemulsion, B) 50.0 v/v %, C) 25.0 v/v 
%, D) 16.7 v/v %, E) 12.5 v/v %, F) 10.0 v/v % , G) 9.1 v/v %, H) 8.3 v/v %, I) 7.8 
v/v %, J) 7.1 v/v %, K) 5.0 v/v %, L) 3.3 v/v % and M) negative control.  
A 
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5.3.4 Antifungal Activity of Amphotericin B Loaded Nanoemulsions 
 
As discussed in Section 5.1.2., Candida is one of the fungal species which leads to 
keratitis. Agricultural workers in developing countries such as India, are most likely 
to contract fungal keratitis as ocular traumas frequently occur and lead to the fungal 
infection.163 Candida is an opportunistic species and can also cause infection post 
ocular surgery. Despite antifungal therapy this can occasionally lead to corneal 
grafting, and accounts for more fungal corneal infections at temperature latitudes172, 
but has a worldwide incidence of approximately 1 per 1,000,000.164 In this study, Amp 
B loaded nanoemulsions were tested for efficacy to inhibit the growth of the Candida 
albicans (C. albicans) yeast strain. 
For this study, DBiB-p(OEGMA50-co-EGDMA0.8) was used as the polymeric 
surfactant and the nanoemulsions formulated at a 99:1 ratio of ethyl acetate:castor oil. 
Nanoemulsions were loaded with Amp B at an overall concentration of 194 mg/mL, 
282 mg/mL and 4118 mg/mL. The controls used were an unloaded nanoemulsion, 
expected to have no effect on the C. albicans, and fungizone (f), a current Amp B 
marketed product with drug concentration of 250 μg/mL expected to demonstrate a 
considerable effect. 
A 194 mg/mL concentration of Amp B was formulated by saturating a castor oil and 
ethyl acetate mix with Amp B before homogenisation with aqueous polymer solution 
(5 wt %). Following emulsion formulation (homogenisation for 2 minutes at 24,000 
rpm and removal of volatile oil phase), excess Amp B was removed by centrifugation 
and final concentration determined gravimetrically by the loss of Amp B. To further 
increase the drug concentration in the sample, the continuous phase (water) was 
evaporated to generate a higher internal phase volume isolate higher oil droplet 
content.  
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Table 5.6 DLS analysis of Amp B loaded nanoemulsions: DBiB-p(OEGMA50-co-
EGDMA0.8) as polymeric surfactant and castor oil as non-volatile oil phase for zone 
of inhibition study of candida albicans. 
Polymer AmpB Conc. 
(mg/mL) 
Dz 
(nm) 
Dn 
(nm) 
PdI 
 194 260 225 0.15 
DBiB-p(OEGMA50-co-
EGDMA0.8) 
282 221 190 0.09 
 4118 225 192 0.10 
 
Preparation of the C. alibcans culture was completed as followed: C. albicans strain 
SC5314 was revived from -80 °C storage on potato dextrose-agar (PD-agar) 
(Formedium Ltd., Norfolk, England) and streak plates incubated at 37 °C overnight. 
C. albicans was sub-cultured by inoculating a PD-agar streak plate with one colony 
taken from a previous PD-agar plate and incubated overnight at 37 °C. Colonies were 
maintained on PD-agar stored at 5 °C. Broth cultures were initiated by inoculating 
potato dextrose media (10 mL) with one colony of C. albicans taken from a PD-agar 
plate. Cultures were incubated overnight at 37 °C with constant shaking at 100 RPM. 
These were sub-cultured by taking an aliquot of C. albicans broth culture (0.5 mL) 
and diluting it in sterile PD broth (10 mL). An initial optical density, OD600, measured 
between 0.1 - 0.2 and was monitored until an OD600 0.5 - 0.6 was obtained. This was 
the working stock dilution of C. albicans for the following experiments. 
An aliquot (20 μL) of each sample was pipetted carefully to minimise spreading on to 
potato dextrose agar plates. Samples were spaced to avoid cross-contamination and 
agar plates left at room temperature for 20 minutes to allow the samples to dry. An 
aliquot of C. albicans stock solution (1 mL) was pipetted onto the centre of each agar 
plate. A glass spreader sterilised with ethanol and following aseptic technique was 
used to uniformly spread the culture broth around the agar plate. The plate was again 
allowed to dry for 30 minutes before turning the plates upside down and placing in an 
  Chapter 5 
203 
 
incubator at 37 °C for 24 hours. The samples were then checked for a zone of inhibition 
and measurements taken of the diameter of each zone if applicable. 
 
Figure 5.20 Amp B zone of inhibition study with C. albicans, assessing the inhibition 
level of nanoemulsions with DBiB-p(OEGMA50-co-EGDMA0.8) as polymeric 
surfactant and castor oil as non-volatile oil phase. Nanoemulsions were dosed at 
varying concentrations; F) Fungizone, negative control, 1) 194 mg/mL, 2) 282 mg/mL, 
3) 4117 mg/mL and B) 0 mg/mL (unloaded nanoemulsion). 
As shown in Figure 5.20, blank emulsions showed no inhibiting effect on the C. 
albicans, whereas all concentrations of AmpB nanoemulsions displayed an inhibition 
level similar to that of Fungizone.  
As Amp B loaded nanoemulsions were at a much higher concentration than that of 
Fungizone, a further two samples were formulated at lower Amp B concentrations for 
testing alongside the previously tested 194 mg/mL concentration nanoemulsion. The 
194 mg/mL sample was diluted in water to 9.1 v/v % to reflect the non-toxic dose, 
yielding a final concentration of 17.65 mg/mL of Amp B. A second sample was 
formulated with an original concentration of 2750 μg/mL, which after dilution to the 
non-toxic range yielded a final concentration of 250 μg/mL for dosing. A third 
nanoemulsion was prepared at a concentration of 250 μg/mL and was dosed without 
further dilution. As shown in Figure 5.21, the unloaded emulsion showed no inhibition 
of c. albicans growth as expected, and the two diluted samples showed a slight 
inhibition effect. However, the concentrated sample, 3, had a zone of inhibition level 
comparable to Fungizone.  
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Table 5.7 DLS analysis of Amp B loaded non-mucoadhesive nanoemulsions, with 
DBiB-p(OEGMA50-co-EGDMA0.8) as polymeric surfactant and castor oil as non-
volatile oil phase, for zone of inhibition study.  
Polymer Amp B Conc. 
(μg/mL) 
Dz 
(nm) 
Dn 
(nm) 
PdI 
 1,765 260 225 0.15 
DBiB-p(OEGMA50-co-EGDMA0.8) 250
 240 210 0.22 
 250 240 220 0.07 
 
 
Figure 5.21 Amp B inhibition study with C. albicans, assessing the zone of inhibition 
of nanoemulsions with DBiB-p(OEGMA50-co-EGDMA0.8) as polymeric surfactant 
and castor oil as non-volatile oil phase at varying drug concentrations. F) Fungizone 
as negative control (250 μg/mL), 1) 17,654 μg/mL, 2) 250 μg/mL, 3) 250 μg/mL 
(concentrated) and B) blank emulsion as positive control. 
Nanoemulsions with Amp B concentrations comparative to Fungizone showed 
promising efficacy against the growth of C. albicans however it should be noted that 
a concentrated dosing of Amp B at 250 μg/mL led to the biggest zone of inhibition, 
with diluted nanoemulsions not providing as greater effect against the yeast strain.  As 
shown in Figure 5.22, when the number of droplets dosed to C. albicans is calculated, 
assuming fully spherical droplets and using Dz values as average droplet diameter, by 
diluting the emulsions to the non-toxic range the amount of droplets dosed is 
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drastically reduced. Therefore, less Amp B is effectively dosed per 1 μL sample, 
further experimentation would benefit from increased drug concentration per droplet 
to match the Fungizone concentration after taking into account the loss of droplets due 
to dilution. Further studies would need to evaluate the effect of a nanoemulsion 
containing high oil droplet concentration with lower drug loading against a 
nanoemulsion with low oil concentration and high drug loading. This would therefore 
determine which system would have their greatest inhibiting effect on c. albicans and 
be the optimum dosing option. 
 
Figure 5.22 Theoretical number of droplets dosed to c. albicans per 1 μL aliquot of 
Amp B loaded nanoemulsions with DBiB-p(OEGMA50-co-EGDMA0.8) as polymeric 
surfactant and castor oil as non-volatile oil phase. 
5.3.5 Release Study of Radiolabelled CsA Loaded Nanoemulsion  
 
To determine if CsA was being released from nanoemulsions, a dialysis experiment 
was designed to quantify the release of CsA from nanoemulsions over time using 
tritiated CsA so low concentrations could be determined. Tritium isotope was chosen 
as the radionuclide as it has a long half-life (12.43 years) and decay during 
experimental time periods would not need to be accounted for, it is also a relatively 
safe beta emitter as it produces a maximum energy of 0.0186 MeV which only 
penetrates 4 mm of air and is incapable of passing through the dead outermost layer 
of skin (0.05 mm). Due to the nature of radiometrics, the amount of drug released can 
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be quantified very accurately; down to extremely small quantities. This is possible if 
the specific activity used is sufficient. Specific activity is the amount of radiolabelled 
drug added to unlabelled drug i.e. the concentration of activity. Due to the low energy 
emitted by tritium the only way to detect radiation from this isotope is liquid 
scintillation counting. This study determined CsA release from a nanoemulsion via 
radioactivity measurements.  
Liquid scintillation counting (LSC) relies upon the use of a scintillation cocktail which 
contains scintillants; the most common scintillants used in liquid scintillation cocktails 
is 2,5-diphenyloxazole (PPO) which exhibits luminescence when excited by ionising 
radiation.  The solvent molecules absorb energy emitted from radioactive beta 
particles and transfer energy until it reaches a scintillant.  The scintillants then emits 
photons after the energy absorption which are detectable by a scintillation counter.  
Tritiated CsA (specific activity 54 µCi/mg) and castor oil were solubilised in ethyl 
acetate at ambient temperature overnight, with the oil phase in a 99:1 ratio of ethyl 
acetate:castor oil. DBiB-p(OEGMA50-co-EGDMA0.8) was used as the polymeric 
surfactant (5 wt % in the aqueous phase) and the nanoemulsion was generated via 
homogenisation (24000 rpm, 2 minutes) followed by evaporation of volatile oil phase 
(ethyl acetate).  Emulsion size was analysed by DLS, see Figure 5.23. 
 
Figure 5.23 DLS trace of nanoemulsion stabilised by DBiB-p(OEGMA50-co-
EGDMA0.8) with castor oil as non-volatile oil and loaded with CsA and tritiated CsA 
for dialysis release study. 
For dialysis, 1 mL of nanoemulsion was added to a double sided biodialyser and sealed 
with a 3,500 Da molecular weight cut off membrane and placed in a reservoir of 100 
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mL deionised water heated to 37 ᵒC. A biodialyser is used for dialysis experiments 
involving radiolabelled substances as it is a more secure container compared to 
traditional dialysis tubing. It also increases the reproducibility of experiments as the 
surface area 1 mL of sample is exposed to is consistently 2 cm3. 1 mL samples of the 
reservoir were taken hourly for eight hours and then further samples were taken at 24 
and 144 hours and the reservoir was replaced. The sample was measured by LSC and 
radioactivity measured converted to mass of CsA released.   
 
Figure 5.24 Release of radiolabelled CsA from castor oil based nanoemulsions 
stabilised with DBiB-p(OEGMA50-co-EGDMA0.8) through a 3500 Da MWCO 
membrane into a deionised water reservoir at 37 ᵒ C; red open boxes cumulative release 
(%), blue open squares cumulative release (mg).   
Figure 5.24 shows the release of CsA from the nanoemulsion over time; a linear 
release profile of CsA through the dialysis membrane is determined not only over the 
initial 8 hours but also at 24 and 144 hours. Another 8 hour time period was tested 
between 172 – 180 hours, and again the linear release profile was seen.  Overall 30 % 
of the encapsulated CsA was released after 180 hours, therefore, it may be necessary 
to make nanoemulsions more potent and have a higher loading to have a therapeutic 
benefit in the eye as currently the therapeutic dose is only 0.05 % w/v.  
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5.4 IN-VIVO EVALUATION OF MUCOADHESIVE 
NANOEMULSIONS 
 
Improved delivery and pharmacokinetics of oral therapeutic compounds is of great 
importance in the development of drug formulations. This is particularly true for 
chronic, life-long conditions such as human immunodeficiency virus, where there is 
an associated pill burden and high dosage for patients, with the need for strict 
compliance with antiretroviral regimens. Advances have been made in the 
nanoformulation of hydrophobic drug compounds, however, water soluble anti-
retrovirals are not suitable for common nanoformulation approaches, such as milling 
or o/w emulsion templating.190 Here we describe the formation of nanoemulsions 
consisting of hydrophobic emtricitabine (FTC) prodrugs, for use as oral formulations, 
Figure 5.25. The FTC-prodrug was selected as it has converted a hydrophilic drug into 
a novel hydrophobic drug compound; this change in solubility of the FTC to the 
hydrophobic FTC-prodrug allowed solubilisation into oil and therefore formulation 
into nanoemulsions. FTC-prodrug was synthesised by Amer from Johns Hopkins 
Medical School as part of an ongoing NIH funded collaboration with Dr Caren Freel-
Meyers. It was hypothesised that an orally administered mucoadhesive emulsion 
would improve the retention time of the FTC-prodrug in the gut due to its binding 
capabilities with the mucosal surface in the GI tract. The aim of this study was to 
establish if nanoemulsions can deliver drugs through the gut and to then determine if 
there was any difference in the release profiles of a mucoadhesive nanoemulsion to 
that of a non-mucoadhesive, highly penetrating nanoemulsion. This study will also 
establish whether the oral dosing of an oil-soluble prodrug in a nanoemulsion 
formulation would be substantially different to the FTC parent drug solubilised in 
water. Finally, this experiment will determine whether the nanoemulsion system can 
be orally administered and provide good drug exposure. 
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Figure 5.25 Chemical structure of FTC-prodrug, and subsequent hydrolysis to FTC 
as observed in plasma. FTC-prodrug was synthesised by researchers at Johns Hopkins 
Medical School. 
FTC-prodrug nanoemulsions were formulated using polymeric surfactants 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) or DBiB-p(OEGMA50-co-EGDMA0.8) 
to formulate mucoadhesive and non-mucoadhesive nanoemulsions respectively. FTC-
prodrug was solubilised into the oil phase, 99:1 ethyl acetate:castor oil and underwent 
homgenisation (2 minutes, 24,000 rpm) followed by evaporation of the volatile oil 
phase produced the nanoemulsions to yield a final concentration of 4.875 mg/mL. As 
detailed in Table 5.8 and Figure 5.26, the inclusion of FTC-prodrug produced larger 
nanoemulsions than their unloaded counterparts at 390 and 340 nm for mucoadhesive 
and non-mucoadhesive formulations respectively.  
 
Figure 5.26 DLS analysis of FTC-prodrug loaded nanoemulsions (4.875 mg/mL) with 
A) SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) B) DBiB-p(OEGMA50-co-
EGDMA0.8) as polymeric surfactants with castor oil as non-volatile oil.  
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Table 5.8 DLS characterisation of FTC-prodrug (4.085 mg/mL) loaded 
nanoemulsions formulated using SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) or 
DBiB-p(OEGMA50-co-EGDMA0.8) as the polymeric surfactant and castor oil as the 
non-volatile oil phase.  
Polymer Dz (nm) Dn (nm) PdI Zeta (mV) 
SH0.75DBiB0.25-
p(OEGMA50-co-
EGDMA0.8) 
390 380 0.11 -9.40 
DBiB-
p(OEGMA50-co-
EGDMA0.8) 
340 250 0.12 -10.4 
 
FTC was dosed orally to male wistar rats at 5 mg/kg as conventional FTC as well as 
the formulated FTC-prodrug in nanoemulsions. All treatment conditions were 
reproduced (n=4) to validate results and overcome experimental error inherent with in 
vivo work. The three treatments tested during this study were hydrophilic FTC 
solubilised in water, a mucoadhesive nanoemulsion loaded with FTC-prodrug and a 
non-mucoadhesive nanoemulsions loaded with FTC-prodrug. Following habituation 
(7 days) where food and water were provided ad libitum, the rats received a single 
dose of either FTC or the FTC-prodrug nanoemulsions (5 mg/Kg FTC) via oral 
gavage. Blood samples were collected to determine plasma concentrations of FTC at 
0.5, 1, 2, 4, 6, 8 hours post dosing from the tail vein. Bioanalysis of the blood samples 
was performed by measurement of FTC parent drug by liquid chromatography 
followed by combination of two mass spectrometry analysers (LC-MS/MS).  At the 
24 hour time point, the rats were sacrificed using cardiac puncture under terminal 
anaesthesia. 
As mentioned, the FTC parent drug was measured by LC-MS/MS, therefore the 
concentration of FTC-prodrug in systemic circulation which has not yet been 
metabolised to the parent drug cannot be determined. Plasma concentrations of the 
FTC measured over 8 and 24 hour time points are highlighted in Figure 5.27. Although 
the formulation of FTC-prodrug into mucoadhesive or non-mucoadhesive 
  Chapter 5 
211 
 
nanoemulsions seems to have no great effect on the concentration of FTC in the blood 
plasma compared to dosed, unformulated FTC it does show that the FTC-prodrug 
nanoemulsions permeate through the gut and are able to deliver prodrug and parent 
FTC to the body, and release profiles mimic those of the pure drug.  
 
Figure 5.27 Oral dosing of unformulated FTC in water dispersant (black circle), 
DBiB-p(OEGMA50-co-EGDMA0.8) stabilised non-mucoadhesive nanoemulsion (blue 
triangle) and SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) stabilised mucoadhesive 
nanoemulsion (red square). FTC-prodrug loaded nanoemulsions dosed to rats at 5 
mg/Kg, n=4 at A) 8 hours and B) 24 hours. Bioanalysis was performed by LC-MS/MS. 
Pharmacokinetic parameters calculated in the blood plasma are: the maximum, 
minimum and average FTC concentration achieved after dosage (Cmax, Cmin and Cavg), 
the area under the curve which is dependent on clearance time (AUC0-24) and the half-
life of the drug which is the time required for the concentration of FTC to be reduced 
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by one half (t1/2), Table 5.9. Although the release profiles of the unformulated FTC 
and FTC-prodrug nanoemulsions were comparable the Cmax achieved from the 
nanoemulsions was lower than parent FTC meaning a lower concentration was 
reached, however the AUC is only slightly lower meaning retention in the blood 
plasma for a similar time period. This is similar for Cavg and Cmin which were 
comparable for both nanoemulsions studied, with almost identical Cmins for the FTC 
parent drug as well. However, the Cavg was over 100 ng/mL higher than both 
nanoemulsions meaning a greater average drug concentration of parent FTC was 
observed.  
Table 5.9 In vivo oral pharmacokinetic parameters comparing plasma concentrations 
of FTC from unformulated FTC and FTC-prodrug in mucoadhesive and non-
mucoadhesive nanoemulsions. 
PK Parameter FTC 
Non-
mucoadhesive 
FTC-prodrug 
Emulsion 
Fold 
Change 
Mucoadhesive 
FTC-prodrug 
Emulsion 
Fold 
Change 
Cmax (ng/mL) 618.76 376.81 0.61 393.31 0.64 
Cmin (ng/mL) 2.49 2.69 1.08 2.93 1.17 
Cavg (ng/mL) 248.44 160.94 0.65 166.96 0.67 
AUC0-24 (ng.h/mL) 1842.19 1439.77 0.78 1518.95 0.82 
Half-life (t1/2) (h) 3.87 4.10 1.06 3.76 0.97 
5.5 CONCLUSIONS 
 
Mucoadhesive, SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8), and non-mucoadhesive, 
DBiB-p(OEGMA50-co-EGDMA0.8) polymeric surfactants were used to formulate 
macroemulsions and nanoemulsions using squalene and castor oil as the non-volatile 
oil phase.  Analogous emulsions were successfully formulated which included Amp 
B and CsA at varying concentrations around the topical dose currently used in clinic. 
Nanoemulsions were taken forward for biological evaluation to assess their potential 
as ophthalmic treatments for corneal disease. Blank nanoemulsions were tested for the 
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cytotoxic effect on two corneal cell lines, HCjE-Gi and HCE-T, and a non-toxic 
concentration of 9.1 v/v % was determined. Phalloidin staining confirmed no drug 
loaded nanoemulsions induced cell death apart from when 100 % nanoemulsion i.e. 
undiluted was dosed. Unfortunately, the mucoadhesive character of the emulsion did 
not show any signs of adhesion when exposed to HCjE-Gi cells. It is thought that the 
secretion of mucus was not great enough to show any benefit of adhesive character, 
and the concentration of mucins too low in comparison to the data shown in the 
previous chapter. The mucus penetrating characteristics of nanoemulsions formulated 
using DBiB-p(OEGMA50-co-EGDMA0.8) was then studied. Amp B loaded 
nanoemulsions were tested for their ability inhibit the growth of C. albicans, which 
causes fungal infections in the cornea. It was successfully shown to be able to inhibit 
the growth of yeast culture at the same concentrations as a current fungal treatment 
(250 μg/mL), however it is worth noting that the undiluted nanoemulsion had the 
greatest effect on C. albicans growth. This highlights the difference in oil droplet 
number between diluted and non-diluted Amp B nanoemulsions, where further 
experimentation could look at increasing the amount of Amp B per droplet to mitigate 
the effects of dilution. CsA loaded nanoemulsions were successfully formulated and 
the release of CsA confirmed via dialysis using tritium labelled CsA to measure small 
quantities.  It was shown that CsA was steadily released from the emulsion over a 180 
hrs, time period.  
Finally, an in vivo experiment confirmed that the nanoemulsions can deliver drugs 
through the gut and into systemic circulation and an FTC-prodrug delivered orally via 
an emulsion can be metabolised in the body. FTC concentrations in the blood plasma 
were unchanged when hydrophilic FTC in water or FTC-prodrug formulated into 
nanoemulsions were dosed.  There was also no significant difference in the release 
profiles of the two nanoemulsions, however as a proof of concept study of the prodrug 
against pure FTC, it was shown that the prodrug was well metabolised. 
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6.1 CONCLUSIONS  
 
The aim of this research was to investigate the nature of linear and branched polymeric 
architectures as surfactants for o/w macroemulsions and nanoemulsions. Our 
hypothesis was that functionality could be introduced at the chain ends of the 
copolymer structures, with an emphasis on thiol functionality to allow the potential 
development of mucoadhesive drug delivery vehicles. Initially, the principle of mixing 
chain end chemistries was established by studying the systematic replacement of 
hydrophobic chain ends with hydrophilic PEG groups within branched copolymers. 
The minimum number of hydrophobic chain ends required to generate stable 
emulsions was determined using DBiB and PBiB co-initiation and shown to be 
approximately 25 mol %. The potential to include functionality was then established 
using a XanBiB initiator containing a masked thiol group, in place of PBiB in the co-
initiated branched polymerisations, with the aim of xanthate cleavage and formation 
of thiol-functional stabilisers able to create mucoadhesive macroemulsions and 
nanoemulsions. The response of these macro- and nanoemulsions to mucus substrates 
was established using a novel flow-through model with biosimilar mucus and an ex 
vivo MPT system with porcine intestinal mucus.  The different sized emulsions were 
also shown to encapsulate drugs and enable studies of drug delivery for ophthalmic 
treatments and, in in vivo tests as oral administration options. 
To assess the effect of polymeric architecture on the ability of polymers to act as 
surfactants, a number of linear and branched copolymers with varying hydrophilicity 
were synthesised. The branched architecture was repeatedly shown to be critical to the 
emulsion formation and stability, where branched copolymers were able to 
successfully stabilise emulsions (macro and nano) over sustained periods of time when 
stored under ambient conditions. The role of the multiple-anchoring points derived 
from the numerous conjoined chains, appears to be key, suggesting the branched 
architecture holds desorbed polymer chain ends close to the surface of the oil droplet 
rather than allowing a dynamic equilibrium with the continuous phases that would be 
seen in linear polymer analogues. 
The thiol-functional branched copolymer stabilisers were synthesised to generate a 
range of chain end group ratios (DBiB:SH) Surprisingly, thiol-functionalised 
emulsions displayed high levels of stability with no observation of emulsion 
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breakdown or aggregation due to an expected inter-droplet disulphide bond formation 
between neighbouring polymers; four week stability was observed, however this is not 
believed to be a limiting timeframe and longer stabilities may be achieved. 
Macroemulsions and nanoemulsions generated with thiol-functional stabilisers 
exhibited an unexpected size-dependent interaction with mucosal surfaces. When 
tested with a biosimilar mucus, a burst release, captured via optical microscopy, was 
seen on contact of macroemulsions with the substrate; this was not seen when 
nanoemulsions were tested (up to approximately 1 micron) and was hypothesised as 
being due to the larger perturbations of the oil-water interface when multiple 
disulphide bonds are formed. For nanoemulsions, decreasing droplet diameters led to 
an increase in mucoadhesion, which was interpreted as being due to the larger 
percentage of surface area per droplet that contacts the mucosal surface when droplets 
are small; this is yet to be verified  
Varying the number of thiols at the nanoemulsion surface, whilst attempting to 
maintain the size of the droplets, showed a clear correlation between thiol chain end 
concertation increasing mucoadhesion using the flow-model. Similar results were seen 
when using an ex vivo MPT analysis to track and quantify the diffusive properties of 
thiol-functional nanoemulsions through porcine intestinal mucus 
A conceptual model of the behaviour of the branched copolymers and the resulting 
nanoemulsions has transpired when considering the different behaviour across the 
varying structures and emulsions that have been studied.  Decreasing the number of 
hydrophobic chain ends potentially leads to a subsequent decrease in the density of 
packing of the branched copolymer at the surface of the oil droplet. As the number of 
hydrophobic anchoring chain ends are reduced, there is fewer anchoring points per oil 
droplet, but also fewer primary chains within the branched structure actually tethered 
to the oil/water interface. This would also correspond to some of the primary chains 
being able to extend further into the surrounding aqueous medium. The difference 
between the DLS measured hydrodynamic diameters (Dz values) that are seen for 
DBiB, PBiB and SH containing nanoemulsions formed under controlled conditions 
but using varying ratios of volatile to non-volatile oils is certainly pointing to this 
potential interpretation, Figure 6.1 (from Chapter 4). 
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Figure 6.1 Comparison of Dz values for nanoemulsions with different volume fraction 
of volatile oil (ethyl acetate). Nanoemulsions stabilised with branched copolymers; 
DBiB0.25PBiB0.75-p(OEGMA50-co-EGDMA0.8), (SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8) and DBiB-p(OEGMA50-co-EGDMA0.8). 
Also, the different diffusion speeds of the nanoemulsions stabilised by branched 
copolymers with varying thiol content that were tracked through porcine mucus, 
suggests the difference in speed is due to variation in hydrodynamic diameter and 
potentially not due to varying chemical interactions with the mucus. This due to the 
fact that the difference in thiol content varies the physical hydrodynamic size of the 
nanoemulsions. This interpretation is also supported by the study that aimed to 
investigate the ‘leakiness’ of the oil/water interface. The release of Oil blue A from 
DBiB-p(OEGMA50-co-EGDMA0.8)  and SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8) stabilised nanoemulsions, shows a considerable impact that is not 
chemistry-derived, but rather a physical effect, Figure 6.2.  
Finally, drug loading of nanoemulsions was shown to be possible, to high loading, 
with two different drug classes. The route of administration was also shown to be 
variable from topical, ophthalmic candidate therapy, to oral, HIV prodrug delivery. 
Cytotoxicity appeared to show that the fully formulated nanoemulsions would be 
tolerated well in vivo. 
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Figure 6.2 Cumulative percentage release of oil blue A (0.1 wt %) from 
nanoemulsions stabilised with DBiB-p(OEGMA
50
-co-EGDMA
0.8
) (green) and 
SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) (red). 
Interestingly, efficacy testing of Amp B nanoemulsions against a yeast strain, candida 
albicans, also showed the potential for drug release, as also seen in the radiochemical 
dialysis experiments of CsA and Oil blue A. 
 
6.2 FUTURE WORK 
 
Further study into the cytotoxic limits of the drug loaded nanoemulsions could be 
carried out on HCE-T cells, to determine a more precise toxic limit with a secondary 
technique to confirm the non-toxic levels. An enzyme-linked immunosorbent assay 
(ELISA) for determining the efficacy of CsA loaded nanoemulsions would prove 
beneficial to show that the nanoemulsions could be successful as therapeutic treatment 
systems. A future study could also look at the benefit of macroemulsions as drug 
delivery systems to the eye, with the burst release in the presence of mucosa potentially 
leading to an improved topical treatment route to the cornea. The cytotoxic limits and 
also efficacy testing again would have to be performed on these macroemulsions, 
where the oil phase could be further varied to determine the most biologically relevant 
oil for these studies. 
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An interesting prospect from this research would be to determine the emulsion droplet 
size at which the burst release is not shown, potentially between 1 – 15 μm, further 
tailoring the mucoadhesive properties observed. Another development could involve 
zoning the thiol groups within the polymeric structure, where instead of a statistical 
distribution of thiol-chain ends across the surface, each chain end could contain up to 
8 thiol groups. This could be done by including a xanthate-based dendritic initiator, as 
reported previously within the group and discussed in Chapter 4, Section 4.1. Zoning 
of thiol groups could potentially alter the mucoadhesive properties of the 
nanoemulsions, with a question of whether zoning increases the likelihood of thiol-
cysteine bonding at lower mole percent thiol chain ends.  
 
Figure 6.3 A) Non-zoned thiol functional branched copolymer stabilised oil droplet 
with one thiol group per chain end with respect to molar ratio of initiating group and 
B) oil droplet stabilised with zone thiol functional branched copolymer, where one 
primary chain can have four thiol groups. 
Due to the large amount of mucosal surfaces covering the body, the potential for these 
materials is vast. These materials could be loaded with therapeutic agents typical for 
treatment of diseases observed for example, in the nasal cavity, respiratory tract or 
reproductive organs. The tailoring of mucus diffusive properties through the 
manipulation of the polymeric structure as well as emulsion droplet diameter mean 
that these materials could be specifically designed for use, where a highly diffusive or 
a highly adhesive system would be more beneficial.  
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7.1 CHARACTERISATION 
 
7.1.1 NMR Spectroscopy 
 
NMR spectra were recorded using a Bruker DPX-400 spectrometer operating a 400 
MHz for 1H NMR and 100 MHz for 13C NMR. Solvents used for NMR spectroscopy 
were CDCl3, D2O and DMSO-d6.   
7.1.2 Mass Spectrometry 
 
Chemical ionisation (CI) and electrospray (ES) mass spectrometry data was recorded 
at the University of Liverpool in the Mass Spectrometry Laboratory. The CI-MS was 
obtained using an Agilent GCQTOF 7200 using methane gas CI. ES-MS was analysed 
using a MicroMass LCT mass spectrometer using electron ionisation and direct 
infusion syringe pump sampling.  
7.1.3 Gel Permeation Chromatography (GPC) 
 
Double and Triple detection GPC was performed to measure molecular weights and 
molecular weight distributions using Malvern Viscotek instruments. The first GPC 
was equipped with GPCmax VE2001 auto sampler, two Viscotek T600 columns, 
guard column, a refractive index (RI) detector VE3580 and a 270 Dual Detector (light 
scattering and viscometer) with a mobile phase of THF containing 2 v/v % of 
trimethylamine at 35 oC with a flow rate of 1 mL/min.  
The second instrument was equipped with GPCmax VE2001 auto sampler, two 
Viscotek D6000 columns, guard column and a triple detector array TDA305 
(refractive index, light scattering and viscometer) and a mobile phase of DMF 
containing 0.01 M lithium bromide at 60 oC with a flow rate of 1 mL/min.  
GPC determines molecular weight by separating different polymeric chain lengths 
within a molecular weight distribution. The GPC columns contain porous beads with 
different pore sizes;larger polymeric materials cannot pass through the pores therefore 
a shorter pathway is taken through the column and results in earlier elution. Whereas 
smaller polymeric materials are able to pass through the porous beads, this longer 
pathway through the column, results in longer retention and later elution times. The 
triple detection GPC uses refractive index, viscometry and light scattering detectors to 
calculate the absolute molecular weight of the polymer. 
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Due to technical problems with the DMF viscometer, Chapter 2 and 3 polymeric 
materials molecular weights were determined without the viscometer analysis.  
7.1.4 Contact Angle Measurement 
 
Drop shape analysis (DSA) was performed using a Kruss DSA100E located in the 
Materials Innovation Factory (MIF) formulation laboratory. DSA used a manual static 
sessile drop method, using PTFE tape as a hydrophobic substrate. An advanced digital 
camera (x20 magnification) attachment was used to capture water/aqueous polymer 
solution droplets.  
7.1.5 Surface Tensiometer Measurements  
 
Surface tension measurements were performed using a Kibron Delta 8 located in the 
MIF formulation laboratory. This equipment is a high throughput platform for surface 
tension measurements using a standard 96-well microlitre plate format; cross 
contamination between measurements is eliminated by the probes being cleaned using 
a 600 oC furnace between measurements. Surface tension measurements are resolved 
to 0.01 mN/m, using the Du Nouy-Padday method. This is a minimised version of the 
Du Nouy ring technique, which uses a small size rod to determine surface tension, 
allowing for use in small volumes of liquid, which in this experiment was 50 μL. The 
rod is lowered to the surface of the sample until a meniscus is formed and then raised 
till the bottom edge of the rod lies on the plane of the undisturbed surface and the 
surface tension is determined by the programme.  
7.1.6 Mastersizer Analysis 
 
All macroemulsions were characterised using a Malvern Mastersizer 3000A, which 
uses static light scattering to measure the average droplet volume (D[4,3]). Samples are 
dispersed within water and a combination of red (633 nm) and blue (432 nm) lasers 
are used with a series of detectors at set angles to accurately measure particle size from 
1 – 3500 μm.  
7.1.7 Dynamic Light Scattering 
 
All nanoemulsions were characterised by dynamic light scattering (DLS) using 
Malvern Zetasizer ZS. This equipment measures particle size in the range of 0.3 – 
10000 nm, measuring the diffusion of particles moving under Brownian motion which 
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the software converts into size and size distribution using the Stokes-Einstein 
relationship.  
7.1.8 Scintillation Counter 
 
ProSafe+ scintillation cocktail (Meridian Biotechnologies Ltd.) was used as received. 
All radiation measurements were carried out using a liquid scintillation counter 
(Packard Tri-carb 3100TR; Isotech).   
Liquid scintillation counting relies upon the use of a scintillation cocktail which 
contain scintillators (materials which exhibit luminescence when excited by ionising 
radiation).  The solvent molecules absorb energy emitted from beta particles and 
transfer this energy until it is transferred to a scintillant.  The scintillant then emits 
photons following the energy absorption which are detectable by the scintillation 
counter. 
7.2 MATERIALS 
 
All deuterated solvents were purchased from Sigma Aldrich apart from DMSO-d6 
which was purchased from Goss Scientific, and used as received apart from CDCl3 
where 0.1 % TMS was added. All solvents were reagent grade and purchased from 
Fisher Scientific. Dodecane, squalene and castor oil were purchased from Sigma 
Aldrich and used as received. Lumogen F Red 305 was donated by Cardiff University 
and BASF and used as received. Resazurin was purchased from Sigma Aldrich and 
used as received. Alex Fluro 488 Phalloidin (Phallodin) and Live/deadTM full 
viability/cytotoxicity kit was purchased from Invitrogen and used as received. 
Amphotericin B (Amp B) and Cyclosporin A (CsA) were purchased from 
ChemLeader and used as received.  
7.3 CHAPTER 2 
 
7.3.1 Chapter 2 Materials 
 
Magnesium sulphate (MgSO4), sodium hydrogen carbonate (NaHCO3), 
timethylamine (TEA) were purchased from Fischer and used as received. 1-dodecanol, 
α-bromoisobutyl bromide (98 %), anisole, poly(ethylene glycol)methyl ether 
methacrylate (average Mn  = 300 g/mol) (98 %) (OEGMA), ethylene glycol 
dimethacylate (EGDMA), 2,2’-bipyridyl (bpy), copper (I) chloride (Cu(I)Cl) (97 %), 
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activated neutral alumina and basic alumina were purchased from sigma Aldrich and 
used as received.  
7.3.2 Synthesis of ATRP Initiator DBiB  
1-dodecanol (9.32 g, 50 mmol, 1.0 equiv) and trimethylamine (TEA) (6.07 g, 60 
mmol, 1.2 equiv) were dissolved in dichloromethane (70 mL). α-bromoisobutyl 
bromide (13.80 g, 60 mmol, 1.2 equiv) was added dropwise to the mixture via a 
pressure equalising dropping funnel and stirred in an ice bath under nitrogen. After 
addition the reaction vessel was left to warm to ambient temperature and left to stir for 
24 hours. The solution was washed once with NaHCO3 (50 mL) and distilled water (4 
x 50 mL). The organic layer was dried over anhydrous MgSO4, filtered, and 
concentrated in vacuo. If 1H NMR showed the need for additional purification by the 
inclusion of environments assigned to impurities, the product was passed through a 
basic alumina column. 
Yield: 3.155 g, yellow oil, (19 %). 1H NMR (400 MHz, CDCl3) δ (ppm) = 0.81 (t, 
3H), 1.19 (m, 18H), 1.61 (m, 2H), 1.86 (s, 6H, CH3CH3), 4.08 (t, 2H). 
13C NMR (100 
MHz, CDCl3) δ (ppm) = 14.1, 22.7, 25.8, 28.4, 29 - 30, 32.0, 56.0, 66.2, 171.8. Mass 
Spectrometry: [M+H]+ (C16H32BrO2) m/z = 335.0. Experimentally: ES MS [M+H]
+ 
m/z = 335.2.  Elemental Analysis:Calculated (%): (C16H31O2Br) = C, 57.31; H, 9.32. 
Experimental (%) = C, 57.33; H, 9.20. 
7.3.3 ATRP of DBiB-p(OEGMA50)  
OEGMA (5.00 g, 16 mmol, 50 eq.), 2,2’-bipyridyl (0.100 g, 0.64 mmol, 2 eq.) and 
DBiB (0.0268 g, 0.08 mmol, 0.25 eq.) were added to a RBF equipped with magnetic 
stirrer and IPA/H2O (92.5:7.5 v/v, 4.39:0.36 mL, 55 wt%) added as solvent. Anisole 
was added as internal standard for 1H NMR conversion of monomer peaks. The vessel 
was sealed and degassed with dry nitrogen for 5 minutes, CuCl(I) (0.032 g, 0.32 mmol, 
1 eq.) was added and the reaction vessel sealed.  RBF was immersed in silicone oil 
bath at 40 oC and left to react until complete conversion, approx. 8 hrs. The 
polymerisation was terminated by exposure to air and dilution in THF and purified by:  
removal of copper catalyst by a neutral alumina column, removal of solvent in vacuo 
and crude polymer precipitated twice into cold hexane. Residual solvent was removed 
at 40oC in a vacuum oven overnight.  
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7.3.4 ATRP of DBiB-p(OEGMA50-co-EGDMA0.8) 
OEGMA (5.00 g, 16 mmol, 50 eq.), EGDMA (0.051 g, 0.26 mmol, 0.8 eq.), 2,2’-
bipyridyl (0.100 g, 0.66 mmol, 2 eq.), DBiB (0.111 g, 0.34 mmol, 1 eq.) were added 
to a RBF equipped with magnetic stirrer and IPA/H2O (92.5:7.5 v/v, 4.39:0.36 mL, 55 
wt%) added as solvent. Anisole was added as an internal standard for 1H NMR 
conversion of monomer peaks. The vessel was sealed and degassed with dry nitrogen 
for 5 minutes, CuCl(I) (0.032 g, 0.32 mmol, 1 eq.) was added and the reaction vessel 
sealed. RBF was immersed in silicon oil bath at 40 oC and left to react until complete 
conversion, approx. 24 hrs. The polymerisation was terminated by exposure to air and 
dilution in THF and purified by:  removal of copper catalyst by a neutral alumina 
column, removal of solvent in vacuo and crude polymer precipitated twice into cold 
hexane. Residual solvent was removed at 40oC in a vacuum oven overnight. 
7.3.5 Kinetic Studies of ATRP 
 
Kinetic studies (ln[M]0/[M] = conversion) were performed by taking samples of the 
polymerisation reaction medium and analysed by 1H NMR spectroscopy and GPC. 
The monomer conversion was determined by 1H NMR; vinyl protons of monomer 
located at 6.13 and 5.58 ppm were integrated and compared to integrated values for 
pendant polymer chain at 3.4 ppm. Conversion was then calculated by:  
Conversion = ([I1/(I2-3)]/3)*100 
Where I1 = integral at 5.58 ppm and I2 = 3.4 ppm. The catalytic system was removed 
from the samples prior to GPC anaylsis by passing through a neutral alumina column. 
A kinetic plot is produced on a semi-logarithimic scale, plotting monomer conversion 
against time.  
7.3.6 Preparation of Macroemulsion  
 
Aqueous polymer solutions were prepared at a 5 mg/mL concentration of branched 
and linear polymers. Emulsions were prepared at a 1:1 v:v ratio of oil:water, where 
the oil phase was n-dodecane. Emulsions were homogenised via over-head shear 
homogenisation (IKA T 25 ULTRA-TURRAX) for 2 minutes at 24,000 rpm. 
Emulsions were left over night to equilibrate before characterisation of droplet using 
light scattering was carried out (Malvern Mastersizer 2000). 
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7.3.7 Preparation of Nanoemulsion  
 
Nanoemulsions were generated using the solvent evaporation technique, with aqueous 
polymer solutions of branched and linear polymers at a 5 wt % concentration. The oil 
phase is a mixture of two miscible oils with one being a volatile solvent. As the volatile 
solvent evaporated, the non-volatile section of the oil droplet shrinks to the nanoscale. 
The oil phase is composed of ethyl acetate: castor oil in a ratio of 50:50, 60:40, 70:30, 
80:20, 90:10 or 99:1. The oil: water ratio was 1:1, with the water phase being aqueous 
polymer solution at 5 wt%. Emulsions formulated via homogenisation using an over-
head shear homogeniser (IKA T 25 ULTRA-TURRAX) for 2 minutes at 24,000 rpm. 
Emulsions are left overnight until all ethyl acetate is removed which was followed by 
gravimetric analysis and emulsions analysed by dynamic light scattering (Malvern, 
Zetasizer ZS). 
7.4 CHAPTER 3  
 
7.4.1 Chapter 3 Materials 
 
Magnesium sulphate (MgSO4), sodium hydrogen carbonate (NaHCO3), 
timethylamine (TEA) were purchased from Fischer and used as received. Anhydrous 
THF (99%), 1-dodecanol (99 %), α-bromoisobutyl bromide (98 %), anisole (99 %), 
poly(ethylene glycol)methyl ether methacrylate (average Mn  = 300 g/mol) (98 %) 
(OEGMA), ethylene glycol dimethacylate (EGDMA), 2,2’-bipyridyl (bpy), Copper (I) 
chloride (Cu(I)Cl) (97 %), activated neutral alumina and basic alumina were 
purchased from Sigma Aldrich and used as received. 4-(dimethylamino) pyridine (>99 
%) (DMAP), was purchased from Alfa Aesar and used as received. All solvents unless 
stated were reagent grade, purchased from Fischer Scientific and used as received.  
7.4.2 Synthesis of ATRP Initiator PBiB 
Monomethoxy poly(ethylene glycol) Mw ~ 750 g/mol, (23.0 g, 30.7 mmol) was 
dissolved in anhydrous THF (40 oC) under dry N2. DMAP (0.0375 g, 0.3 mmol) and 
TEA (5.6 g, 53.7 mmol) was added and the reaction mixture stirred in an ice bath. 
α-bromoisobutyryl bromide (10.6 g, 46.0 mmol) was added dropwise using a dropping 
funnel over 30 minutes and a white precipitate (Et3NH
+Br- salt) was immediately 
formed. The reaction was conducted over 24 hours, the precipitate removed by 
filteration, solvent removed in vacuo and the resulting crude product was precipitated 
twice from acetone into petroleum ether (30 – 40 oC) to give the final product. Yield: 
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15 g, 65.2 %. yellow oil. 1H NMR (400 MHz, D2O) δ ppm = 1.86 (s, 6H), 3.30 (S, 
2H), 3.64 (m, 60H), 3.77 (m, 2H), 4.32 (m, 2H). 13C NMR (100 MHz, D2O) δ ppm = 
29.8, 56.8, 65.4, 38.3, 69.5, 69.5, 69.7, 70.9, 173.7. Elemental Analysis: Calculated 
(%): (C37H73O18Br) = C, 50.16; H, 8.24. Experimental (%) = C, 49.25; H, 8.31. 
7.4.3 ATRP of PBiB-p(OEGMA50)  
OEGMA (5.00 g, 16 mmol, 50 eq.), 2,2’-bipyridyl (0.100 g, 0.64 mmol, 2 eq.), PBiB 
(0.25 g, 0.34 mmol, 1 eq.) were added to a RBF equipped with magnetic stirrer and 
solvent system IPA/H2O (92.5:7.5 v/v%, 4.39:0.36 mL, 55 wt%) added. Anisole was 
added as internal standard for 1H NMR conversion of monomer peaks. The vessel was 
sealed and degassed with dry nitrogen for 5 minutes, CuCl(I) (0.032 g, 0.32 mmol, 1 
eq.) was added to the reaction mixture and the vessel sealed.  RBF was immersed in a 
silicone oil bath at 40 oC and left to react until complete conversion, approx. 8 hrs. 
The polymerisation was terminated by exposure to air and dilution in THF and purified 
by:  removal of copper catalyst by a neutral alumina column, removal of solvent in 
vacuo and crude polymer precipitated twice into cold hexane. Residual solvent was 
removed at 40oC in a vacuum oven overnight. 
7.4.4 ATRP of PBiB-p(OEGMA50-co-EGDMA0.8) 
OEGMA (5.00 g, 16 mmol, 50 eq.), EGDMA (0.051 g, 0.32 mmol, 0.8 eq.), 2,2’-
bipyridyl (0.100 g, 0.64 mmol, 2 eq.), PBiB (0.25 g, 0.34 mmol, 1 eq.) were added to 
a RBF equipped with magnetic stirrer and solvent system IPA/H2O (92.5:7.5 v/v%, 
4.39:0.36 mL, 55 wt %) added. Anisole was added as internal standard for 1H NMR 
conversion of monomer peaks. The vessel was sealed and degassed with dry nitrogen 
for 5 minutes, Cu(I)Cl (0.032 g, 0.32 mmol, 1 eq.) was added and the reaction vessel 
sealed. RBF was immersed in silicone oil bath at 40 oC and left to react until complete 
conversion, approx. 24 hrs. The polymerisation was terminated by exposure to air and 
dilution in THF and purified by:  removal of copper catalyst by a neutral alumina 
column, removal of solvent in vacuo and crude polymer precipitated twice into cold 
hexane. Residual solvent was removed at 40oC in a vacuum oven overnight. 
7.4.5 ATRP of con-initiated DBiBx/PBiBy-p(OEGMA50-co-EGDMA0.8) 
 
DBiBx/PBiBy-p(OEGMA50-co-EGDMA0.8) was polymerised where x+y = 1 equiv., 
and represent the molar ratio of the initiators DBiB:PBiB. This ratio can be varied 
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and ranges have been generated from 0.9:0.1, 0.75:0.25, 0.5:0.5, 0.25:0.75, 0.1:0.9 
DBiB:PBiB as well as the homopolymers of each prepared. 
In a typical atom-transfer radical polymerisation reaction, OEGMA (5.00 g, 16 mmol, 
50 eq.), EGDMA (0.051 g, 0.32 mmol, 0.8 eq.), 2,2’-bipyridyl (0.100 g, 0.64 mmol, 2 
eq.), DBiB (0.0268 g, 0.08 mmol, 0.25 eq.), PBiB (0.185 g, 0.25 mmol, 0.75 eq.) were 
added to a RBF equipped with magnetic stirrer and solvent system IPA/H2O (92.5:7.5 
v/v, 4.39:0.36 mL, 55 wt%) was added. Anisole was added as internal standard for 1H 
NMR conversion of monomer peaks. The vessel was sealed and degassed with dry 
nitrogen for 5 minutes, CuCl(I) (0.032 g, 0.32 mmol, 1 eq.) was added and the reaction 
vessel sealed. The RBF was immersed in a silicone oil bath at 40 oC and left to react 
until complete conversion, approx. 24 hrs. The polymerisation was terminated by 
exposure to air and dilution in THF and purified by:  removal of copper catalyst by a 
neutral alumina column, removal of solvent in vacuo and crude polymer precipitated 
twice into cold hexane. Residual solvent was removed at 40oC in a vacuum oven 
overnight. 
  
7.4.6 Kinetic Studies 
Same methodology as 7.3.4. 
 
7.4.7 Preparation of Macroemulsions 
Same methodology as 7.3.5. 
7.4.8 Preparation of Nanoemulsions 
 
Same methodology as 7.3.6. 
7.5 CHAPTER 4 
 
Ex vivo testing of nanoemulsions was conducted in collaboration with Cardiff 
University, in the School of Pharmacy and Pharmacology, with Dr Muthanna Al-
Balwadi, within Prof. Mark Gumbleton’s group. Radiochemical analysis was 
conducted in the Radiomaterials Laboratory in the Department of Chemistry at the 
University of Liverpool by Dr Helen Cauldbeck. Zone of inhibition study was 
performed by Dr Andrew Gallagher from the Department of Eye and Vision Science 
in the Department of Microbiology at the University of Liverpool. 
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7.5.1 Chapter 4 Materials  
 
Magnesium sulphate (MgSO4), sodium hydrogen carbonate (NaHCO3), 
timethylamine (TEA), hydrochloric acid (1M) (HCl) were purchased from Fischer 
Scientific and used as received. Ethylene glycol (99.8 %), anhydrous THF (99%), α-
bromoisobutyl bromide (98 %), butylamine (99 %), anisole (99 %), poly(ethylene 
glycol)methyl ether methacrylate (average Mn  = 300 g/mol) (98 %) (OEGMA), 
ethylene glycol dimethacylate (EGDMA), 2,2’-bipyridyl (bpy), Copper (I) Chloride 
(Cu(I)Cl) (97 %), activated neutral alumina, porcine mucin, bovine serum albumin (> 
98 %) (BSA), cholesterol, phosphatidylchloine and polysorbate 80 were purchased 
from Sigma Aldrich and used as received. Potassium ethyl xanthogenate (96 %), 2-
bromoacetic acid, 4-(dimethylamino) pyridine (>99 %) (DMAP), N-N’-
dicyclohexylcarbodiimide (>99 %) (DCC), 2-bromoacetic acid were all purchased 
from Alfa Aesar and used as received. 4-(dimethylamino)pyridinium-4-toluene 
sulphonate (DPTS) was synthesised Dr Faye Hern of the Rannard research group. Poly 
acrylic acid (Carbopol 940) was donated by Unilever and used as received. Linoleic 
acid was donated by researchers in the Department of Pharamacology. All solvents 
unless stated were reagent grade, purchased from Fischer and used as received.  
7.5.2 Preparation of 2-((Ethoxycarbonothioyl)thio) acetic acid 
 
Potassium ethyl xanthogenate (53.06 g, 311 mmol, 1 equiv.) was added to an RBF and 
stirred in acetone (400 mL). A solution of 2-bromoacetic acid (38.35 g, 276 mmol, 
1.12 equiv.) in acetone (100 mL) was added dropwise via a dropping funnel to the 
reaction vessel over 20 minutes and left to stir at ambient temperature for 16 hours. 
The crude mixture was filtered under vacuum, washed with acetone and solvent 
removed in vacuo. The residual oil was solubilised in a minimum amount of 
dichloromethane and washed with brine (150 mL). The organic layer was dried over 
MgSO4 and solvent removed in vacuo to give a white solid. Yield: 16.28 g, white 
solid, (33%). 1H NMR (400 MHz, CDCl3) δ ppm = 1.43 (t, 3H), 3.98 (s, 2H), 4.65 (q, 
2H), 9.3 (s, br, –OH). 13C NMR (100 MHz, CDCl3) δ ppm = 13.70, 37.63, 70.93, 
173.86, 212.07. Mass Spectrometry: calculated:  [M+H]+ (C6H12BrO3) m/z = 211.0. 
Experimental: CI MS [M+Na]+ m/z = 211.0. Elemental analysis: Calculated (%): 
(C5H8O3S2) = C, 33.32; H, 4.47; S, 35.58. Experimental (%) = C, 32.80; H, 4.40; S, 
34.59.  
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7.5.3 Preparation of 2-Hydroxyethyl 2-Bromoisobutyrate  
 
Ethylene glycol (301.35 g, 4855 mmol, 50 equiv.), TEA (20.33 g, 201 mmol, 2 equiv.) 
were dissolved in anhydrous tetrahydrofuran (100 mL) and the reaction was stirred in 
an ice bath. α-bromoisobutyl bromide (22.32 g, 97.1 mmol, 1 equiv.) was added 
dropwise over 30 minutes and the reaction was left stirring under nitrogen atmosphere 
at ambient temperature for 16 hours. The reaction mixture was poured into distilled 
water (800 mL) and extracted with dichloromethane (6 x 100 mL), the retrieved layers 
were washed with 1M HCl (2 x 300 mL), dried over MgSO4 and solvent removed in 
vacuo. Yield: 18.60 g, yellow oil, (90.80%). 1H NMR (400 MHz, CDCl3) δ ppm = 
1.96 (s, 6H), 3.87 (t, 2H), 4.31 (t, 2H). 13C NMR (100 MHz, CDCl3) δ ppm = 30.7, 
55.8, 60.7, 63.3, 67.4, 171.8. Elemental Analysis: calculated (%) =  (C6H11BrO3) = C, 
34.14; H, 5.25. Experimental (%) = C, 34.09; H, 5.24. 
 
7.5.4 Synthesis of ATRP Initiator XanBiB 
2-((Ethoxycarbanothioyl)thio) acetic acid, XanCOOH (3.85 g, 21.2 mmol, 1 equiv), 
2-hydroxyethyl 2-bromoisobutyrate (4.5 g, 21.2mmol, 1 equiv) and DPTS (6.86g, 
23.32 mmol, 1.1 equiv) were dissolved in anhydrous dichloromethane (40 mL) under 
nitrogen. DCC (4.81 g, 23.32 mmol, 1.1 equiv) was dissolved in anhydrous 
dichloromethane (10 mL) under nitrogen flow and transferred to the main reaction 
vessel via syringe and the reaction was left to stir at ambient temperature for 16 hours. 
The resulting crude mixture was filtered, diluted in dichloromethane (100 mL) and 
washed with distilled water (2 x 100 mL) and once with brine (100 mL). The organic 
layer was dried over MgSO4. After removal of solvents in vacuo the xanthate initiator 
was purified by automated liquid chromatography (silica, eluting hexane increasing 
the polarity to hexane:ethyl acetate 70:30) to give pure product. Yield: 5.08 g, yellow 
oil, (25%). 1H NMR (400 MHz, CDCl3) δ ppm = 1.43 (t, 3H), 1.94 (s, 6H), 3.96 (s, 
4H), 4.41 (m, 4H), 4.66 (q, 2H). 13C NMR (100 MHz, CDCl3) δ ppm = 13.70, 30.7, 
37.7, 63.0, 63.3, 70.8, 167.8, 171.5, 212.5. Mass spectrometry calculated:  [M+Na]+ 
(C11H17BrO5S2Na) m/z = 395.28. Experimental: ES MS [M+Na]
+ m/z = 
395.Elemental Analysis: calculated (%): (C11H17BrO5S2) = C, 35.39; H, 4.59; S, 17.18. 
Experimental (%) = C, 36.29; H, 4.79; S, 17.06. 
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7.5.5 ATRP of XanBiB-p(OEGMA50) 
 
OEGMA (5.00 g, 16 mmol, 50 eq.), 2,2’-bipyridyl (0.100 g, 0.64 mmol, 2 eq.), 
XanBiB (0.089 g, 0.24 mmol, 0.75 eq.) were added to a RBF equipped with a magnetic 
stirrer and the solvent system IPA/H2O (92.5:7.5 v/v%, 4.39:0.36 mL, 55 wt%) was 
added. Anisole was added as internal standard for 1H NMR conversion of monomer 
peaks. The reaction vessel was sealed and degassed with dry nitrogen for 5 minutes, 
CuCl(I) (0.032 g, 0.32 mmol, 1 eq.) was added and the reaction vessel sealed again.  
The RBF was immersed in a silicone oil bath at 40 oC and left to react until complete 
conversion, approx. 8 hrs. The polymerisation was terminated by exposure to air and 
dilution in THF and purified by:  removal of copper catalyst by a neutral alumina 
column, removal of solvent in vacuo and crude polymer precipitated twice into cold 
hexane. Residual solvent was removed at 40oC in a vacuum oven overnight. 
 
7.5.6 ATRP of Mixed Initiator System DBiBx/Xan1-G0-BiBy-p(OEGMA50-co-
EGDMA0.8) 
 
DBiBx/Xan1-G0-BiBy-p(OEGMA50-co-EGDMA0.8) was synthesised where x+y = 1 
equiv., and represent the molar ratio of the initiators DBiB:Xan1-G0-BiB. This ratio 
can be varied and ranges have been generated from 0.9:0.1, 0.75:0.25, 0.5:0.5, 
0.25:0.75, 0.1:0.9 DBiB:Xan1-Go-BiB as well as the homopolymers of each. 
In a typical atom-transfer radical polymerisation reaction, OEGMA (5.00 g, 16 mmol, 
50 eq.), EGDMA (0.051 g, 0.32 mmol, 0.8 eq.), 2,2’-bipyridyl (0.100 g, 0.64 mmol, 2 
eq.), DBiB (0.0268 g, 0.08 mmol, 0.25 eq.), Xan-G0-BiB (0.089 g, 0.24 mmol, 0.75 
eq.) were added to a RBF equipped with magnetic stirrer and solvent system IPA/H2O 
(92.5:7.5 v/v, 4.39:0.36 mL, 55 wt%) was added. Anisole was added as internal 
standard for 1H NMR conversion of monomer peaks. The vessel was sealed and 
degassed with dry nitrogen for 5 minutes, CuCl(I) (0.032 g, 0.32 mmol, 1 eq.) was 
added and the reaction vessel sealed. RBF was immersed in silicone oil bath at 40 oC 
and left to react until complete conversion, approx. 24 hrs.  
The polymerisation was terminated by exposure to air and dilution in THF and purified 
by:  removal of copper catalyst by a neutral alumina column, removal of solvent in 
vacuo and crude polymer precipitated twice into cold hexane. Residual solvent was 
removed at 40oC in a vacuum oven overnight.  
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7.5.7 Deprotection of DBiBx/Xan1-Go-BiBy(pOEGMA50-co-EGDMA0.8) 
 
In a typical experimental procedure to remove the xanthate protecting group, 
DBiBx/Xan1-Go-BiBy(pOEGMA50-co-EGDMA0.8) (0.599 g, 1.66 mmol, 1 equiv.) was 
dissolved in tetrahydrofuran (10 mL) and degassed with dry nitrogen for ~5 minutes. 
Butyl amine (0.38 mL, 4.15 mmol, 2.5 equiv.) was added to the reaction vessel and 
left to stir for 1.5 hours at ambient temperature. The solvent was removed in vacuo 
and crude product precipitated twice into cold hexane to purify. Residual solvent was 
removed in vacuo.  
 
7.5.8 Preparation of Macroemulsions 
Same methodology as Section 7.3.4. 
 
7.5.9 Preparation of Nanoemulsions 
Same methodology as Section 7.3.5. 
 
7.5.10 Preparation of Macroemulsions with Encapsulated Hydrophobic Dyes 
 
Aqueous polymer solutions were prepared at 5 mg/mL and used as the water phase of 
the emulsion. Emulsions were prepared at a 1:1 v:v ratio of oil:water, where the oil 
phase was dodecane or squalene. Oil red O or Oil blue A (0.5 wt% with respect to oil) 
were used as a hydrophobic drug mimic. Emulsions were generated via 
homogenisation using an over-head shear homogeniser (IKA T 25 ULTRA-
TURRAX) for 2 minutes at 24,000 rpm. Emulsions were left over night before 
characterisation of droplets using light scattering was carried out (Malvern Mastersizer 
2000). 
 
7.5.11 Preparation of Nanoemulsions with Encapsulated Hydrophobic Dyes 
 
Nanoemulsions were formulated using the solvent evaporation technique, with 
aqueous polymer solutions of branched copolymers at a 5 wt % concentration. The oil 
phase is a mixture of two miscible oils, one a volatile solvent and one a non-volatile 
oil. As the volatile solvent evaporates, the non-volatile section of the oil droplet 
shrinks to the nanoscale. The oil phase is composed of ethyl acetate:castor oil in a ratio 
of 50:50, 60:40, 70:30, 80:20, 90:10 or 99:1. The oil:water ratio was 1:1, with the 
water phase being aqueous polymer solution (5 wt%). Oil blue or oil red O were 
encapsulated in the oil phase at a concentration (0.1 wt%) with respect to the oil phase. 
Emulsions were generated via homogenisation using an over-head shear homogeniser 
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(IKA T 25 ULTRA-TURRAX) for 2 minutes at 24,000 rpm. Emulsions were left 
overnight until all ethyl acetate is removed (monitored gravimetrically)  and analysis 
performed using dynamic light scattering (Malvern, Zetasizer Nano). 
 
7.5.12 Synthesis of Biosimilar Mucus 
 
Carbopol (0.9 g, 0.9 w/v%) was dissolved in HEPES buffer solution (9 mL) using 
magnetic stirring. A lipid mixture of phosphatidylcholine (0.018 g, 0.18 % w/v), 
cholesterol (0.0036 g, 0.36 w/v%), polysorbate 80 (0.033 g, 4:1 ratio) and buffer 
solution (1 mL) was prepared and added to the carbopol solution once ~ 90 % of the 
carbopol had dissolved. Mucin from porcine stomach (0.5000 g, 5 w/v%) was added 
to the solution and the pH altered to 7.4 with the addition of NaOH (1 M), this was 
monitored using a pH probe.  BSA (0.3100 g, 3.1 w/v%) was added and the pH once 
again adjusted to 7.4 with the addition of NaOH (1 M). Biosimilar mucus was stored 
overnight at 2 – 4 oC before use, with a four day storage life from day of preparation.  
7.5.13 Quantification of Mucoadhesion by Flow-through Model 
 
Biosimilar mucus (1 mL) was placed into the chamber of Kirkstall QV500 weighed 
and sealed. A set volume of emulsion (1 mL) was flowed over the mucus twice at a 
rate of 1 mL/min and free emulsion that did not adhere to the mucus was recovered 
into a pre-weighed outlet chamber. Quantification of mucoadhesion was determined 
gravimetrically by the amount of emulsion collected post-flow. The other components 
of the flow through model were also weighed to mitigate any error. 
7.5.14 Preparation of Fluorescent Nanoemulsions  
 
Nanoemulsions were generated using the solvent evaporation technique, with aqueous 
polymer solutions of branched copolymers at a 5 wt % concentration. The oil phase is 
a mixture of two miscible oils, one a volatile solvent and one a non-volatile oil. As the 
volatile solvent evaporates, the non-volatile section of the oil droplet shrinks to the 
nanoscale. The oil phase is composed of ethyl acetate: castor oil in a ratio of 99:1. The 
oil: water ratio was 1:1, with the water phase being aqueous polymer solution at 5 
wt%. Lumogen F red 305 was encapsulated at a concentration (0.1 wt %) with respect 
to the oil phase. Emulsions formulated via homogenisation using an over-head shear 
homogeniser (IKA T 25 ULTRA-TURRAX) for 2 minutes at 24,000 rpm. Emulsions 
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were left overnight until all ethyl acetate is removed (monitored gravimetrically) and 
analysis performed using DLS. 
 
7.5.15 Ex vivo Study of Mucoadhesive Nanoemulsions 
 
For multiple particle tracking (MPT) studies mucus from fresh porcine intestinal ileum 
(2 m in length) was obtained from a local abattoir and stored in ice-cold oxygenated 
phosphate buffered saline (PBS) prior to sample processing. The ileum was processed 
into 25 cm lengths, incised longitudinally to allow for waste to be gently rinsed away 
using ice-cold PBS. The mucus was harvested by gentle scraping, to increase the yield 
of the loose mucus layer but also include a high content of the adhered layer. Mucus 
was divided into aliquots (0.5 g) and stored at -20 oC until required for use. 
Fluorescently labelled nanoemulsions were inoculated into a sample of mucus (0.5 g) 
at a concentration confirmed not to cause particle aggregation (0.001 %). Samples 
were then incubated for 2 hours at 37 oC before particle tracking, to ensure good 
particle distribution following incubation. Video capture used 2-dimensional imaging 
(Lecia DM IRB wide-field epi-fluorescence microscope, x63 magnification oil 
immersion lens) using a high speed camera (Allied Vision Technologies, UK), at a 
frame rate of 33 ms (30 frames/s), where each video contained 300 frames. For each 
sample of mucus, approx. 120 individual particles were tracked for each 
nanoemulsion, n = 3, therefore, 360 particles were tracked over 3 separate mucus 
samples. Videos were processed using Fiji ImageJ plugin mosaic to track individual 
droplet trajectories through mucus. Each 10 second video was cut down to a 30 frame 
video (1 second) where any individually tracked particle must be continuously in the 
X-Y plane throughout all 30 frames. Individual particle trajectories were converted 
into numeric pixel data using Mosaic Particle Tracker plugin within Fiji ImageJ, which 
based on microscope and video capture settings metric distance was able to be 
determined.  
7.5.16 Preparation of Fluorescent Nanoemulsions  
 
Nanoemulsions were generated using the solvent evaporation technique, with aqueous 
polymer solutions of branched copolymers at a 5 wt % concentration. The oil phase is 
a mixture of two miscible oils, one a volatile solvent and one a non-volatile oil. As the 
volatile solvent evaporates, the non-volatile section of the oil droplet shrinks to the 
nanoscale. The oil phase is composed of ethyl acetate: castor oil in a ratio of 99:1. The 
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oil: water ratio was 1:1, with the water phase being aqueous polymer solution at 5 
wt%. Tritiated oil blue A was encapsulated at a concentration (0.1 wt %) with respect 
to the oil phase. Emulsions formulated via homogenisation using an over-head shear 
homogeniser (IKA T 25 ULTRA-TURRAX) for 2 minutes at 24,000 rpm. Emulsions 
were left overnight until all ethyl acetate is removed (monitored gravimetrically) and 
analysis performed using DLS. 
 
7.5.17 Release of Hydrophobic Dyes from Nanoemulsions 
 
Dialysis through a 3.5 kDa molecular weight cut off membrane was conducted with 
distilled water (100 mL) at 37 °C as the reservoir. Release was monitored for 24 hrs 
with 1 mL sampled at t = 0.5 hrs and 1 hr, then subsequent 1 hr time points for 8 hrs 
and a final 24 h timepoint. After each time point, the reservoir was replaced to ensure 
sink conditions remained constant throughout the experiment. Quantification of dye 
released was calculated from liquid scintillation counting (LSC) radiation released. 
LSC of a reservoir sample (1 mL) plus liquid scintillation cocktail (20 mL) provided 
disintegrations per minute (DPM) which is a measure of the source of radioactivity. 
DPM is then converted to mass of dye by the following equations: 
DPM / 2.22 x106 = Radioactivity (µCi) (1) 
Radioactivity (µCi) / Specific Activity (µCi/mg) = Mass of dye within 
the 1 mL sample (mg)      (2) 
Mass of dye within the 1 mL sample (mg) x 100 = Mass of dye within 
the 100 mL reservoir (mg)     (3) 
7.6 CHAPTER 5 
 
Radiochemical analysis was again conducted in the Radiomaterials Laboratory within 
the University of Liverpool and experimentation done by Dr Helen Cauldbeck. In vivo 
testing was conducted in collaboration with the Department of Pharmacology in the 
Materials Innovation Factory, University of Liverpool by Dr Lee Tatham. 
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7.6.1 Preparation of Macroemulsions with Encapsulated Drugs for Biological 
Evaluation 
 
Aqueous polymer solutions were prepared at 5 mg/mL of branched amphiphilic 
polymer for the water phase of the emulsion. Emulsions were prepared at a 1:1 v:v 
ratio of oil:water, where the oil phase was squalene. Amphotericin B and cyclosporin 
A were loaded in the oil phase at the clinical topical dose concentration, 0.15 w/v% 
and 0.05 w/v% respectively. Emulsions were generated via over-head shear 
homogenisation (IKA T 25 ULTRA-TURRAX) for 2 minutes at 24,000 rpm. 
Emulsions were left over night to equilibrate before characterisation of droplet size 
using light scattering was conducted using a Malvern Mastersizer 2000. 
 
7.6.2 Preparation of Nanoemulsions with Encapsulated Drugs for Biological 
Evaluation 
 
Nanoemulsions were formulated using the solvent evaporation technique, with 
aqueous polymer solutions of branched copolymers at a 5 wt % concentration. The oil 
phase is a mixture of two miscible oils, one a volatile solvent and one a non-volatile 
oil. As the volatile solvent evaporates, the non-volatile section of the oil droplet 
shrinks to the nanoscale. The oil phase is composed of ethyl acetate: castor oil in a 
ratio of 99:1. Amphotericin B and Cyclosporin A were loaded into the oil phase at the 
clinical topical dose concentration, 0.15 w/v % and 0.05 w/v % respectively. 
Emulsions were generated using an over-head shear homogeniser (IKA T 25 ULTRA-
TURRAX) for 2 minutes at 24,000 rpm. Emulsions were left overnight until all ethyl 
acetate is removed (monitored gravimetrically) and analysis performed using DLS. 
 
7.6.3 Preparation of Nanoemulsions for In Vivo Testing 
 
Nanoemulsions were formulated using the solvent evaporation technique, with 
aqueous polymer solutions of branched copolymers at a 5 wt % concentration. The oil 
phase is a mixture of two miscible oils, one a volatile solvent and one a non-volatile 
oil. As the volatile solvent evaporates, the non-volatile section of the oil droplet 
shrinks to the nanoscale. The oil phase is composed of ethyl acetate:castor oil in a ratio 
of 99:1. FTC-prodrug was incorporated into the nanoemulsions at a concentration of 
4.85 mg/mL to yield final concentration of 5 mg/kg for each rat. Emulsions were 
generated using an over-head shear homogeniser (IKA T 25 ULTRA-TURRAX) for 
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2 minutes at 24,000 rpm. Emulsions were left overnight until all ethyl acetate is 
removed, monitored gravimetrically and analysis performed using DLS. 
 
7.6.4 Release Study of CsA from Nanoemulsion 
 
Tritiated CsA (33.7 µCi, specific activity 54 µCi/mg), CsA (0.625 mg, 0.52 µmol) and 
castor oil (12.5 µL) were added to a 20 mL vial and solubilised in ethyl acetate (1.824 
mL) at ambient temperature overnight.  DBiB-p(OEGMA50-co-EGDMA0.8) was used 
as the polymeric surfactant 5 wt % in aqueous phase. The emulsion was formulated 
via homogenisation (24000 rpm, 2 minutes) followed by evaporation of volatile oil 
phase (ethyl acetate) and monitored gravimetrically. DLS measurements were taken 
to ensure incorporation of tritium did not affect droplets. 
Dialysis through a 3.5 kDa molecular weight cut off membrane was conducted with 
distilled water (100 mL) at 37 °C as the reservoir. Release was monitored with 1 mL 
sampled at t = 0.5 hrs and 1 hr, then subsequent 1 hr time points for 8 hrs, a 24 hr and 
144 hr were taken and finally another 8 hour time period was tested between 172 – 
180h hrs. After each time point, the reservoir was replaced to ensure sink conditions 
remained constant throughout the experiment. Quantification of dye released was 
calculated from liquid scintillation counting (LSC) radiation released (same as Section 
7.5.16). 
7.6.5 In Vivo Testing 
 
FTC was dosed to male wistar rats at 5 mg/kg. The three samples tested for this study 
were: 
 Conventional FTC (water diluent) n=4 
 Non-mucoadhesive emulsion, FTC-prodrug loaded (water diluent) n=4 
 Mucoadhesive emulsion, FTC-prodrug loaded (water diluent) n=4  
Following habituation (7-days) where food and water were provided ad libitum, the 
rats received the single dose of either FTC or the FTC-prodrug emulsion (5 mg/Kg 
FTC) via oral gavage. Blood samples were collected (~230 µl) at 0.5, 1, 2, 4, 6, 8 h 
post dosing from the tail vein (~1.4 ml total blood volume). Bioanalysis of the blood 
samples was performed by measurement of FTC parent drug by liquid 
chromatography followed by combination of two mass spectrometry analysers (LC-
MS/MS).  At the 24 h time point, the rats was sacrificed using cardiac puncture under 
terminal anaesthesia (AC). 
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7.7 CELL CULTURE 
 
In vitro testing of nanoemulsions for ophthalmic treatment was conducted in 
collaboration with Prof. Rachel Williams in the Department of Eye and Vision Science 
at the University of Liverpool.  
All cell culture was carried out under strictly aseptic conditions in a class II laminar 
flow biological safety cabinet. All cells were incubated at 37 oC with 5 % CO2 
atmosphere. 
7.7.1 Cell Source 
 
Human Conjunctival Cells, HCjE-Gi and Human Corneal Epithelium cells, HCE-T 
were used throughout. HCE-T cells were donated by Kaura Araki-Sasaki from JCHO 
Hohigaoka Medical Centre and obtained from in house frozen stocks for 
experimentation. HCjE-Gi are a human immortalised cell line which were donated by 
Gibson laboratory at Havard Medical School to the University of Liverpool and  
obtained from in house frozen stocks for the experiments described. 
7.7.2 Media Preparation 
 
The solutions used for media preparation throughout cell culture for this project are 
summarised in Table 7.1 for HCE-T cells and Table 7.2 for HCjE-Gi cells. 
Table 7.1 Solutions used to prepare culture media for HCE-T cells. 
Name Abbreviation Company Catalogue Number 
Dublecco’s Modified 
Eagle Medium/Ham’s 
Nutrient Mixture F-12 
Formulation 
DMEM/F12 Sigma Aldrich D6421 
Foetal Calf Serum FCS BioSera S1900 
 
Cells were cultured in a mixture of DMEM/F12 containing 10 % FCS. 
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Table 7.2 Solutions used to prepare culture media for HCjE-Gi cells. 
Name Abbreviation Company Catalogue 
Number 
Keratinocyte 
Serum Free Media 
KFSM Sigma Aldrich 133-500 
Calcium Chloride CaCl2 Sigma Aldrich C5670 
Bovine Pituitary 
Extract 
BPE Sigma Aldrich P1476 
Epidermal Growth 
Factor 
EGF Sigma Aldrich E4127 
 
7.7.3 Cell Retrieval 
 
HCjE-Gi and HCE-T cells were stored in 1mL cryovials under liquid nitrogen in 
complete culture media with 10 % DMSO. To retrieve cells, cryovials were warmed 
in a water bath at 37 oC then emptied into a 30 mL universal, with 15 mL pre-warmed 
media. This was split evenly into 3 T75 flasks with an additional 7 mL of media added. 
Cells were then incubated in a microplasma free incubator at 37 oC under 5 % CO2. 
 
7.7.4 Cell Culture Maintenance  
 
HCjE-Gi and HCE-t cell flasks were fed every other day, removing 7 mL of old media 
and replacing with 8 mL of fresh pre-warmed media. Cells were examined using light 
microscopy to check for any abnormalities or preliminary infections. For these studies, 
cells were used between passages 4 – 22 for HCjE-Gi and 15 – 37 for HCE-T.  
Both cell lines were split when the flasks reached >80 % confluence, this was checked 
via an optical microscope.  T75 flasks were split by removing 10 mL of media, rinsing 
with 5 mL PBS solution and adding 5 mL Trypsin/PBS (1:10) solution to flask. The 
flask was incubated at 37 oC for 5 minutes, with the lifting of cells monitored via 
optical light microscopy. Cells that were rounded but still attached were removed by 
gently agitation of the flask. Media (5 mL) was added to inactivate and neutralise the 
trypsin reaction. For HCjE-Gi cells cultured in serum free media, HCE-T culture 
media was used to neutralise trypsin. For subculture 2.5 mL of the HCE-T cell 
suspension was placed into a fresh flask with 9 mL fresh culture media, for HCjE-Gi 
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cells culture media was removed gently to assure no disturbance of the pellet and re-
suspended with KSFM. To seed samples for experiments, the cell suspension was 
pipetted into a centrifuge tube and centrifuged at 1200 rpm for 4 minutes.  The 
supernatant was removed and the cell pellet re-suspended in culture media (1 mL).   A 
haemocytometer was prepared by cleaning all surfaces with 70 % ethanol and dried 
before the coverslip was centred.  20 µL of cell suspension was pipetted onto the top 
edge of the coverslip to allow the cells to enter the counting chamber.  After cells were 
counted calculations were made to determine the volumes needed to obtain the desired 
seeding density for experimental procedures. 
7.7.5 Cellular Assays 
  
Multiple assays were carried out on HCE-T and HCjE-Gi cells to study cytotoxicity 
and effects of different drug concentrations of cells. 15,000 cells/well were seeded into 
a 48 well tissue culture plate and left for 7 days to adhere to the plate and produce a 
cell monolayer. The cells were nourished twice a week by replacing 150 μL of old 
media with 150 μL of fresh culture media. After this the media was removed and 
replaced with either unloaded nanoemulsion in media or drug loaded nanoemulsion in 
media.  
7.7.6 Resazurin Assay 
 
Resazurin was dissolved in PBS at 0.1 mg/mL and filtered to sterilise, this was stored 
at 4 °C in the dark. Stock resazurin solution (10 μL per 100 μL media) was added to 
wells of the assay apart from control wells, plates were incubated at 37 oC for 4 hours. 
Media was removed and put in black 96-well plastic plates; resorufin fluorescence was 
read using a Biotek FLx800 spetrofluorometer (λExcitation = 530 nm; λEmission = 
590 nm).  All values were normalised to control wells on each plate which contained 
culture medium from cells.  
7.7.7 Phalloidin Staining 
 
In a 48 well tissue culture plate, cells were seeded at 15,000 cells/well then the same 
protocol as in Section 7.7.6 was followed.  After incubation the media was discarded 
and the cells washed with PBS (500 µL) then fixed for 10 minutes in 10 % neutral 
buffered formalin (NBF; 10 % formalin, approximately 4 % formaldehyde).  NBF was 
discarded and the cells washed again with PBS.  A phalloidin solution was used to 
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stain the F-actin of the cytoskeleton of the cell.  A phalloidin solution was produced 
at 1 mg powder in 1.5 mL MeOH according to manufacturer’s instruction.  The 
solution was then diluted 1 in 100 (in fresh PBS) and 75 µL was placed in each well 
followed by 30 minutes of incubation at 4 °C.  Phalloidin solution was removed and 
the cells washed with PBS.    
4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI, purchased from Invitrogen) 
was used to stain the nuclei of the cell.  A stock solution of DAPI was made at 1:1,000 
with PBS, then further diluted to a working solution of 1:10 PBS, 75 µL was placed 
in each well and incubated for 10 minutes at 4 °C.  Cells were washed with PBS and 
placed under 500 µL PBS. 
7.7.8 Zone of Inhibition Study 
 
Preparation of the C. albicans culture was done as followed: C. albicans strain SC5314 
was revived from -80 °C storage on potato dextrose-agar (PD-agar; Formedium Ltd., 
Norfolk, England) and streak plates incubated at 37 °C overnight. C. albicans was sub-
cultured by inoculating a PD-agar streak plate with one colony taken from a previous 
PD-agar plate and incubated overnight at 37 °C. Colonies were maintained on PD-
agar stored at 5 °C. Broth cultures were initiated by inoculating PD media (10 cm3) 
with one colony of C. albicans taken from a PD-agar plate. Cultures were incubated 
overnight at 37 °C with constant agitation at 100 RPM. These were sub-cultured by 
taking an aliquot of C. albicans broth culture (0.5 cm3) and diluted in sterile PD broth 
(10 cm3). An initial OD600 measured between 0.1 - 0.2 and was monitored until an 
OD600 0.5-0.6 was obtained. This was the working stock dilution of C. albicans for the 
following experiments. 
 
An aliquot (20 mm3) of each sample was pipetted carefully to minimise spreading on 
to potato dextrose agar plates. Samples were spaced to avoid cross-contamination and 
agar plates left at room temperature for 20 minutes to allow the samples to dry. An 
aliquot of C. albicans stock solution (1 cm3) was pipetted onto the centre of each agar 
plate. A glass spreader sterilised with ethanol and following aseptic technique was 
used to uniformly spread the culture broth around the agar plate. The plate was again 
allowed to dry for 30 minutes before turning the plates upside down and placing in an 
incubator at 37 °C for 24 h. The samples were then checked for a zone of inhibition 
and measurements taken of the diameter of each zone if applicable. 
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A1 Mass spectrum (CI-MS) of DBiB. 
 
A2 1H NMR (CDCl3, 400 MHz) of DBiB-p(OEGMA50-co-EGDMA0.8) at t = 0 and t 
= 24. Percentage conversion determined by ratio of OEGMA vinyl peaks to internal 
standard (anisole). 
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A3 1H NMR (CDCl3, 400 MHz) of purified DBiB-p(OEGMA50-co-EGDMA0.8). 
 
A4 Mass spectrum (ES-MS) of PBiB. 
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A5 1H NMR (CDCl3, 400 MHz) of DBiBxPBiBy-p(OEGMA50-co-EGDMA0.8) at t = 
0 and t = 24. Percentage conversion determined by ratio of OEGMA vinyl peaks to 
internal standard (anisole). 
 
A3 1H NMR (CDCl3, 400 MHz) of purified DBiB0.50PBiB0.50-p(OEGMA50-co-
EGDMA0.8). 
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A6 Frequency distribution of DBiB0.75PBiB0.25-p(OEGMA50-co-EGDMA0.8) 
stabilised squalene macroemulsion. 
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A7 CI-MS of XanCOOH 
 
A8 CI-MS of HEBiB 
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A9 1H NMR (CDCl3, 400 MHz) of XanBiB-p(OEGMA50-co-EGDMA0.8) at t = 0 and 
t = 24. Percentage conversion determined by ratio of OEGMA vinyl peaks to internal 
standard (anisole). 
 
A10 1H NMR (CDCl3, 400 MHz) of purified DBiB0.50XanBiB0.50-p(OEGMA50-co-
EGDMA0.8). 
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A11 Typical deprotection of XanBiB0.90DBiB0.08-p(OEGMA50-co-EGMDA0.8) to 
yield SH0.90DBiB0.08-p(OEGMA50-co-EGDMA0.8) in the presence of n-butylamine 
after reaction for 1.5 hrs. 
 
A12 Frequency distribution of SH0.90DBiB0.10-p(OEGMA50-co-EGDMA0.8) stabilised 
squalene macroemulsion. 
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A13 Frequency distribution of SH0.50DBiB0.50-p(OEGMA50-co-EGDMA0.8) stabilised 
squalene macroemulsion. 
 
A14 Frequency distribution of SH0.10DBiB0.90-p(OEGMA50-co-EGDMA0.8) stabilised 
squalene macroemulsion. 
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A15 Frequency distribution of SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) stabilised 
squalene macroemulsion. 
 
 
 
 
A16 1H NMR (DMSO, 400 MHz) of A) Pure Amp B and B) Amp B pellet after 
centrifugation of sedimented free drug. 
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A17 1H NMR (DMSO, 400 MHz) of FTC-prodrug.  
Table A1 DLS analysis of tailored nanoemulsion droplets by varying the ratio of 
volatile:non-volatile oil, with SH0.75DBiB0.25-p(OEGMA50-co-EGDMA0.8) as 
polymeric surfactant. 
Polymer EtOAc:cast
or oil 
Dz  
(nm) 
Dn  
(nm) 
PdI 
SH0.75DBiB0.25-p(OEGMA50-co-
EGDMA0.8) 
 
50:50 1370 1220 0.11 
60:40 960 870 0.14 
70:30 706 670 0.02 
80:20 620 580 0.18 
    
90:10 530 480 0.12 
    
99:1 280 270 0.13 
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